<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="icon" href="assets/images/favicon.ico" />
  <title>RYBREVANT, LAZCLUZE - MARIPOSA Study</title>
  <link rel="stylesheet" href="assets/css/bootstrap.min.css">
  <link rel="stylesheet" href="assets/css/fonts.css">
  <link rel="stylesheet" href="assets/css/main.css">
</head>

<body>
  <div id="cts-content">
    <div class="container-fluid full-width">
      <div class="row">
        <div class="col-12">
          <h1 class="page-title">RYBREVANT® (amivantamab-vmjw)<br>LAZCLUZE™ (lazertinib)<br>RYBREVANT, LAZCLUZE – MARIPOSA Study</h1>
          <span class="date-updated">Last Updated: 11/05/2024</span>
        </div>
      </div>
    </div>

    <div class="overlay"></div>

    <div class="container-fluid full-width">
      <div class="mobile-navigation">
        <nav class="navbar navbar-expand-lg navbar-light pt-0 pb-0">
          <div class="navbar-heading d-flex justify-content-between align-items-center">
            <a class="navbar-brand" href="#" id="selectedTab">Selected Tab</a>
            <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#mobileNavDropdown"
              aria-controls="mobileNavDropdown" aria-expanded="false" aria-label="Toggle navigation">
              <span class="menu">Menu</span>
            </button>
          </div>
          <div class="collapse navbar-collapse" id="mobileNavDropdown">
            <ul class="navbar-nav">
              <li class="nav-item dropdown">
                <p>
                  <a data-toggle="collapse" href="#collapseExample-executive-summary" role="button"
                    aria-expanded="false" aria-controls="collapseExample-executive-summary" class="collapsed">Executive
                    Summary</a>
                </p>
                <div class="second-level-dropdown collapse" id="collapseExample-executive-summary">
                  <ul class="nav nav-tabs flex-column">
                    <li class="nav-item">
                      <a class="nav-link" href="#page-1" data-subtabs="page-1_executive-summary">Page 1</a>
                    </li>
                    <li class="nav-item">
                      <a class="nav-link" href="#page-2" data-subtabs="page-2_executive-summary">Page 2</a>
                    </li>
                  </ul>
                </div>
              </li>
              <li class="nav-item">
                <a class="nav-link" href="#overview" data-subtabs="overview">Overview</a>
              </li>
              <li class="nav-item">
                <a class="nav-link" href="#study-design-p" data-subtabs="study-design-p">Study Design</a>
              </li>
              <li class="nav-item">
                <a class="nav-link" href="#patient-characteristics-p" data-subtabs="patient-characteristics-p">Patient
                  Characteristics</a>
              </li>
              <li class="nav-item dropdown">
                <p>
                  <a data-toggle="collapse" href="#collapseExample-efficacy-p" role="button" aria-expanded="false"
                    aria-controls="collapseExample-efficacy-p" class="collapsed">Efficacy</a>
                </p>
                <div class="second-level-dropdown collapse" id="collapseExample-efficacy-p">
                  <ul class="nav nav-tabs flex-column">
                    <li class="nav-item">
                      <a class="nav-link" href="#primary-endpoints" data-subtabs="primary-endpoints_efficacy-p">Primary
                        Endpoint</a>
                    </li>
                    <li class="nav-item">
                      <a class="nav-link" href="#secondary-endpoints"
                        data-subtabs="secondary-endpoints_efficacy-p">Secondary Endpoints</a>
                    </li>
                    <li class="nav-item">
                      <p>
                        <a data-toggle="collapse" href="#collapseExample-long-term-analysis" role="button"
                          aria-expanded="false" aria-controls="collapseExample-long-term-analysis"
                          class="collapsed">Long-term Analysis</a>
                      </p>
                      <div class="third-level-dropdown collapse" id="collapseExample-long-term-analysis">
                        <ul class="nav nav-tabs flex-column">
                          <li class="nav-item">
                            <a class="nav-link" href="#efficacy-1_long-term-analysis"
                              data-subtabs="efficacy-1_long-term-analysis_efficacy-p">Efficacy - Page 1</a>
                          </li>
                          <li class="nav-item">
                            <a class="nav-link" href="#efficacy-2_long-term-analysis"
                              data-subtabs="efficacy-2_long-term-analysis_efficacy-p">Efficacy - Page 2</a>
                          </li>
                        </ul>
                      </div>
                    </li>
                  </ul>
                </div>
              </li>
              <li class="nav-item">
                <a class="nav-link" href="#safety-p" data-subtabs="safety">Safety</a>
              </li>
              <li class="nav-item dropdown">
                <p>
                  <a data-toggle="collapse" href="#collapseExample-additional-analysis" role="button"
                    aria-expanded="false" aria-controls="collapseExample-additional-analysis" class="collapsed">
                    Additional Analyses</a>
                </p>
                <div class="second-level-dropdown collapse" id="collapseExample-additional-analysis">
                  <ul class="nav nav-tabs flex-column">
                    <li class="nav-item">
                      <p>
                        <a data-toggle="collapse" href="#collapseExample-high-risk-subgroup-analysis" role="button"
                          aria-expanded="false" aria-controls="collapseExample-high-risk-subgroup-analysis"
                          class="collapsed">High-risk Subgroup Analysis</a>
                      </p>
                      <div class="third-level-dropdown collapse" id="collapseExample-high-risk-subgroup-analysis">
                        <ul class="nav nav-tabs flex-column">
                          <li class="nav-item">
                            <a class="nav-link" href="#study-design_high-risk-subgroup-analysis"
                              data-subtabs="study-design_high-risk-subgroup-analysis_additional-analysis">Study
                              Design</a>
                          </li>
                          <li class="nav-item">
                            <a class="nav-link" href="#results_high-risk-subgroup-analysis"
                              data-subtabs="results_high-risk-subgroup-analysis_additional-analysis">Results</a>
                          </li>
                        </ul>
                      </div>
                    </li>
                    <li class="nav-item">
                      <p>
                        <a data-toggle="collapse" href="#collapseExample-asian-subgroup-analysis" role="button"
                          aria-expanded="false" aria-controls="collapseExample-asian-subgroup-analysis"
                          class="collapsed">Asian Subgroup Analysis</a>
                      </p>
                      <div class="third-level-dropdown collapse" id="collapseExample-asian-subgroup-analysis">
                        <ul class="nav nav-tabs flex-column">
                          <li class="nav-item">
                            <a class="nav-link" href="#patient-characteristics_asian-subgroup-analysis"
                              data-subtabs="patient-characteristics_asian-subgroup-analysis_additional-analysis">Patient
                              Characteristics</a>
                          </li>
                          <li class="nav-item">
                            <a class="nav-link" href="#efficacy_asian-subgroup-analysis"
                              data-subtabs="efficacy_asian-subgroup-analysis_additional-analysis">Efficacy</a>
                          </li>
                          <li class="nav-item">
                            <a class="nav-link" href="#safety_asian-subgroup-analysis"
                              data-subtabs="safety_asian-subgroup-analysis_additional-analysis">Safety</a>
                          </li>
                        </ul>
                      </div>
                    </li>
                    <li class="nav-item">
                      <p>
                        <a data-toggle="collapse" href="#collapseExample-post-progression-analysis" role="button"
                          aria-expanded="false" aria-controls="collapseExample-post-progression-analysis"
                          class="collapsed">Post-Progression and Safety Analysis</a>
                      </p>
                      <div class="third-level-dropdown collapse" id="collapseExample-post-progression-analysis">
                        <ul class="nav nav-tabs flex-column">
                          <li class="nav-item">
                            <a class="nav-link" href="#efficacy-1_post-progression-analysis"
                              data-subtabs="efficacy-1_post-progression-analysis_additional-analysis">Efficacy - Page
                              1</a>
                          </li>
                          <li class="nav-item">
                            <a class="nav-link" href="#efficacy-2_post-progression-analysis"
                              data-subtabs="efficacy-2_post-progression-analysis_additional-analysis">Efficacy - Page
                              2</a>
                          </li>
                          <li class="nav-item">
                            <a class="nav-link" href="#safety_post-progression-analysis"
                              data-subtabs="safety_post-progression-analysis_additional-analysis">Safety</a>
                          </li>
                        </ul>
                      </div>
                    </li>
                    <li class="nav-item">
                      <p>
                        <a data-toggle="collapse" href="#collapseExample-exploratory-analysis" role="button"
                          aria-expanded="false" aria-controls="collapseExample-exploratory-analysis"
                          class="collapsed">Exploratory Analyses</a>
                      </p>
                      <div class="third-level-dropdown collapse" id="collapseExample-exploratory-analysis">
                        <ul class="nav nav-tabs flex-column">
                          <li class="nav-item">
                            <a class="nav-link" href="#effect_exploratory-analysis"
                              data-subtabs="effect_exploratory-analysis_additional-analysis">Effect of RYBREVANT Dose
                              Interruptions</a>
                          </li>
                          <li class="nav-item">
                            <a class="nav-link" href="#comparison_exploratory-analysis"
                              data-subtabs="comparison_exploratory-analysis_additional-analysis">Comparison of
                              Lazertinib with Osimertinib</a>
                          </li>
                        </ul>
                      </div>
                    </li>
                    <li class="nav-item">
                      <p>
                        <a data-toggle="collapse" href="#collapseExample-ctdna-analysis" role="button"
                          aria-expanded="false" aria-controls="collapseExample-ctdna-analysis" class="collapsed">ctDNA
                          Analysis for Acquired Resistance</a>
                      </p>
                      <div class="third-level-dropdown collapse" id="collapseExample-ctdna-analysis">
                        <ul class="nav nav-tabs flex-column">
                          <li class="nav-item">
                            <a class="nav-link" href="#patient-characteristics_ctdna-analysis"
                              data-subtabs="patient-characteristics_ctdna-analysis_additional-analysis">Patient
                              Characteristics</a>
                          </li>
                          <li class="nav-item">
                            <a class="nav-link" href="#mutation_ctdna-analysis"
                              data-subtabs="mutation_ctdna-analysis_additional-analysis">Mutation Profiling of ctDNA</a>
                          </li>
                        </ul>
                      </div>
                    </li>
                    <li class="nav-item">
                      <a class="nav-link" href="#patient-relevant-outcomes"
                        data-subtabs="patient-relevant-outcomes_additional-analysis">Patient-Relevant Outcomes</a>
                    </li>
                  </ul>
                </div>
              </li>
              <li class="nav-item dropdown">
                <p>
                  <a data-toggle="collapse" href="#collapseExample-abbreviations-and-references" role="button"
                    aria-expanded="false" aria-controls="collapseExample-abbreviations-and-references"
                    class="collapsed">Abbreviations and References</a>
                </p>
                <div class="second-level-dropdown collapse" id="collapseExample-abbreviations-and-references">
                  <ul class="nav nav-tabs flex-column">

                    <li class="nav-item">
                      <p>
                        <a data-toggle="collapse" href="#collapseExample-abbreviations" role="button"
                          aria-expanded="false" aria-controls="collapseExample-abbreviations"
                          class="collapsed">Abbreviations</a>
                      </p>
                      <div class="third-level-dropdown collapse" id="collapseExample-abbreviations">
                        <ul class="nav nav-tabs flex-column">

                          <li class="nav-item">
                            <a class="nav-link" href="#part12"
                              data-subtabs="part12_abbreviations_abbreviations-and-references">Page 1 of 2</a>
                          </li>

                          <li class="nav-item">
                            <a class="nav-link" href="#part22"
                              data-subtabs="part22_abbreviations_abbreviations-and-references">Page 2 of 2</a>
                          </li>
                        </ul>
                      </div>
                    </li>
                    <li class="nav-item">
                      <a class="nav-link" href="#literature-search"
                        data-subtabs="literature-search_abbreviations-and-references">Literature Search</a>
                    </li>
                    <li class="nav-item">
                      <a class="nav-link" href="#references"
                        data-subtabs="references_abbreviations-and-references">References</a>
                    </li>
                  </ul>
                </div>
              </li>
            </ul>
          </div>
        </nav>
      </div>
    </div>

    <div class="container-fluid full-width">
      <div class="row">
        <div class="col-12">
          <div class="desktop-navigation">
            <div class="first_level_inner_tabs">
              <ul class="nav nav-tabs w-100 d-flex justify-content-center flex-column flex-md-row" id="myTab"
                role="tablist">
                <li class="nav-item" role="presentation">
                  <button class="nav-link" data-subtabs="executive-summary" data-toggle="tab"
                    data-target="#executive-summary">Executive Summary</button>
                </li>
                <li class="nav-item" role="presentation">
                  <button class="nav-link" data-subtabs="overview" data-toggle="tab"
                    data-target="#overview">Overview</button>
                </li>
                <li class="nav-item" role="presentation">
                  <button class="nav-link" data-subtabs="study-design-p" data-toggle="tab"
                    data-target="#study-design-p">Study Design</button>
                </li>
                <li class="nav-item" role="presentation">
                  <button class="nav-link" data-subtabs="patient-characteristics-p" data-toggle="tab"
                    data-target="#patient-characteristics-p">Patient Characteristics</button>
                </li>
                <li class="nav-item" role="presentation">
                  <button class="nav-link" data-subtabs="efficacy-p" data-toggle="tab"
                    data-target="#efficacy-p">Efficacy</button>
                </li>
                <li class="nav-item" role="presentation">
                  <button class="nav-link" data-subtabs="safety-p" data-toggle="tab"
                    data-target="#safety-p">Safety</button>
                </li>
                <li class="nav-item" role="presentation">
                  <button class="nav-link" data-subtabs="additional-analysis" data-toggle="tab"
                    data-target="#additional-analysis">Additional Analyses</button>
                </li>
                <li class="nav-item" role="presentation">
                  <button class="nav-link" data-subtabs="abbreviations-and-references" data-toggle="tab"
                    data-target="#abbreviations-and-references">Abbreviations and References</button>
                </li>
              </ul>
            </div>
          </div>

          <div id="content">
            <div class="tab-content" id="myTabContent">
              <div class="tab-pane fade" id="executive-summary" aria-labelledby="executive-summary-tab">
                <div class="second_level_inner_tabs">
                  <ul class="nav nav-tabs w-100 d-flex justify-content-center" id="myTab_executive-summary"
                    role="tablist">
                    <li class="nav-item w-100" role="presentation">
                      <button class="nav-link second active" data-subtabs="page-1_executive-summary" data-toggle="tab"
                        data-target="#page-1">Page 1</button>
                    </li>
                    <li class="nav-item w-100" role="presentation">
                      <button class="nav-link second " data-subtabs="page-2_executive-summary" data-toggle="tab"
                        data-target="#page-2">Page 2</button>
                    </li>
                  </ul>

                  <div class="tab-content" id="myTab_executive-summary">
                    <div class="tab-pane show active" id="page-1" aria-labelledby="page-1-tab">
                      <div class="content-wrapper-section pt-3">
                        <div class="row">
                          <div class="col-12 mb-5 pb-1">
                            <div class="content-wrap h-100">
                              <ul class="cw-list text-left pl-3 mb-4">
                                <li class="pl-0">RYBREVANT (amivantamab-vmjw) is a low fucose, fully human IgG1-based
                                  bispecific antibody
                                  with immune cell-directing activity that targets <i>EGFR</i> mutations
                                  and <i>MET</i>
                                  mutations and amplifications in NSCLC.<sup>1</sup></li>
                                <li class="pl-0">LAZCLUZE (lazertinib) is a third-generation EGFR TKI.<sup>2</sup></li>
                              </ul>
                            </div>
                          </div>

                          <div class="col-12 mb-5 pb-1">
                            <div class="content-wrap h-100">
                              <div class="cw-heading text-center">
                                <h3 class="text-white">Guidelines</h3>
                              </div>
                              <div class="cw-content-box d-flex flex-column justify-content-center h-100">
                                <ul class="cw-list text-left pl-3 mb-4">
                                  <li class="pl-0">
                                    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC recommends
                                    amivantamab-vmjw (RYBREVANT) as a first-line therapy option in combination with lazertinib for <i>EGFR</i>
                                    Exon 19 deletion or Exon 21 L858R mutation discovered prior to first-line systemic therapy (NCCN Category 1, other recommended). If <i>EGFR</i> mutation is discovered during first-line systemic therapy,
                                    amivantamab-vmjw is recommended in combination with lazertinib (NCCN Category 2A).<sup>3</sup>
                                    <ul>
                                      <li>Prophylactic anticoagulation is recommended for amivantamab-vmjw + lazertinib at the time of initiation to prevent venous thromboembolic events.
                                      </li>
                                    </ul>
                                  </li>
                                  <li class="pl-0">
                                    National Comprehensive Cancer Network® (NCCN®) Categories of Evidence are defined as<sup>3</sup>:
                                    <ul>
                                      <li>Category 1 is based upon high-level evidence, and there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.
                                      </li>
                                      <li>Category 2A is based upon lower-level evidence, and there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.</li>
                                    </ul>
                                  </li>
                                  <li class="pl-0">NCCN Category of Preference of other recommended intervention is defined as other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes.<sup>3</sup></li>
                                  <li class="pl-0">Please refer to the NCCN Guidelines® for NSCLC at <a href="https://www.nccn.org">www.nccn.org</a> for current and complete recommendations for the use of amivantamab-vmjw in NSCLC.<sup>3</sup></li>
                                </ul>
                              </div>
                            </div>
                          </div>

                          <div class="col-12 pb-1">
                            <div class="content-wrap h-100">
                              <div class="cw-heading text-center">
                                <h3 class="text-white">MARIPOSA Study</h3>
                              </div>
                              <div class="cw-content-box d-flex flex-column justify-content-center h-100">
                                <ul class="cw-list text-left pl-3 mb-4">
                                  <li class="pl-0">
                                    MARIPOSA (NCT04487080) is an ongoing, phase 3, randomized, international study
                                    evaluating
                                    the efficacy and safety of RYBREVANT and lazertinib combination therapy (open-label,
                                    n=429)
                                    vs osimertinib (double-blind, n=429) vs lazertinib (double-blind, n=216) as
                                    first-line treatment
                                    in patients with <i>EGFR</i>-mutated (Exon19del or Exon 21 L858R substitution)
                                    locally advanced or
                                    metastatic NSCLC. The primary endpoint is PFS, based on BICR.<sup>2,4,5
                                    </sup>
                                    <ul>
                                      <li>At a median follow-up of 22 months, median PFS by BICR for RYBREVANT plus
                                        lazertinib
                                        vs osimertinib was 23.7 months (95% CI, 19.1-27.7) vs 16.6 months (95% CI, 14.8-18.5;
                                        HR, 0.70 [95% CI, 0.58-0.85]; <i>P</i>&lt;0.001).<sup>5</sup>
                                        <ul>
                                          <li>For patients with a history of brain metastases, median PFS by BICR for
                                            RYBREVANT plus
                                            lazertinib vs osimertinib was 18.3 months (95% CI, 16.6-23.7) vs 13 months
                                            (95% CI,
                                            12.2-16.4; HR, 0.69 [95% CI, 0.53-0.92]).<sup>5,6</sup></li>
                                        </ul>
                                      </li>
                                      <li>Grade ≥3 AEs occurred in 75% of patients treated with RYBREVANT plus
                                        lazertinib and
                                        43% of patients treated with osimertinib. VTE rates were increased with
                                        RYBREVANT plus
                                        lazertinib vs osimertinib. TRAEs leading to discontinuation of all agents
                                        occurred in 10% of
                                        patients treated with RYBREVANT plus lazertinib and in 3% of patients treated
                                        with
                                        osimertinib.<sup>5</sup></li>
                                      <li>At a median long-term follow-up of 31.1 months, median OS for RYBREVANT plus
                                        lazertinib
                                        vs osimertinib was NE vs 37.3 months (95% CI, 32.5-NE; HR, 0.77 [95% CI,
                                        0.61-0.96];
                                        <i>P</i>=0.019<sup>a</sup>).<sup>7</sup>
                                        <ul>
                                          <li>For patients with a history of brain metastases, median icPFS for
                                            RYBREVANT plus
                                            lazertinib vs osimertinib was 24.9 months (95% CI, 20.1-34.7) vs 22.2 months
                                            (95% CI,
                                            18.4-26.1; HR, 0.82 [95% CI, 0.62-1.09];<i>P</i>=0.165<sup>a</sup>).</li>
                                        </ul>
                                      </li>
                                    </ul>
                                  </li>
                                </ul>
                              </div>
                            </div>
                          </div>

                          <div class="col-12">
                            <p class="footnote mb-5">
                              Note: AE, adverse event; BICR, blinded independent central review; CI,
                              confidence interval;
                              <i>EGFR</i>, epidermal growth factor receptor; Exon19del,
                              Exon 19 deletion; HR, hazard
                              ratio; icPFS, intracranial PFS; IgG1, immunoglobulin G1; <i>MET</i>,
                              mesenchymal-epithelial transition; NCCN, National Comprehensive Cancer Network; NE, not estimable;
                              NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival;
                              TKI, tyrosine kinase inhibitor;
                              TRAE, treatment-related AE; VTE, venous thromboembolism.<br>
                              <sup>a</sup>The endpoint was not part of formal statistical testing; the <i>P</i>-value
                              displayed is nominal.
                            </p>
                          </div>
                        </div>
                      </div>
                    </div>

                    <div class="tab-pane " id="page-2" aria-labelledby="page-2-tab">
                      <div class="content-wrapper-section pt-3">
                        <div class="row">
                          <div class="col-12 pb-1">
                            <div class="content-wrap h-100">
                              <div class="cw-heading text-center">
                                <h3 class="text-white">MARIPOSA Study</h3>
                              </div>
                              <div class="cw-content-box d-flex flex-column justify-content-center h-100">
                                <ul class="cw-list text-left pl-3 mb-4">
                                  <li class="pl-0">
                                    A secondary analysis in high-risk patients reported<sup>6,8</sup>:
                                    <ul>
                                      <li>For patients with high-risk disease (≥1 high-risk feature at baseline), median
                                        PFS by BICR for
                                        RYBREVANT plus lazertinib (n=280) vs osimertinib (n=288) was 20.3 months (95%
                                        CI, 18.2-24.0) vs 15 months (95% CI, 13.0-16.8; HR, 0.72 [95% CI, 0.58-0.90];
                                        <i>P=</i>0.004;
                                        <i>P</i>-values in these secondary analyses are nominal).
                                        <ul>
                                          <li>
                                            Baseline liver metastases: HR, 0.58 (95% CI, 0.37-0.91); <i>P</i>=0.017;
                                            <i>TP53</i> co-mutations: HR, 0.65 (95% CI, 0.48-0.87); <i>P</i>=0.003;
                                            detectable baseline <i>EGFR</i>-mutated ctDNA:
                                            HR, 0.68 (95% CI, 0.53-0.86); <i>P</i>=0.002; without <i>EGFR</i>-mutated
                                            ctDNA clearance at C3D1:
                                            HR, 0.49 (95% CI, 0.27-0.87); <i>P</i>=0.015.
                                          </li>
                                        </ul>
                                      </li>
                                    </ul>
                                  </li>
                                  <li class="pl-0">
                                    An Asian subgroup analysis reported<sup>9</sup>:
                                    <ul>
                                      <li>At a median follow-up of 22.5 months, median PFS by BICR for RYBREVANT plus
                                        lazertinib vs
                                        osimertinib was 27.5 months (95% CI, 20.3-NE) vs 18.3 months (95% CI, 15.8-20.2;
                                        HR, 0.65 [95% CI, 0.50-0.83]; <i>P</i>&lt;0.001<sup>a</sup>).</li>
                                      <li>EGFR- and MET-related AEs were increased with RYBREVANT plus lazertinib vs
                                        osimertinib
                                        and were mostly grade 1-2. VTE rates were also increased with RYBREVANT plus
                                        lazertinib vs
                                        osimertinib and were mostly grade 1-2. There were no grade 4-5 VTEs.</li>
                                    </ul>
                                  </li>
                                  <li class="pl-0">
                                    A post-progression and safety analysis reported<sup>10</sup>:
                                    <ul>
                                      <li>At a median follow-up of 22 months, in the RYBREVANT plus lazertinib vs
                                        osimertinib arm,
                                        35% (147/421) vs 47% (203/428) of patients had PD, median TTD was 26.2 (95% CI,
                                        22.1-NE) vs 23 months (95% CI, 20.3-25.3; HR, 0.88; 95% CI, 0.73-1.07;
                                        <i>P=</i>0.21<sup>a</sup>), and
                                        median TTST was NE (95% CI, 26.8-NE) vs 24.1 months (95% CI, 22-29; HR, 0.82;
                                        95% CI,
                                        0.66-1; <i>P=</i>0.05<sup>a</sup>).
                                      </li>
                                      <li>Key AEs occurred within the first 4 months of treatment. Late onset AEs were
                                        uncommon.</li>
                                    </ul>
                                  </li>
                                  <li class="pl-0">
                                    An exploratory analysis for RYBREVANT dose interruptions in the first 4 months of
                                    RYBREVANT exposure reported<sup>11</sup>:
                                    <ul>
                                      <li>At a median follow-up of 22 months, median PFS in patients with (n=188) vs
                                        without (n=190) RYBREVANT dose interruptions after the first 4 months of RYBREVANT
                                        exposure was 27 months (95% CI, 20.3-NE) vs 25.7 months (95% CI, 22.2-NE). No significant
                                        association was
                                        found between dose interruptions and PFS after 4 months of RYBREVANT exposure
                                        (HR,
                                        1.06; 95% CI, 0.73-1.44).</li>
                                      <li>Key AEs occurred most frequently during the first 4 months and declined over
                                        the next
                                        4 months.
                                      </li>
                                    </ul>
                                  </li>
                                  <li class="pl-0">
                                    An exploratory analysis for lazertinib vs osimertinib reported<sup>12</sup>:
                                    <ul>
                                      <li>At a median follow-up of 22 months, median PFS by BICR for lazertinib vs
                                        osimertinib was
                                        18.5 months (95% CI, 14.8-20.1) vs 16.6 months (95% CI, 14.8-18.5; HR, 0.98 [95%
                                        CI,
                                        0.79-1.22]).</li>
                                      <li>Most TEAEs were grade 1-2 in severity for lazertinib and osimertinib.</li>
                                    </ul>
                                  </li>
                                  <li class="pl-0">
                                    A ctDNA analysis for acquired resistance reported<sup>13</sup>:
                                    <ul>
                                      <li>In the RYBREVANT plus lazertinib vs osimertinib arm, 4.4% vs 13.6% of patients
                                        had <i>MET</i>
                                        amplifications (<i>P</i>=0.017) and 0.9% vs 7.9% of patients had secondary
                                        <i>EGFR</i> resistance
                                        mutations (<i>P</i>=0.014).
                                      </li>
                                    </ul>
                                  </li>
                                  <li class="pl-0">
                                    A patient-relevant outcome analysis for TTSP and PROs reported<sup>14</sup>:
                                    <ul>
                                      <li>At a median follow-up of 22 months, median TTSP for RYBREVANT plus lazertinib
                                        vs
                                        osimertinib was NE vs 29.3 months (95% CI, 25.3-NE; HR, 0.72 [95% CI,
                                        0.57-0.91];
                                        <i>P</i>=0.005).
                                      </li>
                                      <li>In the RYBREVANT plus lazertinib vs osimertinib arm, no meaningful changes
                                        from baseline
                                        were observed in patient-reported functioning; patient-reported total symptom
                                        scores and
                                        individual lung cancer-associated symptom scores were comparable.</li>
                                    </ul>
                                  </li>
                                </ul>
                              </div>
                            </div>
                          </div>

                          <div class="col-12">
                            <p class="footnote mb-5">
                              Note: AE, adverse event; BICR, blinded independent central review; C, cycle; CI, confidence
                              interval; ctDNA, circulating
                              tumor DNA; D, day; EGFR, epidermal growth factor receptor; Exon19del, Exon 19 deletion; HR, hazard
                              ratio; MET, mesenchymal-
                              epithelial transition; NE, not estimable; NSCLC, non-small cell lung cancer; PD,
                              progressive disease; PFS, progression-free
                              survival; PRO, patient-reported outcome; TEAE, treatment-emergent AE; TTD, time to
                              treatment discontinuation;
                              TTSP, time to subsequent progression; TTST, time to subsequent therapy; VTE, venous
                              thromboembolism.<br>
                              <sup>a</sup>The endpoint was exploratory and not part of hierarchical hypothesis testing.
                              This
                              endpoint was not adjusted for multiple comparisons. Therefore, the <i>P</i>-value
                              displayed is
                              nominal, and statistical significance has not been established.
                            </p>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>

              <div class="tab-pane fade" id="overview" aria-labelledby="overview-tab">
                <div class="content-wrapper-section pt-3">
                  <div class="row align-items-stretch">
                    <div class="col-12 col-lg-4 mb-5 pb-1">
                      <div class="content-wrap h-100">
                        <div class="cw-heading text-center">
                          <h3 class="text-white">MARIPOSA<sup>2,4,5</sup></h3>
                        </div>
                        <div class="cw-content-box">
                          <p class="cw-para text-center pr-md-3 pl-md-3">
                            MARIPOSA (NCT04487080) is an
                            ongoing, phase 3, randomized study
                            designed to evaluate the efficacy
                            and safety of RYBREVANT and
                            lazertinib combination therapy (open-label, n=429) vs osimertinib (double-blind, n=429) vs lazertinib (double-
                            blind, n=216) as first-line treatment
                            in patients with <i>EGFR</i>-mutated (Exon19del or
                            Exon 21 L858R substitution) locally
                            advanced or metastatic NSCLC.
                            <br><br>
                            N=1074
                          </p>
                        </div>
                      </div>
                    </div>

                    <div class="col-12 col-lg-4 mb-5 pb-1">
                      <div class="content-wrap h-100">
                        <div class="cw-heading text-center">
                          <h3 class="text-white">Key Eligibility Criteria<sup>2,4,5</sup></h3>
                        </div>
                        <div class="cw-content-box h-100 d-flex flex-column justify-content-between">
                          <div class="inner-content">
                            <div class="row">
                              <div class="col-12">
                                <ul class="cw-list text-left pl-3 mb-4">
                                  <li class="pl-0">Age ≥18 years</li>
                                  <li class="pl-0">Locally advanced or metastatic NSCLC</li>
                                  <li class="pl-0">Treatment naïve for advanced disease</li>
                                  <li class="pl-0"><i>EGFR</i> Exon19del or Exon 21 L858R substitution</li>
                                  <li class="pl-0">ECOG PS 0 or 1</li>
                                </ul>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>

                    <div class="col-12 col-lg-4 mb-5 pb-1">
                      <div class="content-wrap h-100">
                        <div class="cw-heading text-center">
                          <h3 class="text-white">Study Design<sup>2,4,5</sup></h3>
                        </div>
                        <div class="cw-content-box h-100 d-flex flex-column justify-content-between">
                          <div class="inner-content">
                            <div class="text-center">
                              <img src="assets/images/mariposa-study-design-overview-mobile.svg" alt=""
                                class="m-auto mb-2 w-100 study-design-image d-md-none">
                              <img src="assets/images/mariposa-study-design-overview-tablet.svg" alt=""
                                class="m-auto mb-2 w-100 study-design-image d-none d-md-block d-lg-none">
                              <img src="assets/images/mariposa-study-design-overview-desktop.svg" alt=""
                                class="m-auto mb-2 w-100 study-design-image d-none d-lg-block" style="max-width: 300px;">
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>

                    <div class="col-12 col-lg-4 mb-5 mb-lg-0 pb-1">
                      <div class="content-wrap h-100">
                        <div class="cw-heading text-center">
                          <h3 class="text-white">Efficacy Results<sup>5,7</sup></h3>
                        </div>
                        <div class="cw-content-box h-100 d-flex flex-column justify-content-between ">
                          <div class="inner-content text-center">
                            <div class="row">
                              <div class="col-12 col-lg-12">
                                <ul class="cw-list text-left pl-3 mb-0">
                                  <li class="pl-0 pr-3">
                                    At a median follow-up of 22 months,
                                    median PFS by BICR was
                                    23.7 months (95% CI, 19.1-27.7)
                                    for RYBREVANT plus lazertinib and
                                    16.6 months (95% CI, 14.8-18.5)
                                    for Osimertinib (HR, 0.70; 95% CI,
                                    0.58-0.85; <i>P</i>&lt;0.001).<sup>5</sup>
                                    <ul>
                                      <li>The 18-month PFS for
                                        RYBREVANT plus lazertinib vs
                                        osimertinib was 60% (95% CI,
                                        55-64) vs 48% (95% CI, 43-53).</li>
                                      <li>The 24-month PFS for
                                        RYBREVANT plus lazertinib vs
                                        osimertinib was 48% (95% CI,
                                        42-54) vs 34% (95% CI, 28-39).</li>
                                    </ul>
                                  </li>
                                  <li class="pl-0 pr-3">Median PFS was 18.5 months
                                    (95% CI, 14.8-20.1) for Lazertinib monotherapy.<sup>5</sup></li>
                                  <li class="pl-0 pr-3">At a median long-term follow-up
                                    of 31.1 months, median OS was
                                    NE for RYBREVANT plus
                                    lazertinib and 37.3 months
                                    (95% CI, 32.5-NE) for
                                    osimertinib (HR, 0.77; 95% CI,
                                    0.61-0.96;
                                    <i>P</i>=0.019<sup>d</sup>).<sup>7</sup>
                                  </li>
                                </ul>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>

                    <div class="col-12 col-lg-4 mb-5 mb-lg-0 pb-1">
                      <div class="content-wrap h-100">
                        <div class="cw-heading text-center">
                          <h3 class="text-white">Safety Results<sup>5</sup></h3>
                        </div>
                        <div class="cw-content-box h-100 d-flex flex-column justify-content-between ">
                          <div class="inner-content text-center">
                            <div class="row">
                              <div class="col-12 col-lg-12">
                                <ul class="cw-list text-left pl-3 mb-0">
                                  <li class="pl-0 pr-3">
                                    TRAEs leading to
                                    discontinuation of all
                                    agents occurred in
                                    10% of patients
                                    treated with
                                    RYBREVANT plus
                                    lazertinib and 3%
                                    with osimertinib.
                                  </li>
                                  <li class="pl-0 pr-3">
                                    Grade ≥3 AEs were
                                    75% vs 43% in the
                                    RYBREVANT plus
                                    lazertinib vs
                                    osimertinib arm.
                                  </li>
                                  <li class="pl-0 pr-3">
                                    VTE rates were higher
                                    with RYBREVANT plus
                                    lazertinib vs
                                    osimertinib.
                                  </li>
                                </ul>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>

                    <div class="col-12 col-lg-4 mb-5 mb-lg-0 pb-1">
                      <div class="content-wrap  h-100">
                        <div class="cw-heading text-center">
                          <h3 class="text-white">Additional Analyses<sup>6,8-14</sup></h3>
                        </div>
                        <div class="cw-content-box h-100 d-flex flex-column justify-content-between ">
                          <div class="inner-content text-center">
                            <div class="row">
                              <div class="col-12 col-lg-12">
                                <ul class="cw-list text-left pl-3 mb-0">
                                  <li class="pl-0 pr-3">
                                    Secondary analysis of high-risk patients<sup>6,8</sup>: HR (95% CI) for
                                    median PFS: 0.72 (0.58-0.90; <i>P</i>=0.004) for RYBREVANT
                                    plus lazertinib vs osimertinib.
                                  </li>
                                  <li class="pl-0 pr-3">
                                    Subgroup analysis in Asian patients<sup>9</sup>: HR (95% CI) for
                                    median PFS: 0.65 (0.50-0.83; <i>P</i>&lt;0.001<sup>d</sup>) for RYBREVANT
                                    plus lazertinib vs osimertinib. Safety profile: comparable to
                                    the overall MARIPOSA study.
                                  </li>
                                  <li class="pl-0 pr-3">
                                    Post-progression and safety analysis<sup>10</sup>: HR (95% CI) for
                                    median TTD and TTST: 0.88 (0.73-1.07; <i>P</i>=0.21<sup>d</sup>) and 0.82
                                    (0.66-1; <i>P</i>=0.05<sup>d</sup>) for RYBREVANT plus lazertinib vs
                                    osimertinib. Key AEs occurred within the first 4 months;
                                    late onset AEs were uncommon.
                                  </li>
                                  <li class="pl-0 pr-3">
                                    Exploratory analyses<sup>11,12</sup>:
                                    <ul>
                                      <li>Dose interruption: median PFS was 27.5 vs 25.7 months
                                        in patients with vs without RYBREVANT dose interruption
                                        after 4 months. The prevalence of key AEs was
                                        comparable in patients with and without RYBREVANT dose
                                        interruptions at all time points.<sup>11</sup></li>
                                      <li>Lazertinib vs osimertinib: median PFS was 18.5 vs
                                        16.6 months. Most TEAEs were grade 1-2 in
                                        severity.<sup>12</sup></li>
                                    </ul>
                                  </li>
                                  <li class="pl-0 pr-3">
                                    ctDNA analysis for acquired resistance<sup>13</sup>: RYBREVANT plus
                                    lazertinib vs osimertinib: <i>MET</i> amplifications in 4.4% vs
                                    13.6% (<i>P</i>=0.017); secondary <i>EGFR</i> resistance mutations
                                    in 0.9% vs 7.9% of patients (<i>P</i>=0.014), respectively.
                                  </li>
                                  <li class="pl-0 pr-3">
                                    Patient-relevant outcome analysis<sup>14</sup>: RYBREVANT plus
                                    lazertinib vs osimertinib: HR (95% CI) for median TTSP of
                                    0.72 (0.57-0.91; <i>P</i>=0.005); no meaningful changes from
                                    baseline in patient-reported functioning; and comparable
                                    patient-reported total symptom scores and individual lung cancer-associated symptom scores.
                                  </li>
                                </ul>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>

                    <div class="col-12">
                      <p class="footnote mb-5">
                        Note: AE, adverse event; BICR, blinded independent central review; C, cycle; CI,
                        confidence interval; D, day;
                        ECOG PS, Eastern Cooperative Oncology Group performance status; <i>EGFR</i>, epidermal growth factor
                        receptor;
                        Exon19del, Exon 19 deletion; HR, hazard ratio; IV, intravenous; NE, not estimable; NSCLC,
                        non-small cell lung cancer;
                        OS, overall survival; PFS, progression-free survival; PO, orally; QD, once daily; Q2W, every 2
                        weeks; QW, once weekly;
                        R, randomization; TEAE, treatment-emergent AE; TRAE, treatment-related AE; TTD, time to
                        treatment discontinuation;
                        TTSP, time to subsequent progression; TTST, time to subsequent therapy; VTE, venous
                        thromboembolism.<br><br>
                        <sup>a</sup>In patients &lt;80 kg.<br>
                        <sup>b</sup>In patients ≥80 kg.<br>
                        <sup>c</sup>The first infusion was split over 2 days (350 mg on C1D1, and the remainder on
                        C1D2).<br>
                        <sup>d</sup>The endpoint was not part of formal statistical testing; the <i>P</i>-value
                        displayed is nominal.
                      </p>
                    </div>
                  </div>
                </div>
              </div>

              <div class="tab-pane fade" id="study-design-p" aria-labelledby="study-design-p-tab">
                <div class="content-wrapper-section pt-3">
                  <div class="row align-items-stretch">
                    <div class="col-12 mb-5 pb-1">
                      <ul class="cw-list text-left pl-3 mb-4">
                        <li class="pl-0">
                          MARIPOSA (NCT04487080) is an ongoing, phase 3, randomized study designed to evaluate the
                          efficacy
                          and safety of RYBREVANT and lazertinib combination therapy (open-label, n=429) vs osimertinib
                          (double-blind, n=429) vs lazertinib (double-blind, n=216) as first-line treatment in patients
                          with <i>EGFR</i>-mutated (Exon19del or Exon 21 L858R substitution) locally advanced or metastatic NSCLC.<sup>2,4,5</sup>
                        </li>
                      </ul>
                    </div>

                    <div class="col-12 mb-5 pl-md-5 pb-1">
                      <h3 class="d-none d-md-block modal-title table-header  font-weight-bold mb-3">
                        MARIPOSA Study Design<sup>2,4,5,14</sup>
                      </h3>

                      <div class="row max-width-1200">
                        <div class="col-12 left-wrapper">
                          <img src="assets/images/scroll-band-img.svg" alt="" class="w-100 mb-3 d-md-none">
                          <div class="table_overflow_scroll mb-5">
                            <img src="assets/images/mariposa-studydesign-tabletmobile.svg" alt=""
                              class="m-auto mb-2 d-md-none max-width-image">
                            <img src="assets/images/mariposa-studydesign-tabletmobile.svg" alt=""
                              class="m-auto mb-2 d-none d-md-block d-xl-none sd-image">
                            <img src="assets/images/mariposa-studydesign-desktop.svg" alt=""
                              class="m-auto mb-2 w-100 d-none d-xl-block sd-image">
                          </div>
                        </div>

                        <div class="d-md-flex justify-content-between col-12 my-4">
                          <div class="col-lg-5 col-md-5 col-12 content-wrap pt-0 px-0 mr-lg-5 mb-md-0 mb-4">
                            <h3 style="border-top-left-radius: 20px; border-top-right-radius: 20px;"
                              class="text-white bg-gray7 text-center p-2">
                              Primary Endpoint
                            </h3>

                            <ul class="cw-list text-left pl-3 mt-4 ml-4 mr-3">
                              <li class="pl-0">PFS by BICR per RECIST v1.1 in Arm A vs Arm B</li>
                            </ul>
                          </div>

                          <div class="col-lg-6 col-md-5 col-12 content-wrap pt-0 px-0 ml-lg-5">
                            <h3 style="border-top-left-radius: 20px; border-top-right-radius: 20px;"
                              class="text-white bg-gray7 text-center p-2">
                              Secondary Endpoints
                            </h3>

                            <strong class="pl-3">Arm A vs Arm B</strong>
                            <ul class="grid-list cw-list text-left pl-3 mt-4 mx-4 mb-0">
                              <li class="pl-0">OS<sup>e</sup></li>
                              <li class="pl-0 text-nowrap">Symptomatic PFS<sup>f</sup></li>
                              <li class="pl-0">PRO<sup>h</sup></li>
                              <li class="pl-0">ORR</li>
                              <li class="pl-0">icPFS</li>
                              <li class="pl-0">DOR</li>
                              <li class="pl-0 mb-0">Safety</li>
                              <li class="pl-0">PFS2</li>
                              <li class="pl-0">TTSP<sup>g</sup></li>
                            </ul>
                          </div>
                        </div>

                        <div class="col-12">
                          <p class="footnote mb-5">
                            MARIPOSA (ClinicalTrials.gov Identifier: NCT04487080) enrollment period: November 2020 to
                            May 2022; data cutoff: August 11, 2023.<br>
                            <sup>a</sup>In patients &lt;80 kg.<br>
                            <sup>b</sup>In patients ≥80 kg.<br>
                            <sup>c</sup>The first infusion was split over 2 days (350 mg on C1D1, and the remainder
                            on C1D2).<br>
                            <sup>d</sup>Serial brain MRIs were required for all patients. Baseline brain MRI was
                            required for all patients and performed ≤28 days
                            prior to randomization; patients who could not have MRIs were allowed to have CT scans.
                            Brain scan frequency was every
                            8 weeks for the first 30 months and then every 12 weeks thereafter for patients with a
                            history of brain metastasis and
                            every 24 weeks for patients with no history of brain metastasis. Extracranial tumor
                            assessments were conducted every 8
                            weeks for the first
                            30 months and then every 12 weeks until disease progression is confirmed by BICR.<br>
                            <sup>e</sup>Statistical hypothesis testing included PFS and then OS.<br>
                            <sup>f</sup>This secondary endpoint will be presented at a future congress.<br>
                            <sup>g</sup>Also included death.<br>
                            <sup>h</sup>Assessed using EORTC-QLQ-C30 (threshold of 10-point difference for a clinically
                            meaningful change) and NSCLC-SAQ.
                          </p>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>

              <div class="tab-pane fade" id="patient-characteristics-p" aria-labelledby="patient-characteristics-p-tab">
                <div class="content-wrapper-section pt-3">
                  <div class="row align-items-stretch">
                    <div class="col-12 mb-5 pb-1">
                      <div class="cw-content-box d-flex flex-column justify-content-center h-100">
                        <ul class="cw-list text-left pl-3 mb-4">
                          <li class="pl-0">
                            A total of 1074 patients were randomized to receive RYBREVANT plus lazertinib (n=429),
                            osimertinib (n=429), or lazertinib (n=216).<sup>5</sup></li>
                        </ul>
                      </div>
                    </div>

                    <div class="col-12 mb-5 pb-1">
                      <h3 class="modal-title table-header table_header_text font-weight-bold">
                        Demographics and Baseline Disease Characteristics<sup>5,15</sup>
                      </h3>

                      <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                      <div class="table_overflow_scroll">
                        <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                          <thead>
                            <tr>
                              <th scope="col" class="w-25">Characteristic</th>
                              <th scope="col" class="text-center table-header bg-red text-white w-25">
                                RYBREVANT
                                <br>+ Lazertinib
                                <br>(n=429)
                              </th>
                              <th scope="col" class="text-center table-header bg-dark-Gray text-white w-25">
                                Osimertinib
                                <br>(n=429)
                              </th>
                              <th scope="col" class="text-center table-header bg-blue text-white w-25">
                                Lazertinib
                                <br>(n=216)
                              </th>
                            </tr>
                          </thead>
                          <tbody>
                            <tr>
                              <td>Median age, years (range)</td>
                              <td class="text-center">64 (25-88)</td>
                              <td class="text-center">63 (28-88)</td>
                              <td class="text-center">63 (31-87)</td>
                            </tr>
                            <tr>
                              <td>Female, n (%)</td>
                              <td class="text-center">275 (64)</td>
                              <td class="text-center">251 (59)</td>
                              <td class="text-center">136 (63)</td>
                            </tr>
                            <tr>
                              <td class="border-right-0">Race,<sup>a</sup> n (%)</td>
                              <td class="border-right-0 border-left-0"></td>
                              <td class="border-right-0 border-left-0"></td>
                              <td class="border-left-0"></td>
                            </tr>
                            <tr>
                              <td class="pl-4">Asian</td>
                              <td class="text-center">250 (58)</td>
                              <td class="text-center">251 (59)</td>
                              <td class="text-center">128 (59)</td>
                            </tr>
                            <tr>
                              <td class="pl-4">White</td>
                              <td class="text-center">164 (38)</td>
                              <td class="text-center">165 (38)</td>
                              <td class="text-center">79 (37)</td>
                            </tr>
                            <tr>
                              <td class="pl-4">American Indian or Alaska Native</td>
                              <td class="text-center">7 (2)</td>
                              <td class="text-center">7 (2)</td>
                              <td class="text-center">-</td>
                            </tr>
                            <tr>
                              <td class="pl-4">Black or African American</td>
                              <td class="text-center">4 (1)</td>
                              <td class="text-center">3 (1)</td>
                              <td class="text-center">-</td>
                            </tr>
                            <tr>
                              <td class="pl-4">Native Hawaiian or Pacific Islander</td>
                              <td class="text-center">1 (0.2)</td>
                              <td class="text-center">1 (0.2)</td>
                              <td class="text-center">-</td>
                            </tr>
                            <tr>
                              <td class="pl-4">Multiple</td>
                              <td class="text-center">1 (0.2)</td>
                              <td class="text-center">1 (0.2)</td>
                              <td class="text-center"></td>
                            </tr>
                            <tr>
                              <td class="pl-4">Unknown</td>
                              <td class="text-center">2 (0.5)</td>
                              <td class="text-center">1 (0.2)</td>
                              <td class="text-center">-</td>
                            </tr>
                            <tr>
                              <td>ECOG PS 0, n (%)</td>
                              <td class="text-center">141 (33)</td>
                              <td class="text-center">149 (35)</td>
                              <td class="text-center">76 (35)</td>
                            </tr>
                            <tr>
                              <td>ECOG PS 1, n (%)</td>
                              <td class="text-center">288 (67)</td>
                              <td class="text-center">280 (65)</td>
                              <td class="text-center">140 (65)</td>
                            </tr>
                            <tr>
                              <td>History of smoking, n (%)</td>
                              <td class="text-center">130 (30)</td>
                              <td class="text-center">134 (31)</td>
                              <td class="text-center">73 (34)</td>
                            </tr>
                            <tr>
                              <td>History of brain metastases, n (%)</td>
                              <td class="text-center">178 (41)</td>
                              <td class="text-center">172 (40)</td>
                              <td class="text-center">86 (40)</td>
                            </tr>
                            <tr>
                              <td class="border-right-0"><i>EGFR</i> mutation,<sup>b</sup> n (%)</td>
                              <td class="border-right-0 border-left-0"></td>
                              <td class="border-right-0 border-left-0"></td>
                              <td class="border-left-0"></td>
                            </tr>
                            <tr>
                              <td class="pl-4">Exon19del</td>
                              <td class="text-center">258 (60)</td>
                              <td class="text-center">257 (60)</td>
                              <td class="text-center">131 (61)</td>
                            </tr>
                            <tr>
                              <td class="pl-4">Exon 21 L858R</td>
                              <td class="text-center">172 (40)</td>
                              <td class="text-center">172 (40)</td>
                              <td class="text-center">85 (39)</td>
                            </tr>
                            <tr>
                              <td>Adenocarcinoma subtype, n (%)</td>
                              <td class="text-center">417 (97)</td>
                              <td class="text-center">415 (97)</td>
                              <td class="text-center">212 (98)</td>
                            </tr>
                            <tr>
                              <td colspan="4" class="position-static">
                                <p class="footnote mt-0">
                                  <sup>a</sup>Race or ethnic group was reported by the patients.<br>
                                  <sup>b</sup>One patient in the RYBREVANT + lazertinib arm had both Exon19del and Exon
                                  21 L858R.
                                </p>
                              </td>
                            </tr>
                          </tbody>
                        </table>
                      </div>
                    </div>
                  </div>
                </div>
              </div>

              <div class="tab-pane fade" id="efficacy-p" aria-labelledby="efficacy-tab">
                <div class="second_level_inner_tabs">
                  <ul class="nav nav-tabs w-100 d-flex justify-content-center" id="myTab_efficacy-p" role="tablist">

                    <li class="nav-item w-100" role="presentation">
                      <button class="nav-link second active" data-subtabs="primary-endpoints_efficacy-p"
                        data-toggle="tab" data-target="#primary-endpoints">Primary Endpoint</button>
                    </li>

                    <li class="nav-item w-100" role="presentation">
                      <button class="nav-link second " data-subtabs="secondary-endpoints_efficacy-p" data-toggle="tab"
                        data-target="#secondary-endpoints">Secondary Endpoints</button>
                    </li>
                    <li class="nav-item w-100" role="presentation">
                      <button class="nav-link second " data-subtabs="long-term-analysis_efficacy-p" data-toggle="tab"
                        data-target="#long-term-analysis">Long-term Analysis</button>
                    </li>
                  </ul>

                  <div class="tab-content" id="myTab_efficacy-p">
                    <div class="tab-pane show active" id="primary-endpoints" aria-labelledby="primary-endpoints-tab">
                      <div class="content-wrapper-section mb-5">
                        <div class="row">
                          <div class="col-12 mb-5 pb-1">
                            <ul class="cw-list text-left pl-3 mb-4">
                              <li class="pl-0">Efficacy was evaluated at a median follow-up of 22 months (data cutoff:
                                August 11, 2023).<sup>5</sup></li>
                              <li class="pl-0">
                                Median PFS by BICR was 23.7 months (95% CI, 19.1-27.7) for RYBREVANT plus lazertinib and
                                16.6 months (95% CI, 14.8-18.5) for osimertinib (HR, 0.70 [95% CI, 0.58-0.85];
                                <i>P</i>&lt;0.001).<sup>5</sup>
                                <ul>
                                  <li>The 12-month PFS for RYBREVANT plus lazertinib vs osimertinib was 73% (95% CI,
                                    69-77) vs
                                    65% (95% CI, 60-69).</li>
                                  <li>The 18-month PFS for RYBREVANT plus lazertinib vs osimertinib was 60% (95% CI,
                                    55-64) vs
                                    48% (95% CI, 43-53).</li>
                                  <li>The 24-month PFS for RYBREVANT plus lazertinib vs osimertinib was 48% (95% CI,
                                    42-54) vs
                                    34% (95% CI, 28-39).</li>
                                </ul>
                              </li>
                              <li class="pl-0">Median PFS was 18.5 months (95% CI, 14.8-20.1) for lazertinib
                                monotherapy.<sup>5</sup></li>
                              <li class="pl-0">Median extracranial PFS (defined as time from randomization to disease
                                progression as detected
                                by extracranial scans or death) by BICR was 27.5 months (95% CI, 22.1-NE) for RYBREVANT
                                plus
                                lazertinib and 18.4 months (95% CI, 16.5-20.2) for osimertinib (HR, 0.68 [95% CI,
                                0.55-0.83].<sup>5</sup></li>
                              <li class="pl-0">For patients with a history of brain metastases, median PFS by BICR was
                                18.3 months (95% CI,
                                16.6-23.7) for RYBREVANT plus lazertinib and 13 months (95% CI, 12.2-16.4) for
                                osimertinib
                                (HR, 0.69 [95% CI, 0.53-0.92]). For patients without a history of brain metastases,
                                median PFS
                                by BICR was 27.5 months (95% CI, 22.1-NE) for RYBREVANT plus lazertinib and 19.9 months
                                (95% CI, 16.6-22.9) for osimertinib (HR, 0.69 [95% CI, 0.53-0.89]).<sup>5</sup></li>
                            </ul>
                          </div>

                          <div class="col-12 mb-5 pb-1">
                            <div class="popup-btn-wrapper text-center mt-4 pt-3">
                              <button type="button" class="btn popup-btn" data-toggle="modal"
                                data-target="#efficacy-primary-popup">
                                <h3>
                                  PFS By BICR Across Predefined Subgroups:
                                  <br>
                                  RYBREVANT Plus Lazertinib vs Osimertinib
                                </h3>
                              </button>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>

                    <div class="tab-pane " id="secondary-endpoints" aria-labelledby="secondary-endpoints-tab">
                      <div class="content-wrapper-section mb-5">
                        <div class="row">
                          <div class="col-12">
                            <ul class="cw-list text-left pl-3 mb-4">
                              <li class="pl-0">Median DOR by BICR among confirmed responders for RYBREVANT plus
                                lazertinib vs osimertinib
                                was 25.8 months (95% CI, 20.1-NE) vs 16.8 months (95% CI, 14.8-18.5).<sup>5</sup>
                              </li>
                              <li class="pl-0">
                                At a median follow-up of 22 months, median PFS2 estimates were not reliable (HR, 0.75
                                [95% CI,
                                0.58-0.98]; <i>P</i>=0.03).<sup>5,a</sup>
                                <ul>
                                  <li>In the RYBREVANT plus lazertinib arm, 98 patients started subsequent therapy, with
                                    48 patients
                                    receiving EGFR TKI monotherapy and 32 patients receiving chemotherapy alone. In the
                                    osimertinib arm, 137 patients started subsequent therapy, with 37 patients receiving
                                    EGFR TKI
                                    monotherapy and 53 patients receiving chemotherapy alone.</li>
                                </ul>
                              </li>
                              <li class="pl-0">There were 214 deaths in the study at the time of the prespecified
                                interim OS analysis
                                (~390 projected deaths for the final OS analysis). Medians were NE (HR, 0.80 [95% CI,
                                0.61-1.05]).<sup>5</sup></li>
                            </ul>

                            <h3 class="mb-4 table_header_text ">
                              ORR and Best Response by BICR<sup>5</sup>
                            </h3>
                            <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                            <div class="table_overflow_scroll">
                              <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                                <thead>
                                  <tr>
                                    <th scope="col" class="d-lg-none px-3" style="width: 0%;">BICR-Assessed<br>Response<sup>a</sup></th>
                                    <th scope="col" class="d-none d-lg-table-cell w-25">BICR-Assessed Response<sup>a</sup></th>
                                    <th scope="col" class="text-center table-header bg-red text-white w-25">
                                      RYBREVANT + Lazertinib
                                      <br>
                                      (n=429)
                                    </th>
                                    <th scope="col" class="text-center table-header bg-dark-Gray text-white w-25">
                                      Osimertinib
                                      <br>
                                      (n=429)
                                    </th>
                                  </tr>
                                </thead>
                                <tbody>
                                  <tr>
                                    <td class="border-right-0">ORR, % (95% CI)</td>
                                    <td class="border-right-0 border-left-0"></td>
                                    <td class="border-left-0"></td>
                                  </tr>
                                  <tr>
                                    <td class="pl-4" rowspan="2" style="z-index: 1;">All responders</td>
                                    <td class="text-center">86 (83-89)</td>
                                    <td class="text-center">85 (81-88)</td>
                                  </tr>
                                  <tr>
                                    <td class="d-none"></td>
                                    <td class="text-center" colspan="2">Odds ratio: 1.15 (0.78-1.70)<sup>b</sup></td>
                                  </tr>
                                  <tr>
                                    <td class="pl-4">Confirmed responders</td>
                                    <td class="text-center">80 (76-84)</td>
                                    <td class="text-center">76 (71-80)</td>
                                  </tr>
                                  <tr>
                                    <td class="border-right-0">Best responses,<sup>c</sup> n (%)</td>
                                    <td class="border-right-0 border-left-0"></td>
                                    <td class="border-left-0"></td>
                                  </tr>
                                  <tr>
                                    <td class="pl-4">CR<sup>c</sup></td>
                                    <td class="text-center">29 (7)</td>
                                    <td class="text-center">15 (4)</td>
                                  </tr>
                                  <tr>
                                    <td class="pl-4">PR<sup>c</sup></td>
                                    <td class="text-center">334 (79)</td>
                                    <td class="text-center">335 (81)</td>
                                  </tr>
                                  <tr>
                                    <td class="pl-4">SD</td>
                                    <td class="text-center">30 (7)</td>
                                    <td class="text-center">42 (10)</td>
                                  </tr>
                                  <tr>
                                    <td class="pl-4">PD</td>
                                    <td class="text-center">7 (2)</td>
                                    <td class="text-center">11 (3)</td>
                                  </tr>
                                  <tr>
                                    <td class="pl-4">NE/UNK</td>
                                    <td class="text-center">21 (5)</td>
                                    <td class="text-center">11 (3)</td>
                                  </tr>
                                  <tr>
                                    <td colspan="3" class="position-static">
                                      <p class="footnote mt-0">
                                        <sup>a</sup>Number of patients with measurable disease at baseline by BICR was
                                        421 for RYBREVANT + lazertinib and 414
                                        for osimertinib.<br>
                                        <sup>b</sup>The odds ratio is from a logistic regression model stratified by <i>EGFR</i>
                                        mutation type, Asian race, and history of
                                        brain metastasis; 95% CI widths have not been adjusted for multiplicity and
                                        cannot be used to infer definitive
                                        treatment effects.<br>
                                        <sup>c</sup>Includes all responders.
                                      </p>
                                    </td>
                                  </tr>
                                </tbody>
                              </table>
                            </div>
                          </div>

                          <div class="col-12">
                            <p class="footnote mb-5">
                              <sup>a</sup>The endpoint was not part of hierarchical hypothesis testing. This endpoint
                              was not adjusted for multiple comparisons.
                              Therefore, the <i>P</i>-value displayed is nominal, and statistical significance has not been
                              established.
                            </p>
                          </div>
                        </div>
                      </div>

                    </div>

                    <div class="tab-pane " id="long-term-analysis" aria-labelledby="long-term-analysis-tab">
                      <div class="third_level_inner_tabs">
                        <ul class="nav nav-tabs w-100 d-flex justify-content-center" id="myTab_long-term-analysis"
                          role="tablist">
                          <li class="nav-item w-100" role="presentation">
                            <button class="nav-link active" data-subtabs="efficacy-1_long-term-analysis_efficacy-p"
                              data-toggle="tab" data-target="#efficacy-1_long-term-analysis">Efficacy - Page 1</button>
                          </li>

                          <li class="nav-item w-100" role="presentation">
                            <button class="nav-link" data-subtabs="efficacy-2_long-term-analysis_efficacy-p"
                              data-toggle="tab" data-target="#efficacy-2_long-term-analysis">Efficacy - Page 2</button>
                          </li>
                        </ul>

                        <div class="tab-content" id="myTab_long-term-analysis">
                          <div class="tab-pane fade show active" id="efficacy-1_long-term-analysis"
                            aria-labelledby="efficacy-1_long-term-analysis-tab">
                            <div class="content-wrapper-section mb-5">
                              <div class="row">
                                <div class="col-12">
                                  <div class="col-12 pb-1">
                                    <ul class="cw-list text-left pl-3 mb-4">
                                      <li class="pl-0">
                                        At a median long-term follow-up of 31.1 months (data cutoff: May 13, 2024),
                                        median OS for
                                        RYBREVANT plus lazertinib vs osimertinib was NE vs 37.3 months (95% CI, 32.5-NE;
                                        HR, 0.77
                                        [95% CI, 0.61-0.96];
                                        <i>P</i>=0.019<sup>a</sup>).<sup>7</sup>
                                        <ul>
                                          <li>The OS rates for RYBREVANT plus lazertinib vs osimertinib were 75% vs 70%
                                            at 24 months
                                            and 61% vs 53% at 36 months, respectively.</li>
                                        </ul>
                                      </li>
                                    </ul>
                                  </div>

                                  <div class="col-12 pb-1">
                                    <h3 class="modal-title table-header font-weight-bold mb-4">
                                      Intracranial Outcomes<sup>7</sup>
                                    </h3>

                                    <ul class="cw-list text-left pl-3 mb-4">
                                      <li class="pl-0">
                                        In patients with a history of brain metastases, median icPFS (defined as the
                                        time from
                                        randomization until the date of intracranial disease progression<sup>b</sup> or
                                        death) by BICR for RYBREVANT
                                        plus lazertinib vs osimertinib was 24.9 months (95% CI, 20.1-34.7) vs 22.2
                                        months (95% CI,
                                        18.4-26.1; HR, 0.82 [95% CI, 0.62-1.09];
                                        <i>P</i>=0.165<sup>c</sup>).
                                        <ul>
                                          <li>The icPFS rates for RYBREVANT plus lazertinib vs osimertinib were 51% vs
                                            48% at 24 months
                                            and 38% vs 18% at 36 months, respectively.
                                          </li>
                                        </ul>
                                      </li>
                                      <li class="pl-0">
                                        In patients with a history of brain metastases at screening, median icDOR
                                        (defined as the time from
                                        the date of first documented intracranial CR or PR until the date of documented
                                        intracranial
                                        progression or death, whichever occurred first) by BICR for RYBREVANT plus
                                        lazertinib vs
                                        osimertinib was NE (95% CI,<sup>d</sup> 21.4-NE) vs 24.4 months (95%
                                        CI,<sup>d</sup> 22.1-31.2).
                                        <ul>
                                          <li>The icDOR rates for RYBREVANT plus lazertinib vs osimertinib were 59% vs
                                            52% at 24 months
                                            and 51% vs 0% at 36 months, respectively.</li>
                                        </ul>
                                      </li>
                                      <li class="pl-0">The icORR for RYBREVANT plus lazertinib vs osimertinib was 77%
                                        (95% CI, 70-83) vs 77% (95% CI, 71-83).</li>
                                    </ul>
                                  </div>

                                  <div class="col-12">
                                    <p class="footnote mb-5">
                                      <sup>a</sup>The endpoint was not part of formal statistical testing; the
                                      <i>P</i>-value displayed is nominal. <i>P</i>-value was calculated from a log-
                                      rank test stratified by mutation type (Exon19del or Exon 21 L858R), race (Asian or
                                      Non-Asian), and history of brain
                                      metastasis (present or absent). HR was calculated from a stratified proportional
                                      hazards model.<br>
                                      <sup>b</sup>Progression of brain metastasis or occurrence of new brain
                                      lesions.<br>
                                      <sup>c</sup>The endpoint was not part of formal statistical testing; the
                                      <i>P</i>-value displayed is nominal. <i>P</i>-value was calculated from a log-
                                      rank test stratified by mutation type (Exon19del or Exon 21 L858R) and race (Asian
                                      or Non-Asian). HR was calculated from
                                      a stratified proportional hazards model.<br>
                                      <sup>d</sup>95% CI was estimated using the Kaplan-Meier method.
                                    </p>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>

                          <div class="tab-pane fade " id="efficacy-2_long-term-analysis"
                            aria-labelledby="efficacy-2_long-term-analysis-tab">
                            <div class="content-wrapper-section mb-5">
                              <div class="row">
                                <div class="col-12">
                                  <h3 class="modal-title table-header font-weight-bold mb-3">Post-Progression
                                    Outcomes<sup>7</sup></h3>
                                  <ul class="cw-list text-left pl-3 mb-4">
                                    <li>
                                      Median TTD (defined as the time from randomization to discontinuation of treatment
                                      for any
                                      reason, including disease progression, treatment toxicity, or death) for RYBREVANT
                                      plus
                                      lazertinib vs osimertinib was 26.3 months (95% CI, 22.3-30.4) vs 22.6 months (95%
                                      CI, 20.3-
                                      24.5; HR, 0.80 [95% CI, 0.68-0.96]; <i>P</i>=0.014<sup>a</sup>).
                                      <ul>
                                        <li>At 24 and 36 months, respectively, 52% vs 46% and 40% vs 29% of patients in
                                          the
                                          RYBREVANT plus lazertinib vs osimertinib arm remained on treatment.</li>
                                      </ul>
                                    </li>
                                    <li>
                                      Median TTST (defined as the time from the date of randomization to the start date
                                      of the
                                      subsequent anticancer therapy following study treatment discontinuation or death,
                                      whichever
                                      occurs first) for RYBREVANT plus lazertinib vs osimertinib was 30 months (95% CI,
                                      26.3-36) vs
                                      24 months (95% CI, 22.5-26.2; HR, 0.77 [95% CI, 0.65-0.93];
                                      <i>P</i>=0.005<sup>a</sup>).
                                      <ul>
                                        <li>
                                          At 24 and 36 months, respectively, 57% vs 50% and 45% vs 32% of patients in
                                          the
                                          RYBREVANT plus lazertinib vs osimertinib arm did not initiate the first
                                          subsequent
                                          therapy.
                                        </li>
                                      </ul>
                                    </li>
                                    <li>
                                      In the RYBREVANT plus lazertinib vs osimertinib arm, 72% vs 74% of patients had
                                      disease progression, discontinued treatment, and received subsequent therapies.
                                    </li>
                                  </ul>

                                  <div class="popup-btn-wrapper text-center mt-4 mb-4 py-3">
                                    <button type="button" class="btn popup-btn w-50" data-toggle="modal"
                                      data-target="#first-subsequent-popup">
                                      <h3>First Subsequent Therapies</h3>
                                    </button>
                                  </div>

                                  <ul>
                                    <li>
                                      Median PFS2 (defined as the time from randomization until the date of the second
                                      objective
                                      disease progression after initiation of subsequent anticancer therapy, based on
                                      clinical
                                      progression as determined by the investigator or death, whichever occurred first)
                                      for RYBREVANT
                                      plus lazertinib vs osimertinib was NE (95% CI, 36-NE) vs 32.4 months (95% CI,
                                      29.3-NE;
                                      HR, 0.73 [95% CI, 0.59-0.91]; <i>P</i>=0.004<sup>a</sup>).
                                      <ul>
                                        <li>
                                          The PFS2 rates for RYBREVANT plus lazertinib vs osimertinib were 73% vs 65% at
                                          24 months
                                          and 57% vs 49% at 36 months, respectively.
                                        </li>
                                      </ul>
                                    </li>
                                  </ul>

                                  <p class="footnote mt-0">
                                    <sup>a</sup>The endpoint was not part of formal statistical testing; the
                                    <i>P</i>-value displayed is nominal. <i>P</i>-value was calculated from a log-
                                    rank test stratified by mutation type (Exon19del or Exon 21 L858R), race (Asian or
                                    Non-Asian), and history of brain
                                    metastasis (present or absent). HR was calculated from a stratified proportional
                                    hazards model.
                                  </p>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>

              <div class="tab-pane fade" id="safety-p" aria-labelledby="safety-p-tab">
                <div class="content-wrapper-section pt-3">
                  <div class="row align-items-stretch">
                    <div class="col-12 pb-1">
                      <div class="cw-content-box d-flex flex-column justify-content-center h-100">
                        <ul class="cw-list text-left pl-3">
                          <li class="pl-0">
                            Median duration of treatment was 18.5 months (range, 0.2-31.4) for RYBREVANT plus lazertinib
                            and
                            18 months (range, 0.2-32.7) for osimertinib.<sup>5</sup>
                          </li>
                          <li class="pl-0">
                            Serious AEs and AEs leading to treatment interruptions, reductions, or discontinuations of
                            any agent
                            were higher with RYBREVANT plus lazertinib compared with osimertinib.<sup>5</sup>
                            <ul>
                              <li>IRR (5%), rash (3%), and paronychia (3%) were the most common causes of treatment discontinuation in the RYBREVANT plus lazertinib group.</li>
                            </ul>
                          </li>
                          <li class="pl-0">
                            TRAEs leading to discontinuation of all agents occurred in 10% of patients
                            treated
                            with RYBREVANT plus lazertinib and in 3% with osimertinib.<sup>5</sup>
                          </li>
                        </ul>
                      </div>
                    </div>

                    <div class="col-12 mb-5 pb-1">
                      <h3 class="modal-title table-header table_header_text  font-weight-bold">
                        Safety Summary<sup>5</sup>
                      </h3>

                      <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                      <div class="table_overflow_scroll">
                        <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                          <thead>
                            <tr>
                              <th scope="col" class="w-25">TEAE, n (%)</th>
                              <th scope="col" class="text-center table-header bg-red text-white w-25">
                                RYBREVANT + Lazertinib
                                <br>(n=421)
                              </th>
                              <th scope="col" class="text-center table-header bg-dark-Gray text-white w-25">
                                Osimertinib
                                <br>(n=428)
                              </th>
                            </tr>
                          </thead>
                          <tbody>
                            <tr>
                              <td>Any AE</td>
                              <td class="text-center">421 (100)</td>
                              <td class="text-center">425 (99)</td>
                            </tr>
                            <tr>
                              <td>Grade &#8805;3 AEs</td>
                              <td class="text-center">316 (75)</td>
                              <td class="text-center">183 (43)</td>
                            </tr>
                            <tr>
                              <td>Serious AEs</td>
                              <td class="text-center">205 (49)</td>
                              <td class="text-center">143 (33)</td>
                            </tr>
                            <tr>
                              <td>AEs leading to death</td>
                              <td class="text-center">34 (8)</td>
                              <td class="text-center">31 (7)</td>
                            </tr>
                            <tr>
                              <td class="border-right-0">Any AE leading to:</td>
                              <td class="border-right-0 border-left-0"></td>
                              <td class="border-left-0"></td>
                            </tr>
                            <tr>
                              <td class="pl-4">Treatment interruptions of any agent</td>
                              <td class="text-center">350 (83)</td>
                              <td class="text-center">165 (39)</td>
                            </tr>
                            <tr>
                              <td class="pl-4">Treatment Reductions of any agent</td>
                              <td class="text-center">249 (59)</td>
                              <td class="text-center">23 (5)</td>
                            </tr>
                            <tr>
                              <td class="pl-4">Treatment discontinuations of any agent</td>
                              <td class="text-center">147 (35)</td>
                              <td class="text-center">58 (14)</td>
                            </tr>
                          </tbody>
                        </table>
                      </div>
                    </div>

                    <div class="col-12 pb-1">
                      <div class="cw-content-box d-flex flex-column justify-content-center h-100">
                        <ul class="cw-list text-left pl-3">
                          <li class="pl-0">
                            Grade ≥3 AEs occurred in 75% of patients treated with RYBREVANT plus lazertinib and 43% of
                            patients treated with osimertinib.<sup>5</sup>
                          </li>
                          <li class="pl-0">
                            Incidence of ILD/pneumonitis was low, at ~3%, with 1% being grade ≥3 for both
                            arms.<sup>5</sup>
                          </li>
                          <li class="pl-0">
                            VTE rates were higher with RYBREVANT plus lazertinib compared with osimertinib.<sup>5</sup>
                            <ul>
                              <li>Most common preferred terms were PE and DVT.</li>
                            </ul>
                          </li>
                          <li class="pl-0">
                            At the time of the first VTE, most patients were not on anticoagulants. Majority of first
                            VTE events
                            in the RYBREVANT plus lazertinib arm occurred within the first 4 months.<sup>5</sup>
                          </li>
                          <li class="pl-0">
                            Rates of treatment discontinuations due to VTE were low and comparable between both
                            arms.<sup>5</sup>
                          </li>
                          <li class="pl-0">
                            Study participants receiving the combination of RYBREVANT and lazertinib were recommended to
                            receive prophylactic-dose anticoagulation as per local guidelines during the first 4 months
                            of
                            combination therapy per protocol (amendment). Investigators were instructed to refer to the
                            NCCN Guidelines for examples of prophylactic-dose anticoagulants in ambulatory cancer
                            patients.
                            The benefit-risk assessment for participants to tolerate prophylactic-dose anticoagulation
                            was
                            performed at the discretion of the treating investigator. If a VTE event was diagnosed, the
                            participant was to be treated with treatment-dose anticoagulation as per local guidelines.
                            Vitamin K antagonists were not recommended for VTE prophylaxis or treatment because of
                            numerous drug interactions.<sup>16</sup>
                          </li>
                          <li>Prophylactic dose anticoagulation is recommended for the first 4 months of treatment in
                            ongoing
                            trials of RYBREVANT plus lazertinib.<sup>5</sup></li>
                        </ul>
                      </div>
                    </div>

                    <div class="col-md-12 d-md-flex justify-content-around mb-5">
                      <div class="popup-btn-wrapper text-center pt-3 col-md-6">
                        <button type="button" class="btn popup-btn w-100 h-100" data-toggle="modal"
                          data-target="#summary-of-aes-popup">
                          <h3>Summary of AEs</h3>
                        </button>
                      </div>

                      <div class="popup-btn-wrapper text-center pt-3 col-md-6">
                        <button type="button" class="btn popup-btn w-100 h-100" data-toggle="modal"
                          data-target="#aes-special-interest-popup">
                          <h3>AEs of Special Interest: VTE</h3>
                        </button>
                      </div>
                    </div>
                  </div>
                </div>
              </div>

              <div class="tab-pane fade" id="additional-analysis" aria-labelledby="additional-analysis-tab">
                <div class="second_level_inner_tabs">
                  <ul class="nav nav-tabs w-100 d-flex justify-content-center" id="myTab_additional-analysis"
                    role="tablist">
                    <li class="nav-item w-100" role="presentation">
                      <button class="nav-link second active"
                        data-subtabs="high-risk-subgroup-analysis_additional-analysis" data-toggle="tab"
                        data-target="#high-risk-subgroup-analysis">High-risk Subgroup Analysis</button>
                    </li>

                    <li class="nav-item w-100" role="presentation">
                      <button class="nav-link second " data-subtabs="asian-subgroup-analysis_additional-analysis"
                        data-toggle="tab" data-target="#asian-subgroup-analysis">Asian Subgroup Analysis</button>
                    </li>

                    <li class="nav-item w-100" role="presentation">
                      <button class="nav-link second " data-subtabs="post-progression-analysis_additional-analysis"
                        data-toggle="tab" data-target="#post-progression-analysis">Post-Progression and Safety
                        Analysis</button>
                    </li>

                    <li class="nav-item w-100" role="presentation">
                      <button class="nav-link second " data-subtabs="exploratory-analysis_additional-analysis"
                        data-toggle="tab" data-target="#exploratory-analysis">Exploratory Analyses</button>
                    </li>

                    <li class="nav-item w-100" role="presentation">
                      <button class="nav-link second " data-subtabs="ctdna-analysis_additional-analysis"
                        data-toggle="tab" data-target="#ctdna-analysis">ctDNA Analysis for Acquired Resistance</button>
                    </li>

                    <li class="nav-item w-100" role="presentation">
                      <button class="nav-link second " data-subtabs="patient-relevant-outcomes_additional-analysis"
                        data-toggle="tab" data-target="#patient-relevant-outcomes">Patient-Relevant Outcomes</button>
                    </li>
                  </ul>

                  <div class="tab-content" id="myTab_additional-analysis">
                    <div class="tab-pane show active" id="high-risk-subgroup-analysis"
                      aria-labelledby="high-risk-subgroup-analysis-tab">
                      <div class="third_level_inner_tabs">
                        <ul class="nav nav-tabs w-100 d-flex justify-content-center"
                          id="myTab_high-risk-subgroup-analysis" role="tablist">

                          <li class="nav-item w-100" role="presentation">
                            <button class="nav-link active"
                              data-subtabs="study-design_high-risk-subgroup-analysis_additional-analysis"
                              data-toggle="tab" data-target="#study-design_high-risk-subgroup-analysis">Study
                              Design</button>
                          </li>

                          <li class="nav-item w-100" role="presentation">
                            <button class="nav-link "
                              data-subtabs="results_high-risk-subgroup-analysis_additional-analysis" data-toggle="tab"
                              data-target="#results_high-risk-subgroup-analysis">Results</button>
                          </li>
                        </ul>

                        <div class="tab-content" id="myTab_high-risk-subgroup-analysis">
                          <div class="tab-pane fade show active" id="study-design_high-risk-subgroup-analysis"
                            aria-labelledby="study-design_high-risk-subgroup-analysis-tab">
                            <div class="content-wrapper-section mb-5">
                              <div class="row">
                                <div class="col-12">
                                  <ul class="cw-list text-left pl-3 mb-4">
                                    <li class="pl-0">
                                      In a secondary analysis of patients with high-risk disease biomarkers in the
                                      MARIPOSA study,
                                      patients with ctDNA, ctDNA nonclearance, <i>TP53</i> co-mutations, and liver
                                      metastases at baseline
                                      who were randomized to receive RYBREVANT plus lazertinib (n=429) or osimertinib
                                      (n=429) were
                                      included.<sup>6,8</sup>
                                      <ul>
                                        <li>The presence of ctDNA and co-mutations was detected at baseline by NGS of
                                          blood using
                                          Guardant360 CDx.</li>
                                        <li>The presence and clearance of Exon19del and Exon 21 L858R ctDNA was
                                          evaluated at
                                          baseline and at C3D1 using Biodesix ddPCR.</li>
                                      </ul>
                                    </li>
                                  </ul>
                                </div>
                              </div>
                            </div>
                          </div>

                          <div class="tab-pane fade " id="results_high-risk-subgroup-analysis"
                            aria-labelledby="results_high-risk-subgroup-analysis-tab">
                            <div class="content-wrapper-section mb-5">
                              <div class="row">
                                <div class="col-12">
                                  <div class="col-12 mb-2 pb-1">
                                    <ul class="cw-list text-left pl-3 mb-4">
                                      <li class="pl-0">
                                        Median PFS by BICR for patients with high-risk disease (≥1 high-risk feature at
                                        baseline;
                                        RYBREVANT plus lazertinib, n=280; osimertinib, n=288) was 20.3 months (95% CI,
                                        18.2-24.0)
                                        for RYBREVANT plus lazertinib and 15 months (95% CI, 13.0-16.8) for osimertinib
                                        (HR, 0.72;
                                        95% CI, 0.58-0.90; <i>P</i>=0.004). <i>P</i>-values for subgroup analyses are
                                        all nominal.
                                        <sup>6,8</sup>
                                      </li>
                                      <li class="pl-0">At baseline, 540 patients had ctDNA detectable by NGS. Of them,
                                        85% of patients had pathogenic
                                        ctDNA mutations and 56% vs 53% of patients had <i>TP53</i> co-mutations in the
                                        RYBREVANT plus
                                        lazertinib vs osimertinib arms.<sup>6,8</sup></li>
                                    </ul>
                                  </div>

                                  <h3 class="mb-4 table_header_text regal-blue">
                                    PFS Across Predefined High-Risk Disease Subgroups<sup>6,8</sup>
                                  </h3>
                                  <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                                  <div class="table_overflow_scroll">
                                    <table
                                      class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                                      <thead>
                                        <tr>
                                          <th scope="col" class="w-25" rowspan="2">Subgroup</th>
                                          <th scope="col" class="w-50 text-center" colspan="2">Median PFS (95% CI),
                                            Months</th>
                                          <th scope="col" class="w-25 text-center" rowspan="2">HR (95% CI);
                                            <br><i>P</i>-Value<sup>b</sup>
                                          </th>
                                        </tr>
                                        <tr>
                                          <th class="d-none"></th>
                                          <th scope="col" class="text-center table-header bg-red text-white w-25">
                                            RYBREVANT +
                                            <br>
                                            Lazertinib
                                          </th>
                                          <th scope="col"
                                            class="text-center table-header bg-dark-G ray text-white w-25">
                                            Osimertinib
                                          </th>
                                        </tr>
                                      </thead>
                                      <tbody>
                                        <tr>
                                          <td>Detectable baseline ctDNA by NGS</td>
                                          <td class="text-center">
                                            n=266<br>
                                            20.3 (18.2-23.9)
                                          </td>
                                          <td class="text-center">
                                            n=274<br>
                                            14.8 (12.9-16.6)
                                          </td>
                                          <td class="text-center">
                                            0.71 (0.57-0.89);<br>
                                            <i>P</i>=0.003
                                          </td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4"><i>TP53</i> co-mutation</td>
                                          <td class="text-center">
                                            n=149<br>
                                            18.2 (15.3-22.1)
                                          </td>
                                          <td class="text-center">
                                            n=144<br>
                                            12.9 (11.1-14.7)
                                          </td>
                                          <td class="text-center">
                                            0.65 (0.48-0.87);<br>
                                            <i>P</i>=0.003
                                          </td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4"><i>TP53</i> wild-type</td>
                                          <td class="text-center">
                                            n=117<br>
                                            22.1 (18.5-NE)
                                          </td>
                                          <td class="text-center">
                                            n=130<br>
                                            19.9 (14.8-23.9)
                                          </td>
                                          <td class="text-center">
                                            0.75 (0.52-1.07);<br>
                                            <i>P</i>=0.114
                                          </td>
                                        </tr>
                                        <tr>
                                          <td>Detectable baseline <i>EGFR</i>-mutant ctDNA by ddPCR<sup>a</sup></td>
                                          <td class="text-center">
                                            n=231<br>
                                            20.3 (16.6-24.0)
                                          </td>
                                          <td class="text-center">
                                            n=240<br>
                                            14.8 (12.9-16.5)
                                          </td>
                                          <td class="text-center">
                                            0.68 (0.53-0.86);<br>
                                            <i>P</i>=0.002
                                          </td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4">Not cleared at C3D1</td>
                                          <td class="text-center">
                                            n=29<br>
                                            16.5 (9.3-18.4)
                                          </td>
                                          <td class="text-center">
                                            n=32<br>
                                            9.1 (5.5-11.1)
                                          </td>
                                          <td class="text-center">
                                            0.49 (0.27-0.87);<br>
                                            <i>P</i>=0.015
                                          </td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4">Cleared at C3D1</td>
                                          <td class="text-center">
                                            n=163<br>
                                            24.0 (20.2-NE)
                                          </td>
                                          <td class="text-center">
                                            n=180<br>
                                            16.5 (14.9-19.9)
                                          </td>
                                          <td class="text-center">
                                            0.64 (0.48-0.87);<br>
                                            <i>P</i>=0.004
                                          </td>
                                        </tr>
                                        <tr>
                                          <td class="border-right-0">Liver metastases at baseline</td>
                                          <td class="border-right-0 border-left-0"></td>
                                          <td class="border-right-0 border-left-0"></td>
                                          <td class="border-left-0"></td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4">Present</td>
                                          <td class="text-center">
                                            n=64<br>
                                            18.2 (13.1-NE)
                                          </td>
                                          <td class="text-center">
                                            n=72<br>
                                            11.0 (7.4-12.8)
                                          </td>
                                          <td class="text-center">
                                            0.58 (0.37-0.91);<br>
                                            <i>P</i>=0.017
                                          </td>
                                        </tr>
                                        <td class="pl-4">Absent</td>
                                        <td class="text-center">
                                          n=365<br>
                                          24.0 (20.3-NE)
                                        </td>
                                        <td class="text-center">
                                          n=357<br>
                                          18.3 (16.5-20.1)
                                        </td>
                                        <td class="text-center">
                                          0.74 (0.60-0.91);<br>
                                          <i>P</i>=0.004
                                        </td>
                                        </tr>
                                        <tr>
                                          <td colspan="4" class="position-static">
                                            <p class="footnote mt-0">
                                              <sup>a</sup>Of the 231 patients in the RYBREVANT-lazertinib arm and 240
                                              patients in the osimertinib arm, 192 and 212
                                              patients, respectively, had matched samples at baseline and C3D1.<br>
                                              <sup>b</sup><i>P</i>-values for subgroup analyses are all nominal. The
                                              endpoint was not part of hierarchical hypothesis testing. This
                                              endpoint was not adjusted for multiple comparisons. Therefore, the
                                              <i>P</i>-value displayed is nominal, and statistical
                                              significance has not been established.
                                            </p>
                                          </td>
                                        </tr>
                                      </tbody>
                                    </table>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>

                    <div class="tab-pane " id="asian-subgroup-analysis" aria-labelledby="asian-subgroup-analysis-tab">
                      <div class="third_level_inner_tabs">
                        <ul class="nav nav-tabs w-100 d-flex justify-content-center" id="myTab_asian-subgroup-analysis"
                          role="tablist">

                          <li class="nav-item w-100" role="presentation">
                            <button class="nav-link active"
                              data-subtabs="patient-characteristics_asian-subgroup-analysis_additional-analysis"
                              data-toggle="tab" data-target="#patient-characteristics_asian-subgroup-analysis">Patient
                              Characteristics</button>
                          </li>

                          <li class="nav-item w-100" role="presentation">
                            <button class="nav-link "
                              data-subtabs="efficacy_asian-subgroup-analysis_additional-analysis" data-toggle="tab"
                              data-target="#efficacy_asian-subgroup-analysis">Efficacy</button>
                          </li>

                          <li class="nav-item w-100" role="presentation">
                            <button class="nav-link " data-subtabs="safety_asian-subgroup-analysis_additional-analysis"
                              data-toggle="tab" data-target="#safety_asian-subgroup-analysis">Safety</button>
                          </li>
                        </ul>

                        <div class="tab-content" id="myTab_asian-subgroup-analysis">
                          <div class="tab-pane fade show active" id="patient-characteristics_asian-subgroup-analysis"
                            aria-labelledby="patient-characteristics_asian-subgroup-analysis-tab">
                            <div class="content-wrapper-section mb-5">
                              <div class="row">
                                <div class="col-12">
                                  <ul class="cw-list text-left pl-3 mb-4">
                                    <li class="pl-0">
                                      In a subgroup analysis of Asian patients in the MARIPOSA study, 501 Asian patients
                                      (defined by
                                      race) were randomized to receive RYBREVANT plus lazertinib (n=250) or osimertinib
                                      (n=251).<sup>9</sup>
                                    </li>
                                  </ul>

                                  <h3 class="mb-4 table_header_text">
                                    Demographics and Baseline Disease Characteristics Among Asian Patients<sup>9</sup>
                                  </h3>
                                  <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                                  <div class="table_overflow_scroll">
                                    <table
                                      class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                                      <thead>
                                        <tr>
                                          <th scope="col" class="w-25">Characteristic</th>
                                          <th scope="col" class="text-center table-header bg-red text-white w-25">
                                            RYBREVANT +
                                            <br> Lazertinib
                                            <br>
                                            (n=250)
                                          </th>
                                          <th scope="col"
                                            class="text-center table-header bg-dark-Gray text-white w-25">
                                            Osimertinib
                                            <br>
                                            (n=251)
                                          </th>
                                        </tr>
                                      </thead>
                                      <tbody>
                                        <tr>
                                          <td>Median age, years (range)</td>
                                          <td class="text-center">63 (35-85)</td>
                                          <td class="text-center">63 (28-88)</td>
                                        </tr>
                                        <tr>
                                          <td>Female, n (%)</td>
                                          <td class="text-center">152 (61)</td>
                                          <td class="text-center">143 (57)</td>
                                        </tr>
                                        <tr>
                                          <td>Body Weight &lt;80 kg, n (%)</td>
                                          <td class="text-center">236 (94)</td>
                                          <td class="text-center">238 (95)</td>
                                        </tr>
                                        <tr>
                                          <td>ECOG PS 1, n (%)</td>
                                          <td class="text-center">181 (72)</td>
                                          <td class="text-center">167 (67)</td>
                                        </tr>
                                        <tr>
                                          <td>History of smoking, n (%)</td>
                                          <td class="text-center">70 (28)</td>
                                          <td class="text-center">70 (28)</td>
                                        </tr>
                                        <tr>
                                          <td>History of brain metastases, n (%)</td>
                                          <td class="text-center">110 (44)</td>
                                          <td class="text-center">108 (43)</td>
                                        </tr>
                                        <tr>
                                          <td class="border-right-0"><i>EGFR</i> mutation,<sup>a</sup> n (%)</td>
                                          <td class="border-right-0 border-left-0"></td>
                                          <td class="border-left-0"></td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4">Exon19del</td>
                                          <td class="text-center">138 (55)</td>
                                          <td class="text-center">139 (55)</td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4">Exon 21 L858R</td>
                                          <td class="text-center">113 (45)</td>
                                          <td class="text-center">112 (45)</td>
                                        </tr>
                                        <tr>
                                          <td>Adenocarcinoma histology, n (%)</td>
                                          <td class="text-center">244 (98)</td>
                                          <td class="text-center">239 (95)</td>
                                        </tr>
                                        <td>Median time from metastatic disease diagnosis,
                                          months (range)</td>
                                        <td class="text-center">1.1 (0.2-24.1)</td>
                                        <td class="text-center">1.1 (0.1-9.1)</td>
                                        </tr>
                                        <tr>
                                          <td colspan="3" class="position-static">
                                            <p class="footnote mt-0">
                                              <sup>a</sup>One patient in the RYBREVANT + lazertinib arm had both
                                              Exon19del and Exon 21 L858R.
                                            </p>
                                          </td>
                                        </tr>
                                      </tbody>
                                    </table>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>

                          <div class="tab-pane fade " id="efficacy_asian-subgroup-analysis"
                            aria-labelledby="efficacy_asian-subgroup-analysis-tab">
                            <div class="content-wrapper-section mb-5">
                              <div class="row">
                                <div class="col-12">
                                  <div class="col-12 mb-2 pb-1">
                                    <h3 class="modal-title table-header font-weight-bold mb-2">Primary
                                      Endpoint<sup>9</sup></h3>

                                    <ul class="cw-list text-left pl-3 mb-4">
                                      <li class="pl-0">
                                        At a median follow-up of 22.5 months, median PFS by BICR was 27.5 months (95%
                                        CI, 20.3-NE)
                                        for RYBREVANT plus lazertinib and 18.3 months (95% CI, 15.8-20.2) for
                                        osimertinib (HR, 0.65;
                                        95% CI, 0.50-0.83;
                                        <i>P</i>&lt;0.001<sup>a</sup>).
                                        <ul>
                                          <li>PFS rates at 12 months were 76% and 66% for RYBREVANT plus lazertinib and
                                            osimertinib,
                                            respectively, and at 24 months were 53% and 36%, respectively.</li>
                                        </ul>
                                      </li>
                                      <li class="pl-0">Median PFS was 18.4 months (95% CI, 14.6-20.3) for lazertinib
                                        monotherapy.</li>
                                      <li class="pl-0">PFS across predefined clinically relevant subgroups was evaluated
                                        for RYBREVANT plus lazertinib vs
                                        osimertinib.</li>
                                    </ul>
                                  </div>

                                  <div class="col-12 pb-1">
                                    <h3 class="modal-title table-header font-weight-bold mb-2">Secondary
                                      Endpoints<sup>9</sup></h3>

                                    <ul class="cw-list text-left pl-3">
                                      <li class="pl-0">
                                        Median DOR among confirmed responders by BICR was 26.1 months (95% CI, 20.1-NE)
                                        for
                                        RYBREVANT plus lazertinib and 17.5 months (95% CI, 14.8-20.4) for osimertinib.
                                      </li>
                                      <li class="pl-0">
                                        At a median follow-up of 22.5 months, HR for PFS2 was 0.78 (95% CI, 0.54-1.11;
                                        <i>P=</i>0.17<sup>a</sup>); the
                                        HR for interim OS was 0.84 (95% CI, 0.58-1.23; <i>P=</i>0.38<sup>a</sup>).
                                      </li>
                                    </ul>
                                  </div>

                                  <div class="popup-btn-wrapper text-center mt-4 pt-3">
                                    <button type="button" class="btn popup-btn" style="width: 55%;" data-toggle="modal"
                                      data-target="#asian-efficacy-1-popup">
                                      <h3>PFS Across Predefined Subgroups Among Asian Patients</h3>
                                    </button>
                                  </div>

                                  <div class="popup-btn-wrapper text-center mt-4 pt-3">
                                    <button type="button" class="btn popup-btn" style="width: 55%;" data-toggle="modal"
                                      data-target="#asian-efficacy-2-popup">
                                      <h3>ORR and Best Response by BICR Among Asian Patients</h3>
                                    </button>
                                  </div>

                                  <div class="col-12">
                                    <p class="footnote">
                                      <sup>a</sup>The endpoint was not part of hierarchical hypothesis testing. This endpoint was not adjusted for multiple comparisons. 
                                      Therefore, the <i>P</i>-value displayed is nominal, and statistical significance has not been established.
                                    </p>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>

                          <div class="tab-pane fade " id="safety_asian-subgroup-analysis"
                            aria-labelledby="safety_asian-subgroup-analysis-tab">
                            <div class="content-wrapper-section mb-5">
                              <div class="row">
                                <div class="col-12 pb-1">
                                  <div class="cw-content-box d-flex flex-column justify-content-center h-100">
                                    <ul class="cw-list text-left pl-3 mb-4">
                                      <li class="pl-0">
                                        Median duration of treatment was 19.8 months for RYBREVANT plus lazertinib and
                                        18.7 months for osimertinib.<sup>9</sup>
                                      </li>
                                      <li class="pl-0">Grade ≥3 AEs, serious AEs, and AEs leading to treatment
                                        interruptions, reductions, or
                                        discontinuations of any agent were higher with RYBREVANT plus lazertinib
                                        compared with
                                        osimertinib.<sup>9</sup></li>
                                      <li class="pl-0">
                                        TRAEs leading to discontinuation of all agents occurred in 9% of patients
                                        treated with RYBREVANT plus lazertinib.<sup>9</sup>
                                      </li>
                                    </ul>
                                  </div>
                                </div>

                                <div class="col-12 mb-5 pb-1">
                                  <h3 class="modal-title table-header table_header_text  font-weight-bold">
                                    Safety Summary Among Asian Patients<sup>9</sup>
                                  </h3>

                                  <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                                  <div class="table_overflow_scroll">
                                    <table
                                      class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                                      <thead>
                                        <tr>
                                          <th scope="col" class="w-25">TEAEs, n (%)</th>
                                          <th scope="col" class="text-center table-header bg-red text-white w-25">
                                            RYBREVANT +
                                            <br>Lazertinib
                                            <br>(n=248)
                                          </th>
                                          <th scope="col"
                                            class="text-center table-header bg-dark-gray text-white w-25">
                                            Osimertinib
                                            <br>(n=250)
                                          </th>
                                        </tr>
                                      </thead>
                                      <tbody>
                                        <tr>
                                          <td>Any AE</td>
                                          <td class="text-center">248 (100)</td>
                                          <td class="text-center">247 (99)</td>
                                        </tr>
                                        <tr>
                                          <td>Grade &#8805;3 AEs</td>
                                          <td class="text-center">176 (71)</td>
                                          <td class="text-center">102 (41)</td>
                                        </tr>
                                        <tr>
                                          <td>Serious AEs</td>
                                          <td class="text-center">117 (47)</td>
                                          <td class="text-center">80 (32)</td>
                                        </tr>
                                        <tr>
                                          <td>AEs leading to death</td>
                                          <td class="text-center">17 (7)</td>
                                          <td class="text-center">12 (5)</td>
                                        </tr>
                                        <tr>
                                          <td class="border-right-0">Any AE leading to:</td>
                                          <td class="border-right-0 border-left-0"></td>
                                          <td class="border-left-0"></td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4">Treatment interruptions of any agent<sup>a</sup></td>
                                          <td class="text-center">208 (84)</td>
                                          <td class="text-center">98 (39)</td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4">Treatment reductions of any agent</td>
                                          <td class="text-center">145 (58)</td>
                                          <td class="text-center">14 (6)</td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4">Treatment discontinuations of any agent</td>
                                          <td class="text-center">73 (29)</td>
                                          <td class="text-center">30 (12)</td>
                                        </tr>
                                        <tr>
                                          <td colspan="3" class="position-static">
                                            <p class="footnote mt-0">
                                              <sup>a</sup>Excludes IRRs.
                                            </p>
                                          </td>
                                        </tr>
                                      </tbody>
                                    </table>
                                  </div>
                                </div>

                                <div class="col-12 pb-1">
                                  <div class="cw-content-box d-flex flex-column justify-content-center h-100">
                                    <ul class="cw-list text-left pl-3 mb-4">
                                      <li class="pl-0">EGFR- and MET-related AEs were increased with RYBREVANT plus
                                        lazertinib compared with
                                        osimertinib and were mostly grade 1-2.<sup>9</sup></li>
                                      <li class="pl-0">
                                        Grade ≥3 AEs in the RYBREVANT plus lazertinib arm were driven by grade 3
                                        events.<sup>9</sup>
                                        <ul>
                                          <li>Incidence of grade 4-5 AEs and AEs leading to death were low and
                                            comparable between both
                                            arms.</li>
                                        </ul>
                                      </li>
                                      <li class="pl-0">
                                        Incidence of ILD was low, 4% for RYBREVANT plus lazertinib vs 3% for
                                        osimertinib.<sup>9</sup>
                                      </li>
                                      <li class="pl-0">VTE rates were higher with RYBREVANT plus lazertinib compared
                                        with osimertinib.<sup>9</sup>
                                        <ul>
                                          <li>Most VTEs were grade 1-2. There were no grade 4-5 events.</li>
                                        </ul>
                                      </li>
                                      <li>At the time of first VTE, most patients (99%) were not on anticoagulants.
                                        Majority of first
                                        VTE events in the RYBREVANT plus lazertinib arm occurred within the first 4
                                        months and were
                                        effectively managed with anticoagulants.<sup>9</sup></li>
                                    </ul>
                                  </div>
                                </div>

                                <div class="col-12">
                                  <div class="popup-btn-wrapper text-center mt-4 pt-3">
                                    <button type="button" class="btn popup-btn w-75" data-toggle="modal"
                                      data-target="#asian-safety-popup">
                                      <h3>Summary of AEs Among Asian Patients</h3>
                                    </button>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>

                    <div class="tab-pane " id="post-progression-analysis"
                      aria-labelledby="post-progression-analysis-tab">
                      <div class="third_level_inner_tabs">
                        <ul class="nav nav-tabs w-100 d-flex justify-content-center"
                          id="myTab_post-progression-analysis" role="tablist">
                          <li class="nav-item w-100" role="presentation">
                            <button class="nav-link active"
                              data-subtabs="efficacy-1_post-progression-analysis_additional-analysis" data-toggle="tab"
                              data-target="#efficacy-1_post-progression-analysis">Efficacy - Page 1</button>
                          </li>

                          <li class="nav-item w-100" role="presentation">
                            <button class="nav-link"
                              data-subtabs="efficacy-2_post-progression-analysis_additional-analysis" data-toggle="tab"
                              data-target="#efficacy-2_post-progression-analysis">Efficacy - Page 2</button>
                          </li>

                          <li class="nav-item w-100" role="presentation">
                            <button class="nav-link "
                              data-subtabs="safety_post-progression-analysis_additional-analysis" data-toggle="tab"
                              data-target="#safety_post-progression-analysis">Safety</button>
                          </li>
                        </ul>

                        <div class="tab-content" id="myTab_post-progression-analysis">
                          <div class="tab-pane fade show active" id="efficacy-1_post-progression-analysis"
                            aria-labelledby="efficacy-1_post-progression-analysis-tab">
                            <div class="content-wrapper-section mb-5">
                              <div class="row">
                                <div class="col-12">
                                  <div class="col-12 pb-1">
                                    <ul class="cw-list text-left pl-3">
                                      <li class="pl-0">
                                        An analysis assessed post-progression treatment outcomes and safety in patients
                                        from MARIPOSA receiving RYBREVANT plus lazertinib (open-label) vs osimertinib (double-blind)
                                        as first-line
                                        treatment for <i>EGFR</i>-mutated (Exon19del or Exon 21 L858R) locally advanced or
                                        metastatic
                                        NSCLC.<sup>10</sup>
                                      </li>
                                    </ul>
                                  </div>

                                  <div class="col-12 pb-1">
                                    <h3 class="modal-title table-header  font-weight-bold mb-3">
                                      Post-Progression Treatment Outcomes<sup>10</sup>
                                    </h3>

                                    <ul class="cw-list text-left pl-3">
                                      <li class="pl-0">
                                        At a median follow-up of 22 months, 35% (147/421) of patients in the RYBREVANT
                                        plus lazertinib
                                        arm and 47% (203/428) of patients in the osimertinib arm had PD.
                                        <ul>
                                          <li>Among patients with PD, 53% (78/147) in the RYBREVANT plus lazertinib arm
                                            and 51%
                                            (103/203) in the osimertinib arm continued treatment beyond progression for
                                            a median duration
                                            of 23.6 weeks (range, 16-34.9) and 15.9 weeks (range, 10.7-21.6),
                                            respectively.
                                          </li>
                                        </ul>
                                      </li>
                                      <li class="pl-0">
                                        Median TTD was 26.2 months (95% CI, 22.1-NE) for RYBREVANT plus lazertinib vs 23
                                        months
                                        (95% CI, 20.3-25.3) for osimertinib (HR, 0.88; 95% CI, 0.73-1.07;
                                        <i>P</i>=0.21<sup>a</sup>).
                                        <ul>
                                          <li>At follow-up, 116 patients in the RYBREVANT plus lazertinib arm and 171
                                            patients in the
                                            osimertinib arm discontinued study treatment, respectively.
                                          </li>
                                          <li>At 24 months, 53% and 47% of patients remained on treatment in the
                                            RYBREVANT plus
                                            lazertinib and osimertinib treatment arms, respectively.</li>
                                        </ul>
                                      </li>
                                    </ul>
                                  </div>

                                  <div class="col-12 mb-5 pb-1">
                                    <h3 class="modal-title table-header table_header_text  font-weight-bold">
                                      Patient Disposition<sup>10</sup>
                                    </h3>

                                    <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                                    <div class="table_overflow_scroll">
                                      <table
                                        class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                                        <thead>
                                          <tr>
                                            <th scope="col" class="d-md-none" style="width: 10%;">Patient<br>Disposition</th>
                                            <th scope="col" class="w-25 d-none d-md-table-cell">Patient Disposition</th>
                                            <th scope="col" class="text-center table-header bg-red text-white w-25">
                                              RYBREVANT +
                                              <br>Lazertinib
                                              <br>(n=421)
                                            </th>
                                            <th scope="col"
                                              class="text-center table-header bg-dark-gray text-white w-25">
                                              Osimertinib
                                              <br>(n=428)
                                            </th>
                                          </tr>
                                        </thead>
                                        <tbody>
                                          <tr>
                                            <td>Discontinued study treatment, n</td>
                                            <td class="text-center">116</td>
                                            <td class="text-center">171</td>
                                          </tr>
                                          <tr>
                                            <td class="pl-4">Received subsequent therapy, n (%)</td>
                                            <td class="text-center">78 (67)</td>
                                            <td class="text-center">124 (73)</td>
                                          </tr>
                                          <tr>
                                            <td class="pl-4">Died before receiving subsequent therapy, n (%)</td>
                                            <td class="text-center">25 (22)</td>
                                            <td class="text-center">34 (20)</td>
                                          </tr>
                                        </tbody>
                                      </table>
                                    </div>
                                  </div>

                                  <div class="col-12 mb-5 pb-1">
                                    <ul class="cw-list text-left pl-3 mb-4">
                                      <li class="pl-0">
                                        Median TTST was NE (95% CI, 26.8-NE) for RYBREVANT plus lazertinib vs 24.1
                                        months (95% CI, 22-29) for osimertinib (HR, 0.82; 95% CI, 0.66-1; <i>P</i>=0.05<sup>a</sup>).
                                      </li>
                                    </ul>
                                  </div>

                                  <div class="col-12">
                                    <p class="footnote mb-5">
                                      <sup>a</sup>The endpoint was not part of hierarchical hypothesis testing. This
                                      endpoint was not adjusted for multiple comparisons.<br>
                                      Therefore, the <i>P</i>-value displayed is nominal, and statistical significance
                                      has not been established.
                                    </p>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>

                          <div class="tab-pane fade " id="efficacy-2_post-progression-analysis"
                            aria-labelledby="efficacy-2_post-progression-analysis-tab">
                            <div class="content-wrapper-section mb-5">
                              <div class="row">
                                <div class="col-12">
                                  <ul>
                                    <li>
                                      The most commonly prescribed first subsequent therapies<sup>10</sup>:
                                      <ul>
                                        <li>After RYBREVANT plus lazertinib were doublet chemotherapy (36%) and
                                          third-generation TKIs
                                          (24%).</li>
                                        <li>After osimertinib were doublet chemotherapy (38%) and doublet chemotherapy
                                          plus IO/VEGFi (22%).</li>
                                      </ul>
                                    </li>
                                  </ul>

                                  <h3 class="modal-title table-header table_header_text  font-weight-bold">
                                    First Subsequent Therapies<sup>10</sup>
                                  </h3>

                                  <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                                  <div class="table_overflow_scroll">
                                    <table
                                      class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                                      <thead>
                                        <tr>
                                          <th scope="col" class="d-md-none" style="width: 0%;">First Subsequent<br>Therapies,<sup>a</sup> %</th>
                                          <th scope="col" class="w-25 d-none d-md-table-cell">First Subsequent Therapies,<sup>a</sup> %</th>
                                          <th scope="col" class="text-center table-header bg-red text-white w-25">
                                            RYBREVANT +
                                            <br>Lazertinib
                                            <br>(n=78)
                                          </th>
                                          <th scope="col"
                                            class="text-center table-header bg-dark-gray text-white w-25">
                                            Osimertinib
                                            <br>(n=124)
                                          </th>
                                        </tr>
                                      </thead>
                                      <tbody>
                                        <tr>
                                          <td>Doublet chemotherapy</td>
                                          <td class="text-center">36</td>
                                          <td class="text-center">38</td>
                                        </tr>
                                        <tr>
                                          <td>Doublet chemotherapy + IO/VEGFi</td>
                                          <td class="text-center">12</td>
                                          <td class="text-center">22</td>
                                        </tr>
                                        <tr>
                                          <td>Third-generation TKI</td>
                                          <td class="text-center">24</td>
                                          <td class="text-center">15</td>
                                        </tr>
                                        <tr>
                                          <td>Other TKIs</td>
                                          <td class="text-center">14</td>
                                          <td class="text-center">8</td>
                                        </tr>
                                        <tr>
                                          <td>TKI combination</td>
                                          <td class="text-center">9</td>
                                          <td class="text-center">8</td>
                                        </tr>
                                        <tr>
                                          <td colspan="4" class="position-static">
                                            <p class="footnote mt-0">
                                              <sup>a</sup>Single-agent chemotherapy percentages were not provided for
                                              both arms. Other therapies were reported as 7% for
                                              osimertinib and not provided for RYBREVANT plus lazertinib arm.
                                            </p>
                                          </td>
                                        </tr>
                                      </tbody>
                                    </table>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>

                          <div class="tab-pane fade " id="safety_post-progression-analysis"
                            aria-labelledby="safety_post-progression-analysis-tab">
                            <div class="content-wrapper-section mb-5">
                              <div class="row">
                                <div class="col-12">
                                  <ul>
                                    <li>Median duration of exposure was 18.5 months for RYBREVANT plus
                                      lazertinib.<sup>10</sup></li>
                                    <li>Key AEs occurred within the first 4 months of treatment. Late onset AEs were
                                      uncommon.<sup>10</sup></li>
                                    <li>Some patients in the RYBREVANT plus lazertinib arm were prescribed antibiotics
                                      for rash
                                      management (21%) or were on anticoagulants (5%) at treatment
                                      initiation.<sup>10</sup></li>
                                  </ul>

                                  <h3 class="modal-title table-header table_header_text font-weight-bold">
                                    Summary of AEs for RYBREVANT Plus Lazertinib<sup>10</sup></h3>
                                  <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                                  <div class="table_overflow_scroll">
                                    <table
                                      class="table table-bordered table-sm overflow-table mb-5 adverse-event-table">
                                      <thead>
                                        <tr>
                                          <th scope="col" rowspan="2">Patients With Key AEs, %</th>
                                          <th class="text-center" colspan="3">
                                            Time to Onset
                                          </th>
                                        </tr>
                                        <tr>
                                          <th scope="col" class="position-static text-center table-header">
                                            0-4 Months</th>
                                          <th scope="col" class="text-center table-header">5-8 Months</th>
                                          <th scope="col" class="text-center table-header">9-12 Months</th>
                                        </tr>
                                      </thead>
                                      <tbody>
                                        <tr>
                                          <td>Rash</td>
                                          <td class="text-center">55</td>
                                          <td class="text-center">2</td>
                                          <td class="text-center">1</td>
                                        </tr>
                                        <tr>
                                          <td>Paronychia</td>
                                          <td class="text-center">50</td>
                                          <td class="text-center">12</td>
                                          <td class="text-center">3</td>
                                        </tr>
                                        <tr>
                                          <td>Dermatitis acneiform</td>
                                          <td class="text-center">25</td>
                                          <td class="text-center">1</td>
                                          <td class="text-center">1</td>
                                        </tr>
                                        <tr>
                                          <td>Stomatitis</td>
                                          <td class="text-center">25</td>
                                          <td class="text-center">2</td>
                                          <td class="text-center">0.5</td>
                                        </tr>
                                        <tr>
                                          <td>VTE</td>
                                          <td class="text-center">23</td>
                                          <td class="text-center">6</td>
                                          <td class="text-center">3</td>
                                        </tr>
                                        <tr>
                                          <td>Peripheral edema</td>
                                          <td class="text-center">21</td>
                                          <td class="text-center">6</td>
                                          <td class="text-center">3</td>
                                        </tr>
                                        <tr>
                                          <td>Pruritus</td>
                                          <td class="text-center">17</td>
                                          <td class="text-center">3</td>
                                          <td class="text-center">1</td>
                                        </tr>
                                        <tr>
                                          <td>Fatigue</td>
                                          <td class="text-center">12</td>
                                          <td class="text-center">2</td>
                                          <td class="text-center">1</td>
                                        </tr>
                                      </tbody>
                                    </table>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>

                    <div class="tab-pane " id="exploratory-analysis" aria-labelledby="exploratory-analysis-tab">
                      <div class="third_level_inner_tabs">
                        <ul class="nav nav-tabs w-100 d-flex justify-content-center" id="myTab_exploratory-analysis"
                          role="tablist">
                          <li class="nav-item w-100" role="presentation">
                            <button class="nav-link active"
                              data-subtabs="effect_exploratory-analysis_additional-analysis" data-toggle="tab"
                              data-target="#effect_exploratory-analysis">Effect of RYBREVANT Dose Interruptions</button>
                          </li>

                          <li class="nav-item w-100" role="presentation">
                            <button class="nav-link " data-subtabs="comparison_exploratory-analysis_additional-analysis"
                              data-toggle="tab" data-target="#comparison_exploratory-analysis">Comparison of Lazertinib
                              with Osimertinib</button>
                          </li>
                        </ul>

                        <div class="tab-content" id="myTab_exploratory-analysis">
                          <div class="tab-pane fade show active" id="effect_exploratory-analysis"
                            aria-labelledby="effect_exploratory-analysis-tab">
                            <div class="content-wrapper-section mb-5">
                              <div class="row">
                                <div class="col-12">
                                  <div class="col-12 pb-1">
                                    <ul class="cw-list text-left pl-3">
                                      <li class="pl-0">
                                        An exploratory analysis evaluated the effect of RYBREVANT dose interruptions in
                                        the first 4 months
                                        of RYBREVANT exposure on the efficacy and safety of first-line RYBREVANT plus
                                        lazertinib in
                                        patients enrolled in the MARIPOSA study with <i>EGFR</i>-mutated advanced
                                        NSCLC.<sup>11</sup>
                                        <ul>
                                          <li>Of the 421 patients who received ≥1 dose of RYBREVANT, 206 (49%) had a
                                            dose interruption
                                            within the first 4 months of RYBREVANT exposure.</li>
                                        </ul>
                                      </li>
                                    </ul>
                                  </div>

                                  <div class="col-md-12 mb-5 d-md-flex justify-content-around">
                                    <div class="popup-btn-wrapper text-center mt-4 pt-3 col-md-6">
                                      <button type="button" class="btn popup-btn w-100 h-100" data-toggle="modal"
                                        data-target="#exploratory-effects-1-popup">
                                        <h3>Patient Characteristics</h3>
                                      </button>
                                    </div>
                                  </div>

                                  <div class="col-12 pb-1">
                                    <h3 class="modal-title table-header font-weight-bold">
                                      Efficacy<sup>11</sup>
                                    </h3>

                                    <ul class="cw-list text-left pl-3">
                                      <li class="pl-0">
                                        Median PFS, ORR, and DOR in patients with and without RYBREVANT dose
                                        interruptions in the first
                                        4 months of RYBREVANT exposure are comparable between the groups.
                                        <ul>
                                          <li>Evaluating treatment outcomes during RYBREVANT exposure could lead to bias
                                            since disease
                                            progression or death could occur before RYBREVANT dose interruption. To
                                            minimize this bias,
                                            outcomes were evaluated after the first 4 months of RYBREVANT exposure.
                                          </li>
                                        </ul>
                                      </li>
                                      <li class="pl-0">At a median follow-up of 22 months (data cutoff: August 11,
                                        2023), median PFS and proportion of
                                        patients who achieved PFS at 24 months with vs without RYBREVANT dose
                                        interruptions after the
                                        first 4 months of RYBREVANT exposure are comparable between the groups.</li>
                                    </ul>
                                  </div>

                                  <div class="col-md-12 mb-5 d-md-flex justify-content-around">
                                    <div class="popup-btn-wrapper text-center mt-4 pt-3 col-md-6">
                                      <button type="button" class="btn popup-btn w-100 h-100" data-toggle="modal"
                                        data-target="#exploratory-effects-2-popup">
                                        <h3>Efficacy in Patients With and Without Dose
                                          Interruptions in the First 4 Months of
                                          RYBREVANT Exposures</h3>
                                      </button>
                                    </div>

                                    <div class="popup-btn-wrapper text-center mt-4 pt-3 col-md-6">
                                      <button type="button" class="btn popup-btn w-100 h-100" data-toggle="modal"
                                        data-target="#exploratory-effects-3-popup">
                                        <h3>Efficacy in Patients With and Without Dose
                                          Interruptions After the First 4 Months of
                                          RYBREVANT Exposures</h3>
                                      </button>
                                    </div>
                                  </div>

                                  <div class="col-12 pb-1">
                                    <ul class="cw-list text-left pl-3">
                                      <li class="pl-0">
                                        A multivariate analysis was conducted using a Cox proportional hazards model
                                        (adjusted for age,
                                        ECOG PS, <i>EGFR</i> mutation type, Asian race, and history of brain metastases) in
                                        patients still at
                                        risk for progression after 4 months of RYBREVANT exposure. No significant
                                        association was found
                                        between dose interruptions and PFS after 4 months of RYBREVANT exposure (HR,
                                        1.06;
                                        95% CI, 0.73-1.44).
                                      </li>
                                    </ul>
                                  </div>

                                  <div class="col-12 mb-5 pb-1">
                                    <h3 class="modal-title table-header font-weight-bold">Safety<sup>11</sup>
                                    </h3>

                                    <ul class="cw-list text-left pl-3 mb-4">
                                      <li class="pl-0">
                                        Key AEs reported were rash, paronychia, hypoalbuminemia, dermatitis acneiform,
                                        stomatitis,
                                        decreased appetite, peripheral edema, and diarrhea.
                                        <ul>
                                          <li>The prevalence of key AEs was comparable between patients with and without
                                            RYBREVANT
                                            dose interruptions during the first 4 months of RYBREVANT exposure.
                                          </li>
                                          <li>The prevalence of key AEs was also comparable between patients with and
                                            without RYBREVANT
                                            dose interruptions at 5-8 months of RYBREVANT exposure.</li>
                                        </ul>
                                      </li>
                                      <li class="pl-0">
                                        Key AEs occurred most frequently during the first 4 months and declined over the
                                        next 4 months.
                                        <ul>
                                          <li>Notably, rash decreased by ~50%, paronychia by ~30%, and diarrhea by ~70%.
                                          </li>
                                        </ul>
                                      </li>
                                      <li class="pl-0">
                                        No grade 4 or 5 AEs were reported.
                                      </li>
                                    </ul>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>

                          <div class="tab-pane fade " id="comparison_exploratory-analysis"
                            aria-labelledby="comparison_exploratory-analysis-tab">
                            <div class="content-wrapper-section mb-5">
                              <div class="row">
                                <div class="col-12">
                                  <ul>
                                    <li>A randomized, double-blind, exploratory analysis evaluated the efficacy and
                                      safety of single-agent lazertinib<sup>a</sup> (n=216) vs osimertinib (n=429) in patients with <i>EGFR</i>-mutated
                                      locally
                                      advanced or metastatic NSCLC enrolled in the MARIPOSA study.<sup>12</sup></li>
                                  </ul>
                                </div>

                                <div class="col-12 pb-1">
                                  <h3 class="modal-title table-header  font-weight-bold">Efficacy<sup>12</sup>
                                  </h3>

                                  <ul class="cw-list text-left pl-3">
                                    <li class="pl-0">
                                      At a median follow-up of 22 months, median PFS by BICR for lazertinib vs
                                      osimertinib was
                                      18.5 months (95% CI, 14.8-20.1) vs 16.6 months (95% CI, 14.8-18.5; HR, 0.98 [95%
                                      CI, 0.79-
                                      1.22]; <i>P</i>=0.86).
                                      <ul>
                                        <li>The PFS rates for lazertinib vs osimertinib were 52% vs 48% at 18 months and
                                          35% vs 34%
                                          at 24 months, respectively.
                                        </li>
                                      </ul>
                                    </li>
                                    <li class="pl-0">ORR among all responders for lazertinib vs osimertinib was 83% (95%
                                      CI, 77-88) vs 85%
                                      (95% CI, 81-88; <i>P</i>=0.57).</li>
                                    <li>Median TTSP (defined as the time from randomization to the first onset of
                                      new/worsening of lung
                                      cancer symptoms requiring a change in therapy, clinical intervention, or death)
                                      for lazertinib vs
                                      osimertinib was NE vs 29.3 months (95% CI, 25.3-NE; HR, 0.85 [95% CI, 0.65-1.13];
                                      <i>P</i>=0.27).
                                    </li>
                                    <li>At the interim analysis, median OS for lazertinib vs osimertinib was NE (HR, 1.00 [95% CI, 0.73-1.38]; <i>P</i>=1.00).</li>
                                  </ul>
                                </div>

                                <div class="col-md-12 mb-5 d-md-flex justify-content-around">
                                  <div class="popup-btn-wrapper text-center mt-4 pt-3 col-md-6">
                                    <button type="button" class="btn popup-btn w-100 h-100" data-toggle="modal"
                                      data-target="#exploratory-comparison-1-popup">
                                      <h3>PFS Across Subgroups</h3>
                                    </button>
                                  </div>

                                  <div class="popup-btn-wrapper text-center mt-4 pt-3 col-md-6">
                                    <button type="button" class="btn popup-btn w-100 h-100" data-toggle="modal"
                                      data-target="#exploratory-comparison-2-popup">
                                      <h3>ORR, Best Response, and DOR by BICR</h3>
                                    </button>
                                  </div>
                                </div>

                                <div class="col-12 pb-1">
                                  <h3 class="modal-title table-header  font-weight-bold">Safety<sup>12</sup>
                                  </h3>

                                  <ul class="cw-list text-left pl-3">
                                    <li class="pl-0">
                                      Most TEAEs were grade 1-2 in severity for lazertinib and osimertinib.
                                    </li>
                                    <li class="pl-0">
                                      Serious AEs were reported in 35% of patients treated with lazertinib and 33% of
                                      patients treated with osimertinib.
                                    </li>
                                    <li class="pl-0">
                                      AEs leading to death were reported in 6% of patients treated with lazertinib and
                                      7% of patients treated with osimertinib.
                                    </li>
                                    <li class="pl-0">
                                      The incidence of ILD and pneumonitis was 3% for both lazertinib and osimertinib.
                                    </li>
                                    <li class="pl-0">
                                      Higher incidence rates of rash (45% vs 31%), muscle spasms (23% vs 7%), and
                                      paresthesia (15% vs 6%) were reported with lazertinib vs osimertinib.
                                    </li>
                                    <li class="pl-0">
                                      Lower incidence rates of diarrhea (32% vs 44%), thrombocytopenia (9% vs 20%), and
                                      neutropenia (3% vs 13%) were reported with lazertinib vs osimertinib.
                                    </li>
                                    <li class="pl-0">
                                      Treatment-related discontinuations occurred in 5% of patients treated with
                                      lazertinib and 3% of patients treated with osimertinib.
                                    </li>
                                  </ul>
                                </div>

                                <div class="col-md-12 mb-5 d-md-flex justify-content-around">
                                  <div class="popup-btn-wrapper text-center mt-4 pt-3 col-md-6">
                                    <button type="button" class="btn popup-btn w-100 h-100" data-toggle="modal"
                                      data-target="#exploratory-comparison-3-popup">
                                      <h3>Summary of TEAEs</h3>
                                    </button>
                                  </div>

                                  <div class="popup-btn-wrapper text-center mt-4 pt-3 col-md-6">
                                    <button type="button" class="btn popup-btn w-100 h-100" data-toggle="modal"
                                      data-target="#exploratory-comparison-4-popup">
                                      <h3>Cardiac Safety Profile of Lazertinib vs Osimertinib</h3>
                                    </button>
                                  </div>
                                </div>
                              </div>

                              <div class="col-12">
                                <p class="footnote mb-5">
                                  <sup>a</sup>Lazertinib monotherapy was administered to evaluate the contribution of
                                  the components in the combination treatment.
                                </p>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>

                    <div class="tab-pane " id="ctdna-analysis" aria-labelledby="ctdna-analysis-tab">
                      <div class="third_level_inner_tabs">
                        <ul class="nav nav-tabs w-100 d-flex justify-content-center" id="myTab_ctdna-analysis"
                          role="tablist">
                          <li class="nav-item w-100" role="presentation">
                            <button class="nav-link active"
                              data-subtabs="patient-characteristics_ctdna-analysis_additional-analysis"
                              data-toggle="tab" data-target="#patient-characteristics_ctdna-analysis">Patient
                              Characteristics</button>
                          </li>

                          <li class="nav-item w-100" role="presentation">
                            <button class="nav-link " data-subtabs="mutation_ctdna-analysis_additional-analysis"
                              data-toggle="tab" data-target="#mutation_ctdna-analysis">Mutation Profiling of
                              ctDNA</button>
                          </li>
                        </ul>

                        <div class="tab-content" id="myTab_ctdna-analysis">
                          <div class="tab-pane fade show active" id="patient-characteristics_ctdna-analysis"
                            aria-labelledby="patient-characteristics_ctdna-analysis-tab">
                            <div class="content-wrapper-section mb-5">
                              <div class="row">
                                <div class="col-12">
                                  <div class="col-12 mb-5 pb-1">
                                    <ul class="cw-list text-left pl-3 mb-4">
                                      <li class="pl-0">
                                        An early analysis from the MARIPOSA study evaluated the mechanisms of acquired
                                        resistance
                                        to first-line RYBREVANT plus lazertinib vs osimertinib in patients with
                                        <i>EGFR</i>-mutant locally
                                        advanced or metastatic NSCLC.<sup>13</sup>
                                        <ul>
                                          <li>The analysis of detectable ctDNA was conducted at baseline and EOT
                                            (defined as at disease
                                            progression/treatment discontinuation or within 90 days of discontinuation)
                                            by NGS of paired
                                            blood samples using Guardant 360® companion diagnostics.</li>
                                        </ul>
                                      </li>
                                    </ul>
                                  </div>

                                  <div class="col-12 mb-5 pb-1">
                                    <h3 class="modal-title table-header table_header_text font-weight-bold">
                                      Patient Disposition<sup>13</sup>
                                    </h3>

                                    <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                                    <div class="table_overflow_scroll">
                                      <table
                                        class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                                        <thead>
                                          <tr>
                                            <th scope="col" class="w-25 text-wrap">Patient Disposition</th>
                                            <th scope="col" class="text-center table-header bg-red text-white w-25">
                                              RYBREVANT +
                                              <br>Lazertinib
                                              <br>(n=429)
                                            </th>
                                            <th scope="col"
                                              class="text-center table-header bg-dark-gray text-white w-25">
                                              Osimertinib
                                              <br>(n=429)
                                            </th>
                                          </tr>
                                        </thead>
                                        <tbody>
                                          <tr>
                                            <td>Treatment ongoing, n</td>
                                            <td class="text-center">214</td>
                                            <td class="text-center">177</td>
                                          </tr>
                                          <tr>
                                            <td>Discontinued treatment, n</td>
                                            <td class="text-center">215</td>
                                            <td class="text-center">252</td>
                                          </tr>
                                          <tr>
                                            <td class="pl-4">EOT<sup>a</sup> samples, n</td>
                                            <td class="text-center">119</td>
                                            <td class="text-center">155</td>
                                          </tr>
                                          <tr>
                                            <td class="pl-4">Matched baseline and EOT<sup>a</sup> ctDNA data, n (%)</td>
                                            <td class="text-center">113 (53)</td>
                                            <td class="text-center">140 (56)</td>
                                          </tr>
                                          <tr>
                                            <td colspan="3" class=" position-static">
                                              <p class="footnote m-0">
                                                <sup>a</sup>Samples taken within 90 days of discontinuation if EOT
                                                sample was unavailable; last EOT sample was collected in
                                                February 2024. Median follow-up, 32.6 months.
                                              </p>
                                            </td>
                                          </tr>
                                        </tbody>
                                      </table>
                                    </div>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>

                          <div class="tab-pane fade " id="mutation_ctdna-analysis"
                            aria-labelledby="mutation_ctdna-analysis-tab">
                            <div class="content-wrapper-section mb-5">
                              <div class="row">
                                <div class="col-12">
                                  <h3 class="modal-title table-header table_header_text  font-weight-bold">
                                    Acquired Resistance Mechanisms<sup>13</sup>
                                  </h3>

                                  <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                                  <div class="table_overflow_scroll">
                                    <table
                                      class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                                      <thead>
                                        <tr>
                                          <th scope="col" class="w-25 text-wrap">Incidence of Mutations, %</th>
                                          <th scope="col" class="text-center table-header bg-red text-white w-25">
                                            RYBREVANT + Lazertinib
                                            <br>(n=113)
                                          </th>
                                          <th scope="col"
                                            class="text-center table-header bg-dark-gray text-white w-25">
                                            Osimertinib
                                            <br>(n=140)
                                          </th>
                                        </tr>
                                      </thead>
                                      <tbody>
                                        <tr>
                                          <td class="border-right-0" colspan="2"><i>MET</i>- and <i>EGFR</i>-dependent resistance
                                          </td>
                                          <td class="border-left-0"></td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4"><i>MET</i> amplification<sup>a</sup></td>
                                          <td class="text-center">4.4</td>
                                          <td class="text-center">13.6</td>
                                        </tr>
                                        <tr>
                                          <td class="pl-5"><i>P</i>-value</td>
                                          <td class="text-center" colspan="2">0.017</td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4">Secondary <i>EGFR</i> resistance
                                            mutations<sup>b</sup></td>
                                          <td class="text-center">0.9</td>
                                          <td class="text-center">7.9</td>
                                        </tr>
                                        <tr>
                                          <td class="pl-5"><i>P</i>-value</td>
                                          <td class="text-center" colspan="2">0.014</td>
                                        </tr>
                                        <tr>
                                          <td class="border-right-0" colspan="2"><i>MET</i>- and <i>EGFR</i>-independent resistance
                                          </td>
                                          <td class="border-left-0"></td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4"><i>HER2</i> amplification</td>
                                          <td class="text-center">7.1</td>
                                          <td class="text-center">3.6</td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4"><i>RAS/RAF</i><sup>c</sup></td>
                                          <td class="text-center">9.7</td>
                                          <td class="text-center">12.1</td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4"><i>PI3K</i></td>
                                          <td class="text-center">8</td>
                                          <td class="text-center">8.6</td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4">Cell cycle<sup>d</sup></td>
                                          <td class="text-center">13.3</td>
                                          <td class="text-center">8.6</td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4"><i>TP53/RB1</i> loss</td>
                                          <td class="text-center">0.9</td>
                                          <td class="text-center">2.9</td>
                                        </tr>
                                        <tr>
                                          <td colspan="3" class=" position-static">
                                            <p class="footnote m-0">
                                              <sup>a</sup><i>MET</i> amplifications are defined as >2.2 copy number
                                              alterations. Focal <i>MET</i> amplification incidence: RYBREVANT plus
                                              lazertinib vs osimertinib, 1.8% vs 9.3%.<br>
                                              <sup>b</sup>C797S, L718X, G724X.<br>
                                              <sup>c</sup>Includes <i>BRAF</i> and <i>KRAS</i>.<br>
                                              <sup>d</sup>Includes <i>CCNE1</i>, <i>CDKN2A</i>, <i>CDK4</i>,
                                              <i>CDK6</i>, and <i>CCND2</i>.
                                            </p>
                                          </td>
                                        </tr>
                                      </tbody>
                                    </table>
                                  </div>

                                  <ul class="mt-4">
                                    <li>Resistance mechanisms were unknown for 77 (68%) patients in the RYBREVANT plus
                                      lazertinib arm and 86 (61%) patients in the osimertinib arm.<sup>13</sup></li>
                                    <li>For patients with EGFR/MET-dependent and -independent resistance mechanisms in
                                      the
                                      RYBREVANT plus lazertinib vs osimertinib arm, the frequency of complex resistance
                                      (defined
                                      as ≥2 resistance pathway alterations detected by ctDNA) was 27.8% vs
                                      42.6%.<sup>13</sup></li>
                                  </ul>

                                  <h3 class="modal-title table-header table_header_text  font-weight-bold">
                                    Incidence of Mutations at Baseline and EOT<sup>13</sup>
                                  </h3>

                                  <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                                  <div class="table_overflow_scroll">
                                    <table
                                      class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                                      <thead>
                                        <tr>
                                          <th scope="col" class="w-25">Incidence, %</th>
                                          <th scope="col" class="text-center table-header bg-red text-white w-25">
                                            RYBREVANT + Lazertinib
                                            <br>(n=36)
                                          </th>
                                          <th scope="col"
                                            class="text-center table-header bg-dark-gray text-white w-25">
                                            Osimertinib
                                            <br>(n=54)
                                          </th>
                                        </tr>
                                      </thead>
                                      <tbody>
                                        <tr>
                                          <td colspan="2" class="border-right-0"><i>EGFR</i> driver mutations (Exon19del or
                                            Exon 21 L858R)</td>
                                          <td class="border-left-0"></td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4">Baseline</td>
                                          <td class="text-center">78.8</td>
                                          <td class="text-center">82.9</td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4">EOT</td>
                                          <td class="text-center">53.1</td>
                                          <td class="text-center">72.1</td>
                                        </tr>
                                        <tr>
                                          <td class="border-right-0">Other mutations</td>
                                          <td class="border-left-0 border-right-0"></td>
                                          <td class="border-left-0"></td>
                                        </tr>
                                        <tr>
                                          <td class="pl-4">EOT</td>
                                          <td class="text-center">85</td>
                                          <td class="text-center">88.6</td>
                                        </tr>
                                      </tbody>
                                    </table>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>

                    <div class="tab-pane " id="patient-relevant-outcomes"
                      aria-labelledby="patient-relevant-outcomes-tab">
                      <div class="tab-content" id="myTab_patient-relevant-outcomes">
                        <div class="content-wrapper-section mb-5">
                          <div class="row">
                            <div class="col-12">
                              <div class="col-12 pb-1">
                                <ul class="cw-list text-left pl-3 mb-4">
                                  <li class="pl-0">
                                    An analysis evaluated the patient-relevant outcomes in patients from MARIPOSA
                                    receiving
                                    RYBREVANT plus lazertinib (n=429) vs osimertinib (n=429) as first-line treatment for
                                    <i>EGFR</i>-
                                    mutated (Exon19del or Exon 21 L858R) locally advanced or metastatic
                                    NSCLC.<sup>14</sup>
                                  </li>
                                </ul>
                              </div>

                              <div class="col-12 pb-1">
                                <h3 class="modal-title table-header font-weight-bold">TTSP<sup>14</sup>
                                </h3>

                                <ul class="cw-list text-left pl-3 mb-4">
                                  <li class="pl-0">
                                    At a median follow-up of 22 months, median TTSP<sup>a</sup> for RYBREVANT plus lazertinib vs
                                    osimertinib was NE vs 29.3 months (95% CI, 25.3-NE; HR, 0.72 [95% CI, 0.57-0.91];
                                    <i>P</i>=0.005<sup>b</sup>).
                                    <ul>
                                      <li>The proportion of patients without symptomatic progression in the RYBREVANT
                                        plus lazertinib
                                        and osimertinib arms was 74% and 67% at 18 months and 67% and 59% at 24 months,
                                        respectively.
                                      </li>
                                    </ul>
                                  </li>
                                </ul>
                              </div>

                              <div class="col-12 pb-1">
                                <h3 class="modal-title table-header  font-weight-bold">Patient-Reported
                                  Functioning<sup>14,c</sup>
                                </h3>

                                <ul class="cw-list text-left pl-3 mb-4">
                                  <li class="pl-0">
                                    No meaningful changes from baseline were observed in the global health status and
                                    cognitive
                                    functioning subscales across the RYBREVANT plus lazertinib and osimertinib arms.
                                  </li>
                                </ul>
                              </div>

                              <div class="col-12 pb-1">
                                <h3 class="modal-title table-header font-weight-bold">Patient-Reported
                                  Symptom Scores<sup>14,d</sup>
                                </h3>

                                <ul class="cw-list text-left pl-3 mb-4">
                                  <li class="pl-0">
                                    Patient-reported total symptom scores and individual lung cancer-associated symptom
                                    scores for dyspnea, pain, and cough were comparable across the RYBREVANT plus
                                    lazertinib
                                    and osimertinib arms.
                                  </li>
                                </ul>
                              </div>

                              <div class="col-12">
                                <p class="footnote">
                                  <sup>a</sup>Median TTSP with 95% CI was calculated using the Kaplan-Meier method.<br>
                                  <sup>b</sup>HR with 95% CI calculated using a stratified Cox regression model; nominal
                                  <i>P</i>-value calculated using a stratified log-rank test.<br>
                                  <sup>c</sup>Based on EORTC-QLQ-C30.<br>
                                  <sup>d</sup>Based on NSCLC-SAQ; outcomes were measured on D1 of the cycle.<br>
                                </p>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>

              <div class="tab-pane fade" id="abbreviations-and-references"
                aria-labelledby="abbreviations-and-references-tab">
                <div class="second_level_inner_tabs">
                  <ul class="nav nav-tabs w-100 d-flex justify-content-center" id="myTab_abbreviations-and-references"
                    role="tablist">

                    <li class="nav-item w-100" role="presentation">
                      <button class="nav-link second active" data-subtabs="abbreviations_abbreviations-and-references"
                        data-toggle="tab" data-target="#abbreviations">Abbreviations</button>
                    </li>


                    <li class="nav-item w-100" role="presentation">
                      <button class="nav-link second " data-subtabs="literature-search_abbreviations-and-references"
                        data-toggle="tab" data-target="#literature-search">Literature Search</button>
                    </li>

                    <li class="nav-item w-100" role="presentation">
                      <button class="nav-link second" data-subtabs="references_abbreviations-and-references"
                        data-toggle="tab" data-target="#references">References</button>
                    </li>

                  </ul>

                  <div class="tab-content">
                    <div class="tab-pane show active" id="abbreviations" aria-labelledby="abbreviations-tab">
                      <div class="third_level_inner_tabs">
                        <ul class="nav nav-tabs w-100 d-flex justify-content-center" id="myTab_andromeda"
                          role="tablist">
                          <li class="nav-item w-100" role="presentation">
                            <button class="nav-link active"
                              data-subtabs="part12_abbreviations_abbreviations-and-references" data-toggle="tab"
                              data-target="#part12">Page 1 of 2</button>
                          </li>

                          <li class="nav-item w-100" role="presentation">
                            <button class="nav-link " data-subtabs="part22_abbreviations_abbreviations-and-references"
                              data-toggle="tab" data-target="#part22">Page 2 of 2</button>
                          </li>
                        </ul>

                        <div class="tab-content">
                          <div class="tab-pane fade show active" id="part12" aria-labelledby="#part12-tab">
                            <div class="content-wrapper-section mb-5">
                              <div class="row">
                                <div class="col-12">
                                  <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                                  <div class="table_overflow_scroll">
                                    <table class="table table-bordered reference-table table-sm mb-5 border-0">
                                      <thead>
                                        <tr>
                                          <th>ADC</th>
                                          <td>Antibody-drug conjugate</td>
                                          <th>EOT</th>
                                          <td>End of treatment</td>
                                        </tr>
                                      </thead>
                                      <tbody>
                                        <tr>
                                          <th>AE</th>
                                          <td>Adverse event</td>
                                          <th>Exon19del</th>
                                          <td>Exon 19 deletion</td>
                                        </tr>
                                        <tr>
                                          <th>ALK</th>
                                          <td>Anaplastic lymphoma kinase</td>
                                          <th>HR</th>
                                          <td>Hazard ratio</td>
                                        </tr>
                                        <tr>
                                          <th>ALT</th>
                                          <td>Alanine aminotransferase</td>
                                          <th>icDOR</th>
                                          <td>Intracranial DOR</td>
                                        </tr>
                                        <tr>
                                          <th>AST</th>
                                          <td>Aspartate aminotransferase</td>
                                          <th>icORR</th>
                                          <td>Intracranial ORR</td>
                                        </tr>
                                        <tr>
                                          <th>BICR</th>
                                          <td>Blinded independent central review</td>
                                          <th>icPFS</th>
                                          <td>Intracranial PFS</td>
                                        </tr>
                                        <tr>
                                          <th>C</th>
                                          <td>Cycle</td>
                                          <th>IgG1</th>
                                          <td>Immunoglobulin G1</td>
                                        </tr>
                                        <tr>
                                          <th>c-MET</th>
                                          <td>c-mesenchymal-epithelial
                                            transition factor</td>
                                          <th>ILD</th>
                                          <td>Interstitial lung disease</td>
                                        </tr>
                                        <tr>
                                          <th>CI</th>
                                          <td>Confidence interval</td>
                                          <th>IO</th>
                                          <td>Immuno-oncology</td>
                                        </tr>

                                        <tr>
                                          <th>COVID-19</th>
                                          <td>Coronavirus disease 2019</td>
                                          <th>IQR</th>
                                          <td>Interquartile range</td>
                                        </tr>
                                        <tr>
                                          <th>CR</th>
                                          <td>Complete response</td>
                                          <th>IRR</th>
                                          <td>Infusion-related reaction</td>
                                        </tr>
                                        <tr>
                                          <th>ctDNA</th>
                                          <td>Circulating tumor DNA</td>
                                          <th>IV</th>
                                          <td>Intravenous</td>
                                        </tr>
                                        <tr>
                                          <th>D</th>
                                          <td>Day</td>
                                          <th>LLN</th>
                                          <td>Lower limit of normal</td>
                                        </tr>

                                        <tr>
                                          <th>ddPCR</th>
                                          <td>Droplet digital polymerase
                                            chain reaction</td>
                                          <th>LVEF</th>
                                          <td>Left ventricular ejection fraction</td>
                                        </tr>
                                        <tr>
                                          <th>DOR</th>
                                          <td>Duration of response</td>
                                          <th>MET</th>
                                          <td>Mesenchymal-epithelial transition</td>
                                        </tr>
                                        <tr>
                                          <th>DVT</th>
                                          <td>Deep vein thrombosis</td>
                                          <th>NCCN</th>
                                          <td>National Comprehensive Cancer
                                            Network</td>
                                        </tr>
                                        <tr>
                                          <th>ECOG PS</th>
                                          <td>Eastern Cooperative
                                            Oncology Group
                                            performance status</td>
                                          <th>NE</th>
                                          <td>Not estimable</td>
                                        </tr>
                                        <tr>
                                          <th>EGFR</th>
                                          <td>Epidermal growth factor receptor</td>
                                          <th>NE/UNK</th>
                                          <td>Not evaluable/unknown</td>
                                        </tr>
                                        <tr>
                                          <th>EORTC-
                                            QLQ-C30</th>
                                          <td>European Organisation for
                                            Research and Treatment of Cancer
                                            Quality of Life Questionnaire</td>
                                          <th>NGS</th>
                                          <td>Next-generation sequencing</td>
                                        </tr>
                                      </tbody>
                                    </table>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>

                          <div class="tab-pane fade " id="part22" aria-labelledby="part22-tab">
                            <div class="content-wrapper-section mb-5">
                              <div class="row">
                                <div class="col-12">
                                  <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                                  <div class="table_overflow_scroll">
                                    <table class="table table-bordered reference-table table-sm mb-5 border-0">
                                      <tbody>
                                        <tr>
                                          <th>NSCLC</th>
                                          <td>Non-small cell lung cancer</td>
                                          <th>Q2W</th>
                                          <td>Every 2 weeks</td>
                                        </tr>
                                        <tr>
                                          <th>NSCLC-
                                            SAQ</th>
                                          <td>Non-Small Cell Lung Cancer
                                            Symptom Assessment
                                            Questionnaire</td>
                                          <th>QW</th>
                                          <td>Once weekly</td>
                                        </tr>
                                        <tr>
                                          <th>ORR</th>
                                          <td>Objective response rate</td>
                                          <th>R</th>
                                          <td>Randomization</td>
                                        </tr>
                                        <tr>
                                          <th>OS</th>
                                          <td>Overall survival</td>
                                          <th>RECIST</th>
                                          <td>Response Evaluation Criteria
                                            in Solid Tumors</td>
                                        </tr>
                                        <tr>
                                          <th>PD</th>
                                          <td>Progressive disease </td>
                                          <th>SD</th>
                                          <td>Stable disease</td>
                                        </tr>
                                        <tr>
                                          <th>PE</th>
                                          <td>Pulmonary embolism</td>
                                          <th>TEAE</th>
                                          <td>Treatment-emergent AE</td>
                                        </tr>
                                        <tr>
                                          <th>PFS</th>
                                          <td>Progression-free survival</td>
                                          <th>TRAE</th>
                                          <td>Treatment-related AE</td>
                                        </tr>
                                        <tr>
                                          <th>PFS2</th>
                                          <td>PFS after first subsequent therapy</td>
                                          <th>TTD</th>
                                          <td>Time to treatment discontinuation</td>
                                        </tr>
                                        <tr>
                                          <th>PO</th>
                                          <td>Orally</td>
                                          <th>TTSP</th>
                                          <td>Time to subsequent progression</td>
                                        </tr>
                                        <tr>
                                          <th>PR</th>
                                          <td>Partial response</td>
                                          <th>TTST</th>
                                          <td>Time to subsequent therapy</td>
                                        </tr>
                                        <tr>
                                          <th>PRO</th>
                                          <td>Patient-reported outcome</td>
                                          <th>VEGFi</th>
                                          <td>Vascular endothelial growth
                                            factor inhibitor</td>
                                        </tr>
                                        <tr>
                                          <th>QD</th>
                                          <td>Once daily</td>
                                          <th>VTE</th>
                                          <td>Venous thromboembolism</td>
                                        </tr>
                                      </tbody>
                                    </table>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>

                    <div class="tab-pane " id="literature-search" aria-labelledby="literature-search-tab">
                      <div class="content-wrapper-section mb-5">
                        <div class="row">
                          <div class="col-12">
                            <p>A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or
                              other resources, including internal/external databases) was conducted on 10 September
                              2024.</p>
                          </div>
                        </div>
                      </div>

                    </div>

                    <div class="tab-pane " id="references" aria-labelledby="references-tab">
                      <div class="content-wrapper-section mb-5">
                        <div class="row">
                          <div class="col-12">
                            <div class="references-list">
                              <ol>
                                <li>Moores SL, Chiu ML, Bushey BS, et al. A novel bispecific antibody targeting EGFR
                                  and cMet is effective against EGFR inhibitor-resistant lung tumors. <i>Cancer
                                    Res.</i> 2016;76(13):3942-3953.</li>
                                <li>Cho BC, Felip E, Hayashi H, et al. MARIPOSA: phase 3 study of first-line amivantamab
                                  + lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer. <i>Future
                                    Oncol</i>. 2022;18(6):639-647.</li>
                                <li>Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small 
                                  Cell Lung Cancer V.11.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed 
                                  October 16, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes 
                                  no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for 
                                  their application or use in any way.</li>
                                <li>Janssen Research & Development, LLC. A phase 3, randomized study of
                                  amivantamab and lazertinib combination therapy
                                  versus osimertinib versus lazertinib as first-line treatment in patients with
                                  EGFR-mutated locally advanced or metastatic
                                  non-small cell lung cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National
                                  Library of Medicine (US). 2000- [cited
                                  2024 September 10]. Available from: <a
                                    href="https://clinicaltrials.gov/ct2/show/NCT04487080">https://clinicaltrials.gov/ct2/show/NCT04487080</a>
                                  NLM Identifier: NCT04487080.</li>
                                <li>Cho BC, Lu S, Felip E, et al. Amivantamab plus lazertinib in previously untreated
                                  EGFR-mutated advanced NSCLC. <i>N Engl J Med.</i>
                                  2024;391:1486-1498.
                                </li>
                                <li>Felip E, Cho BC, Gutiérrez V, et al. Amivantamab plus lazertinib vs osimertinib in
                                  first-line EGFR-mutant advanced non-
                                  small cell lung cancer (NSCLC) with biomarkers of high-risk disease: a secondary
                                  analysis from the phase 3 MARIPOSA
                                  study. Oral Presentation presented at: American Society of Clinical Oncology (ASCO)
                                  Annual Meeting; May 31-June 4,
                                  2024; Chicago, IL.</li>
                                <li>Gadgeel SM, Cho BC, Lu S, et al. Amivantamab plus lazertinib vs osimertinib in
                                  first-line EGFR-mutant advanced NSCLC:
                                  longer follow-up of the MARIPOSA study. Oral Presentation presented at: International
                                  Association for the Study of Lung
                                  Cancer (IASLC) World Conference on Lung Cancer (WCLC); September 7-10, 2024; San
                                  Diego, CA.</li>
                                <li>Felip E, Cho BC, Gutiérrez V, et al. Amivantamab plus lazertinib versus osimertinib
                                  in first-line EGFR-mutant advanced
                                  non-small cell lung cancer with biomarkers of high-risk disease: a secondary analysis
                                  from MARIPOSA <i>Ann Oncol</i>. 2024; 35(9):805-816.</li>
                                <li>Lu S, Cho BC, Lee JS, et al. Amivantamab plus lazertinib vs osimertinib as
                                  first-line treatment among Asian patients with
                                  EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis.
                                  Oral Presentation presented
                                  at: European Society for Medical Oncology (ESMO) Asia Congress; December 1-3, 2023;
                                  Singapore.</li>
                                <li>Spira AI, Spigel D, Nguyen D, et al. Amivantamab plus lazertinib versus osimertinib
                                  in first-line EGFR-mutant advanced
                                  NSCLC: a post-progression and safety analysis of MARIPOSA. Oral Presentation presented
                                  at: North America Conference
                                  on Lung Cancer (NACLC); December 1-3, 2023; Chicago, IL.</li>
                                <li>Campelo M del RG, Cho BC, Girard N, et al. Effect of amivantamab dose interruptions
                                  on efficacy and safety of first-line
                                  amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: exploratory analyses from
                                  the MARIPOSA study. Oral
                                  Presentation presented at: European Lung Cancer Congress (ELCC); March 20-23, 2024;
                                  Prague, Czech Republic.</li>
                                <li>Lee S-H, Cho BC, Hayashi H, et al. Lazertinib vs osimertinib in 1L EGFR-mutant
                                  advanced NSCLC: a randomized,
                                  double-blind, exploratory analysis from MARIPOSA. Oral Presentation presented at:
                                  International Association for the
                                  Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC); September 7-10,
                                  2024; San Diego, CA.</li>
                                <li>Besse B, Lee S-H, Lu S, et al. Mechanisms of acquired resistance to first-line
                                  amivantamab plus lazertinib versus
                                  osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: an early
                                  analysis from the phase 3
                                  MARIPOSA study. Oral Presentation presented at: European Society for Medical Oncology
                                  (ESMO) Congress;
                                  September 13-17, 2024; Barcelona, Spain.</li>
                                <li>Nguyen D, Besse B, Cho BC, et al. Amivantamab plus lazertinib vs osimertinib in
                                  first-line, EGFR-mutant advanced
                                  NSCLC: patient-relevant outcomes from MARIPOSA. Oral Presentation presented at:
                                  International Association for
                                  the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC); September
                                  7-10, 2024; San Diego,
                                  CA.</li>
                                <li>Cho BC, Felip E, Spira AI, et al. Amivantamab plus lazertinib vs osimertinib as
                                  first-line treatment in EGFR-mutated,
                                  advanced NSCLC: primary results from MARIPOSA, a phase 3, global, randomized
                                  controlled trial. Oral Presentation
                                  presented at: European Society for Medical Oncology (ESMO) Congress; October 20-24,
                                  2023; Madrid, Spain.</li>
                                <li>Cho BC, Lu S, Felip E, et al. Clinical Protocol for: Amivantamab plus lazertinib in
                                  previously untreated EGFR-
                                  mutated advanced NSCLC. <i>N Engl J Med</i>.
                                  2024;391:1486-1498.</li>
                              </ol>
                              © Janssen Scientific Affairs, LLC 2025. All rights reserved. <br>Last updated: 29 January 2025

                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>

            <div id="popup-content">
              <!-- Efficacy Primary Endpoints Popup Start -->
              <div class="modal fade" id="efficacy-primary-popup" tabindex="-1" role="dialog"
                aria-labelledby="exampleModalLongTitle" aria-hidden="true" data-backdrop="static">
                <div class="modal-dialog modal-dialog-centered" role="document">
                  <div class="modal-content">
                    <div class="modal-header">
                      <h3 class="modal-title table-header font-weight-bold ">PFS by BICR Across Predefined
                        Subgroups: RYBREVANT Plus Lazertinib vs
                        Osimertinib<sup>5</sup>
                      </h3>
                      <button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
                    </div>
                    <div class="modal-body">
                      <div class="content-wrapper-section mt-0">
                        <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                        <div class="table_overflow_scroll">
                          <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                            <thead>
                              <tr>
                                <th class="border-bottom-0"></th>
                                <th class="border-bottom-0"></th>
                                <th class="text-center" colspan="2">Events/N</th>
                              </tr>
                              <tr>
                                <th scope="col" class="border-top-0 text-center">Subgroup</th>
                                <th scope="col" class="border-top-0 text-center">HR (95% CI)</th>
                                <th scope="col" class="text-center table-header bg-red text-white w-25">
                                  RYBREVANT +
                                  <br>
                                  Lazertinib
                                </th>
                                <th scope="col" class="text-center table-header bg-dark-Gray text-white w-25">
                                  Osimertinib</th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td>All randomized patients</td>
                                <td class="text-center">0.7 (0.58-0.85)</td>
                                <td class="text-center">192/429</td>
                                <td class="text-center">252/429</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">Age</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">&lt; 65 years</td>
                                <td class="text-center">0.5 (0.39-0.65)</td>
                                <td class="text-center">94/235</td>
                                <td class="text-center">153/237</td>
                              </tr>
                              <tr>
                                <td class="pl-4">≥ 65 years</td>
                                <td class="text-center">1.06 (0.8-1.41)</td>
                                <td class="text-center">98/194</td>
                                <td class="text-center">99/192</td>
                              </tr>
                              <tr>
                                <td class="pl-4">&lt; 75 years</td>
                                <td class="text-center">0.7 (0.57-0.85)</td>
                                <td class="text-center">165/378</td>
                                <td class="text-center">220/376</td>
                              </tr>
                              <tr>
                                <td class="pl-4">≥ 75 years</td>
                                <td class="text-center">0.77 (0.46-1.3)</td>
                                <td class="text-center">27/51</td>
                                <td class="text-center">32/53</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">Sex</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Female</td>
                                <td class="text-center">0.7 (0.55-0.9)</td>
                                <td class="text-center">112/275</td>
                                <td class="text-center">140/251</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Male</td>
                                <td class="text-center">0.74 (0.55-0.98)</td>
                                <td class="text-center">80/154</td>
                                <td class="text-center">112/178</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">Race</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Asian</td>
                                <td class="text-center">0.67 (0.52-0.86)</td>
                                <td class="text-center">105/250</td>
                                <td class="text-center">144/251</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Non-Asian</td>
                                <td class="text-center">0.75 (0.56-0.99)</td>
                                <td class="text-center">85/117</td>
                                <td class="text-center">108/177</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">Body Weight</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">&lt; 80 kg</td>
                                <td class="text-center">0.7 (0.57-0.86)</td>
                                <td class="text-center">161/376</td>
                                <td class="text-center">209/368</td>
                              </tr>
                              <tr>
                                <td class="pl-4">≥ 80 kg</td>
                                <td class="text-center">0.77 (0.48-1.22)</td>
                                <td class="text-center">31/53</td>
                                <td class="text-center">43/61</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">ECOG PS</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">0</td>
                                <td class="text-center">0.79 (0.56-1.12)</td>
                                <td class="text-center">56/141</td>
                                <td class="text-center">76/149</td>
                              </tr>
                              <tr>
                                <td class="pl-4">1</td>
                                <td class="text-center">0.66 (0.52-0.82)</td>
                                <td class="text-center">136/288</td>
                                <td class="text-center">176/280</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">Smoking history</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Yes</td>
                                <td class="text-center">0.78 (0.56-1.08)</td>
                                <td class="text-center">67/130</td>
                                <td class="text-center">79/134</td>
                              </tr>
                              <tr>
                                <td class="pl-4">No</td>
                                <td class="text-center">0.67 (0.53-0.84)</td>
                                <td class="text-center">125/299</td>
                                <td class="text-center">173/295</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">History of brain metastases</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Yes</td>
                                <td class="text-center">0.69 (0.53-0.92)</td>
                                <td class="text-center">94/178</td>
                                <td class="text-center">111/172</td>
                              </tr>
                              <tr>
                                <td class="pl-4">No</td>
                                <td class="text-center">0.69 (0.53-0.89)</td>
                                <td class="text-center">98/251</td>
                                <td class="text-center">141/257</td>
                              </tr>
                              <tr>
                                <td class="border-right-0"><i>EGFR</i> mutation</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Exon19del</td>
                                <td class="text-center">0.65 (0.51-0.85)</td>
                                <td class="text-center">101/257</td>
                                <td class="text-center">142/257</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Exon 21 L858R</td>
                                <td class="text-center">0.78 (0.59-1.02)</td>
                                <td class="text-center">90/171</td>
                                <td class="text-center">110/172</td>
                              </tr>
                            </tbody>
                          </table>
                        </div>
                      </div>
                      <p class="footnote mt-0">CI, confidence interval; ECOG PS, Eastern Cooperative
                        Oncology Group performance status; <i>EGFR</i>, epidermal
                        growth factor receptor; Exon19del, Exon 19 deletion; HR, hazard ratio; PFS, progression-free
                        survival.</p>
                    </div>
                  </div>
                </div>
              </div>
              <!-- Efficacy Primary Endpoints Popup End -->

              <!-- First Subserquent Therapy Popup Start -->
              <div class="modal fade" id="first-subsequent-popup" tabindex="-1" role="dialog"
                aria-labelledby="exampleModalLongTitle" aria-hidden="true" data-backdrop="static">
                <div class="modal-dialog modal-dialog-centered" role="document">
                  <div class="modal-content">
                    <div class="modal-header">
                      <h3 class="modal-title table-header font-weight-bold">
                        First Subsequent Therapies<sup>7</sup>
                      </h3>
                      <button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
                    </div>
                    <div class="modal-body">
                      <div class="content-wrapper-section mt-0">
                        <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                        <div class="table_overflow_scroll">
                          <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                            <thead>
                              <tr>
                                <th scope="col" class="d-lg-none px-3" style="width: 0%;">First Subsequent<br>
                                  Therapy,<sup>a,b</sup> %</th>
                                <th scope="col" class="w-50 d-none d-lg-table-cell">First Subsequent
                                  Therapy,<sup>a,b</sup> %</th>
                                <th scope="col" class="text-center table-header bg-red text-white w-25">
                                  RYBREVANT+ Lazertinib<br>(n=111)
                                </th>
                                <th scope="col" class="text-center table-header bg-dark-Gray text-white w-25">
                                  Osimertinib<br>(n=173)<sup>c</sup>
                                </th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td>Any TKI</td>
                                <td class="text-center">42</td>
                                <td class="text-center">28</td>
                              </tr>
                              <tr>
                                <td class="pl-4">TKI combination</td>
                                <td class="text-center">8</td>
                                <td class="text-center">7</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Other TKIs</td>
                                <td class="text-center">7</td>
                                <td class="text-center">5</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Osimertinib/other third-generation TKIs</td>
                                <td class="text-center">27</td>
                                <td class="text-center">16</td>
                              </tr>
                              <tr>
                                <td>Any chemotherapy</td>
                                <td class="text-center">54</td>
                                <td class="text-center">68</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Doublet chemotherapy + IO/VEGFi</td>
                                <td class="text-center">12</td>
                                <td class="text-center">20</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Doublet chemotherapy<sup>d</sup></td>
                                <td class="text-center">41</td>
                                <td class="text-center">45</td>
                              </tr>
                            </tbody>
                          </table>
                        </div>
                      </div>
                      <p class="footnote mt-2">
                        <sup>a</sup>Percentages were not provided for single-agent chemotherapy, single-agent
                        chemotherapy + IO/VEGFi, VEGFi alone
                        therapy, or other therapy (including herbals, ADCs, ALK TKIs, C-MET TKIs, RYBREVANT, and
                        investigational
                        agents) for both treatment arms.<br>
                        <sup>b</sup>Percentages may not sum to 100 due to rounding.<br>
                        <sup>c</sup>Two patients in the osimertinib arm received RYBREVANT as a subsequent treatment
                        (monotherapy, n=1; combination with
                        lazertinib, n=1).<br>
                        <sup>d</sup>Includes 1 patient who received herbal + doublet chemotherapy.<br>
                        ADC, antibody-drug conjugate; ALK, anaplastic lymphoma kinase; c-MET, c-mesenchymal-epithelial transition factor;
                        IO, immuno-oncology; TKI, tyrosine kinase inhibitor; VEGFi, vascular endothelial growth factor inhibitor.
                      </p>
                    </div>
                  </div>
                </div>
              </div>
              <!-- First Subserquent Therapy Popup End -->

              <!-- Summary of AEs Popup Start -->
              <div class="modal fade" id="summary-of-aes-popup" tabindex="-1" role="dialog"
                aria-labelledby="exampleModalLongTitle" aria-hidden="true" data-backdrop="static">
                <div class="modal-dialog modal-dialog-centered" role="document">
                  <div class="modal-content">
                    <div class="modal-header">
                      <h3 class="modal-title table-header font-weight-bold">
                        Summary of AEs<sup>5,a</sup>
                      </h3>
                      <button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
                    </div>
                    <div class="modal-body">
                      <div class="content-wrapper-section mt-0">
                        <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                        <div class="table_overflow_scroll">
                          <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                            <thead>
                              <tr>
                                <th scope="col" rowspan="2" class="w-25 text-wrap">
                                  Most Common (≥15% in Either Group) AEs, n (%)
                                </th>
                                <th scope="col" colspan="2" class="text-center table-header bg-red text-white w-25">
                                  RYBREVANT + Lazertinib
                                  <br>
                                  (n=421)
                                </th>
                                <th scope="col" colspan="2"
                                  class="text-center table-header bg-dark-Gray text-white w-25">
                                  Osimertinib
                                  <br>(n=428)
                                </th>
                              </tr>
                              <tr>
                                <th class="d-none"></th>
                                <th class="text-center table-header">All Grades</th>
                                <th class="text-center table-header">Grade &#8805;3</th>
                                <th class="text-center table-header">All Grades</th>
                                <th class="text-center table-header">Grade &#8805;3</th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td class="pr-4">Paronychia</td>
                                <td class="text-center">288 (68)</td>
                                <td class="text-center">46 (11)</td>
                                <td class="text-center">121 (28)</td>
                                <td class="text-center">2 (0.5)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">IRR</td>
                                <td class="text-center">265 (63)</td>
                                <td class="text-center">27 (6)</td>
                                <td class="text-center">0</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Rash</td>
                                <td class="text-center">260 (62)</td>
                                <td class="text-center">65 (15)</td>
                                <td class="text-center">131 (31)</td>
                                <td class="text-center">3 (1)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Hypoalbuminemia</td>
                                <td class="text-center">204 (48)</td>
                                <td class="text-center">22 (5)</td>
                                <td class="text-center">26 (6)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Increased ALT</td>
                                <td class="text-center">152 (36)</td>
                                <td class="text-center">21 (5)</td>
                                <td class="text-center">57 (13)</td>
                                <td class="text-center">8 (2)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Peripheral edema</td>
                                <td class="text-center">150 (36)</td>
                                <td class="text-center">8 (2)</td>
                                <td class="text-center">24 (6)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Constipation</td>
                                <td class="text-center">123 (29)</td>
                                <td class="text-center">0</td>
                                <td class="text-center">55 (13)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Diarrhea</td>
                                <td class="text-center">123 (29)</td>
                                <td class="text-center">9 (2)</td>
                                <td class="text-center">190 (44)</td>
                                <td class="text-center">3 (1)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Dermatitis acneiform</td>
                                <td class="text-center">122 (29)</td>
                                <td class="text-center">35 (8)</td>
                                <td class="text-center">55 (13)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Stomatitis</td>
                                <td class="text-center">122 (29)</td>
                                <td class="text-center">5 (1)</td>
                                <td class="text-center">90 (21)</td>
                                <td class="text-center">1 (0.2)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Increased AST</td>
                                <td class="text-center">121 (29)</td>
                                <td class="text-center">14 (3)</td>
                                <td class="text-center">58 (14)</td>
                                <td class="text-center">5 (1)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">COVID-19</td>
                                <td class="text-center">111 (26)</td>
                                <td class="text-center">8 (2)</td>
                                <td class="text-center">103 (24)</td>
                                <td class="text-center">9 (2)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Decreased appetite</td>
                                <td class="text-center">103 (24)</td>
                                <td class="text-center">4 (1)</td>
                                <td class="text-center">76 (18)</td>
                                <td class="text-center">6 (1)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Pruritus</td>
                                <td class="text-center">99 (24)</td>
                                <td class="text-center">2 (0.5)</td>
                                <td class="text-center">73 (17)</td>
                                <td class="text-center">1 (0.2)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Anemia</td>
                                <td class="text-center">96 (23)</td>
                                <td class="text-center">16 (4)</td>
                                <td class="text-center">91 (21)</td>
                                <td class="text-center">7 (2)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Nausea</td>
                                <td class="text-center">90 (21)</td>
                                <td class="text-center">5 (1)</td>
                                <td class="text-center">58 (14)</td>
                                <td class="text-center">1 (0.2)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Hypocalcemia</td>
                                <td class="text-center">88 (21)</td>
                                <td class="text-center">9 (2)</td>
                                <td class="text-center">35 (8)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Asthenia</td>
                                <td class="text-center">78 (19)</td>
                                <td class="text-center">12 (3)</td>
                                <td class="text-center">46 (11)</td>
                                <td class="text-center">4 (1)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">PE</td>
                                <td class="text-center">73 (17)</td>
                                <td class="text-center">35 (8)</td>
                                <td class="text-center">20 (5)</td>
                                <td class="text-center">10 (2)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Fatigue</td>
                                <td class="text-center">70 (17)</td>
                                <td class="text-center">6 (1)</td>
                                <td class="text-center">42 (10)</td>
                                <td class="text-center">4 (1)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Muscle spasms</td>
                                <td class="text-center">70 (17)</td>
                                <td class="text-center">2 (0.5)</td>
                                <td class="text-center">32 (7)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Dry skin</td>
                                <td class="text-center">67 (16)</td>
                                <td class="text-center">1 (0.2)</td>
                                <td class="text-center">60 (14)</td>
                                <td class="text-center">1 (0.2)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Thrombocytopenia</td>
                                <td class="text-center">66 (16)</td>
                                <td class="text-center">1 (0.2)</td>
                                <td class="text-center">84 (20)</td>
                                <td class="text-center">5 (1)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Cough</td>
                                <td class="text-center">65 (15)</td>
                                <td class="text-center">0</td>
                                <td class="text-center">88 (21)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Pain in extremity</td>
                                <td class="text-center">64 (15)</td>
                                <td class="text-center">1 (0.2)</td>
                                <td class="text-center">22 (5)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Dyspnea</td>
                                <td class="text-center">51 (12)</td>
                                <td class="text-center">6 (1)</td>
                                <td class="text-center">68 (16)</td>
                                <td class="text-center">17 (4)</td>
                              </tr>
                              <tr>
                                <td class="pr-4">Leukopenia</td>
                                <td class="text-center">26 (6)</td>
                                <td class="text-center">1 (0.2)</td>
                                <td class="text-center">66 (15)</td>
                                <td class="text-center">0</td>
                              </tr>
                            </tbody>
                          </table>
                        </div>
                        <table class="table ref_table">
                          <tbody>
                            <tr>
                              <td>
                                <p class="footnote mt-0">
                                  <sup>a</sup>The safety population included all the patients who had undergone
                                  randomization and received ≥1 dose of any trial
                                  treatment.
                                </p>
                              </td>
                            </tr>
                          </tbody>
                        </table>
                      </div>
                      <p class="footnote mt-0">AE, adverse event; ALT, alanine aminotransferase; AST,
                        aspartate aminotransferase; COVID-19, coronavirus
                        disease 2019; IRR, infusion-related reaction; PE,
                        pulmonary embolism.</p>
                    </div>
                  </div>
                </div>
              </div>
              <!-- Summary of AEs Popup End -->

              <!-- AEs of Special Interest Popup Start -->
              <div class="modal fade" id="aes-special-interest-popup" tabindex="-1" role="dialog"
                aria-labelledby="exampleModalLongTitle" aria-hidden="true" data-backdrop="static">
                <div class="modal-dialog modal-dialog-centered" role="document">
                  <div class="modal-content">
                    <div class="modal-header">
                      <h3 class="modal-title table-header font-weight-bolde">AEs of Special
                        Interest: VTE<sup>5</sup>
                      </h3>
                      <button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
                    </div>
                    <div class="modal-body">
                      <div class="content-wrapper-section mt-0">
                        <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                        <div class="table_overflow_scroll">
                          <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                            <thead>
                              <tr>
                                <th scope="col" class="w-25 text-wrap"></th>
                                <th scope="col" class="text-center table-header bg-red text-white w-25">
                                  RYBREVANT +
                                  <br>Lazertinib
                                  <br>(n=421)
                                </th>
                                <th scope="col" class="text-center table-header bg-dark-Gray text-white w-25">
                                  Osimertinib
                                  <br>(n=428)
                                </th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td>Any VTE,<sup>a</sup> n (%)</td>
                                <td class="text-center">157 (37)</td>
                                <td class="text-center">39 (9)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Grade 1</td>
                                <td class="text-center">5 (1)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Grade 2</td>
                                <td class="text-center">105 (25)</td>
                                <td class="text-center">24 (6)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Grade 3</td>
                                <td class="text-center">43 (10)</td>
                                <td class="text-center">12 (3)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Grade 4</td>
                                <td class="text-center">2 (0.5)</td>
                                <td class="text-center">1 (0.2)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Grade 5</td>
                                <td class="text-center">2 (0.5)</td>
                                <td class="text-center">2 (0.5)</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">Anticoagulant use, n (%)</td>
                                <td class="border-left-0 border-right-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">At baseline</td>
                                <td class="text-center">21 (5)</td>
                                <td class="text-center">23 (5)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Concomitant use</td>
                                <td class="text-center">199 (47)</td>
                                <td class="text-center">81 (19)</td>
                              </tr>
                              <tr>
                                <td class="pl-5">First bleeding event while on anticoagulants</td>
                                <td class="text-center">34 (8)</td>
                                <td class="text-center">14 (3)</td>
                              </tr>
                              <tr>
                                <td class="pl-5">Recurrent VTE event while on anticoagulants</td>
                                <td class="text-center">8 (2)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td>Median (range) onset to first VTE, days</td>
                                <td class="text-center">84 (6-777)</td>
                                <td class="text-center">194 (10-675)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Within first 4 months, n (%)</td>
                                <td class="text-center">97/157 (62)</td>
                                <td class="text-center">13/39 (33)</td>
                              </tr>
                              <tr>
                                <td>Any VTE leading to death, n (%)</td>
                                <td class="text-center">2 (0.5)</td>
                                <td class="text-center">2 (0.5)</td>
                              </tr>
                              <tr>
                                <td>Any VTE leading to any discontinuation of any agent, n (%)</td>
                                <td class="text-center">12 (3)</td>
                                <td class="text-center">2 (0.5)</td>
                              </tr>
                            </tbody>
                          </table>
                        </div>
                      </div>
                      <p class="footnote mt-0">
                        <sup>a</sup>VTE grouping includes the following preferred terms: PE, DVT, venous thrombosis
                        limb, thrombosis, venous thrombosis,
                        superficial vein thrombosis, thrombophlebitis, embolism, embolism venous, jugular vein
                        thrombosis, pulmonary infarction,
                        axillary vein thrombosis, portal vein thrombosis, post thrombotic syndrome, sigmoid sinus
                        thrombosis, superior sagittal sinus
                        thrombosis, vena cava thrombosis, pelvic venous thrombosis, and pulmonary thrombosis.<br>
                        AE, adverse event; VTE, venous thromboembolism.
                      </p>
                    </div>
                  </div>
                </div>
              </div>
              <!-- AEs of Special Interest Popup End -->

              <!-- Asian Subgroup Efficacy 1 Popup Start -->
              <div class="modal fade" id="asian-efficacy-1-popup" tabindex="-1" role="dialog"
                aria-labelledby="exampleModalLongTitle" aria-hidden="true" data-backdrop="static">
                <div class="modal-dialog modal-dialog-centered" role="document">
                  <div class="modal-content">
                    <div class="modal-header">
                      <h3 class="modal-title table-header font-weight-bold">
                        PFS Across Predefined Subgroups Among Asian Patients<sup>9</sup>
                      </h3>
                      <button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
                    </div>
                    <div class="modal-body">
                      <div class="content-wrapper-section mt-0">
                        <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                        <div class="table_overflow_scroll">
                          <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                            <thead>
                              <tr>
                                <th class="border-bottom-0"></th>
                                <th class="border-bottom-0"></th>
                                <th class="text-center" colspan="2">Events/N</th>
                              </tr>
                              <tr>
                                <th scope="col" class="border-top-0">Subgroup</th>
                                <th scope="col" class="border-top-0 text-center">HR (95% CI)</th>
                                <th scope="col" class="text-center table-header bg-red text-white w-25">
                                  RYBREVANT
                                  <br>+ Lazertinib
                                  <br>(n=250)
                                </th>
                                <th scope="col" class="text-center table-header bg-dark-Gray text-white w-25">
                                  Osimertinib
                                  <br>(n=251)
                                </th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td>All randomized patients</td>
                                <td class="text-center">0.65 (0.5-0.83)</td>
                                <td class="text-center">105/250</td>
                                <td class="text-center">144/251</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">Age</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">&lt;65 years</td>
                                <td class="text-center">0.5 (0.36-0.7)</td>
                                <td class="text-center">54/143</td>
                                <td class="text-center">88/140</td>
                              </tr>
                              <tr>
                                <td class="pl-4">&#8805;65 years</td>
                                <td class="text-center">0.95 (0.65-1.39)</td>
                                <td class="text-center">51/107</td>
                                <td class="text-center">56/111</td>
                              </tr>
                              <tr>
                                <td class="pl-4">&lt;75 years</td>
                                <td class="text-center">0.65 (0.5-0.85)</td>
                                <td class="text-center">92/224</td>
                                <td class="text-center">131/227</td>
                              </tr>
                              <tr>
                                <td class="pl-4">&#8805;75 years</td>
                                <td class="text-center">0.79 (0.36-1.73)</td>
                                <td class="text-center">13/26</td>
                                <td class="text-center">13/24</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">Sex</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Female</td>
                                <td class="text-center">0.63 (0.45-0.88)</td>
                                <td class="text-center">58/152</td>
                                <td class="text-center">81/143</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Male</td>
                                <td class="text-center">0.72 (0.49-1.05)</td>
                                <td class="text-center">47/98</td>
                                <td class="text-center">63/108</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">Body Weight</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">&lt;80 kg</td>
                                <td class="text-center">0.67 (0.51-0.86)</td>
                                <td class="text-center">96/236</td>
                                <td class="text-center">133/238</td>
                              </tr>
                              <tr>
                                <td class="pl-4">&#8805;80 kg</td>
                                <td class="text-center">0.65 (0.27-1.58)</td>
                                <td class="text-center">9/14</td>
                                <td class="text-center">11/13</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">ECOG PS</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">0</td>
                                <td class="text-center">0.73 (0.44-1.2)</td>
                                <td class="text-center">25/69</td>
                                <td class="text-center">41/84</td>
                              </tr>
                              <tr>
                                <td class="pl-4">1</td>
                                <td class="text-center">0.62 (0.46-0.83)</td>
                                <td class="text-center">80/181</td>
                                <td class="text-center">103/167</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">History of smoking</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Yes</td>
                                <td class="text-center">0.69 (0.43-1.1)</td>
                                <td class="text-center">33/70</td>
                                <td class="text-center">39/70</td>
                              </tr>
                              <tr>
                                <td class="pl-4">No</td>
                                <td class="text-center">0.65 (0.48-0.88)</td>
                                <td class="text-center">72/180</td>
                                <td class="text-center">105/181</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">History of brain metastases</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Yes</td>
                                <td class="text-center">0.72 (0.51-1.02)</td>
                                <td class="text-center">61/110</td>
                                <td class="text-center">70/108</td>
                              </tr>
                              <tr>
                                <td class="pl-4">No</td>
                                <td class="text-center">0.57 (0.39-0.83)</td>
                                <td class="text-center">44/140</td>
                                <td class="text-center">74/143</td>
                              </tr>
                              <tr>
                                <td class="border-right-0"><i>EGFR</i> mutation</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Exon19del</td>
                                <td class="text-center">0.61 (0.42-0.88)</td>
                                <td class="text-center">48/137</td>
                                <td class="text-center">73/139</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Exon 21 L858R</td>
                                <td class="text-center">0.71 (0.5-1)</td>
                                <td class="text-center">56/112</td>
                                <td class="text-center">71/112</td>
                              </tr>
                            </tbody>
                          </table>
                        </div>
                        <table class="table ref_table">
                          <tbody>
                            <tr>
                              <td>
                                <p class="footnote mt-0">
                                  CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group
                                  performance status; <i>EGFR</i>, epidermal
                                  growth factor receptor; HR, hazard ratio; PFS, progression-free survival.
                                </p>
                              </td>
                            </tr>
                          </tbody>
                        </table>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
              <!-- Asian Subgroup Efficacy 1 Popup End -->

              <!-- Asian Subgroup Efficacy 2 Popup Start -->
              <div class="modal fade" id="asian-efficacy-2-popup" tabindex="-1" role="dialog"
                aria-labelledby="exampleModalLongTitle" aria-hidden="true" data-backdrop="static">
                <div class="modal-dialog modal-dialog-centered" role="document">
                  <div class="modal-content">
                    <div class="modal-header">
                      <h3 class="modal-title table-header font-weight-bold">
                        ORR and Best Response by BICR Among Asian Patients<sup>9</sup>
                      </h3>
                      <button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
                    </div>
                    <div class="modal-body">
                      <div class="content-wrapper-section mt-0">
                        <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                        <div class="table_overflow_scroll">
                          <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                            <thead>
                              <tr>
                                <th scope="col" class="d-lg-none px-3" style="width: 0%;">BICR-Assessed<br>Response</th>
                                <th scope="col" class="w-25 text-wrap d-none d-lg-table-cell">BICR-Assessed Response</th>
                                <th scope="col" class="text-center table-header bg-red text-white w-25">
                                  RYBREVANT +
                                  <br>Lazertinib
                                  <br>(n=250)
                                </th>
                                <th scope="col" class="text-center table-header bg-dark-Gray text-white w-25">
                                  Osimertinib
                                  <br>
                                  (n=251)
                                </th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td>ORR,<sup>a</sup> % (95% CI)</td>
                                <td class="text-center">88 (84-92)</td>
                                <td class="text-center">85 (80-90)</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">Best response,<sup>a</sup> n (%)</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">CR</td>
                                <td class="text-center">19 (8)</td>
                                <td class="text-center">10 (4)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">PR</td>
                                <td class="text-center">200 (81)</td>
                                <td class="text-center">202 (81)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">SD</td>
                                <td class="text-center">15 (6)</td>
                                <td class="text-center">25 (10)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">PD</td>
                                <td class="text-center">3 (1)</td>
                                <td class="text-center">4 (2)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">NE</td>
                                <td class="text-center">11 (4)</td>
                                <td class="text-center">7 (3)</td>
                              </tr>
                              <td>Ongoing responses,<sup>b</sup> n (%) </td>
                              <td class="text-center">132 (64)</td>
                              <td class="text-center">93 (49)</td>
                              </tr>
                            </tbody>
                          </table>
                        </div>
                        <table class="table ref_table">
                          <tbody>
                            <tr>
                              <td>
                                <p class="footnote mt-0">
                                  <sup>a</sup>Number of patients with measurable disease at baseline by BICR was 248 for
                                  both groups, including confirmed responders.<br>
                                  <sup>b</sup>Among confirmed responders.<br>
                                  BICR, blinded independent central review; CI, confidence interval; CR,
                                  complete response; NE, not estimable;
                                  ORR, objective response rate; PD, progressive disease; PR, partial response; SD,
                                  stable disease.
                                </p>
                              </td>
                            </tr>
                          </tbody>
                        </table>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
              <!-- Asian Subgroup Efficacy 2 Popup End -->

              <!-- Asian Subgroup Safety Popup Start -->
              <div class="modal fade" id="asian-safety-popup" tabindex="-1" role="dialog"
                aria-labelledby="exampleModalLongTitle" aria-hidden="true" data-backdrop="static">
                <div class="modal-dialog modal-dialog-centered" role="document">
                  <div class="modal-content">
                    <div class="modal-header">
                      <h3 class="modal-title table-header font-weight-bold">
                        Summary of AEs Among Asian Patients<sup>9</sup>
                      </h3>
                      <button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
                    </div>
                    <div class="modal-body">
                      <div class="content-wrapper-section mt-0">
                        <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                        <div class="table_overflow_scroll">
                          <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                            <thead>
                              <tr>
                                <th scope="col" rowspan="2" class="w-25 text-wrap">
                                  Most Common TEAEs (&#8805;25%) by Preferred Term,<br class="d-none d-md-block"> n (%)
                                </th>
                                <th scope="col" colspan="2" class="text-center table-header bg-red text-white w-25">
                                  RYBREVANT + Lazertinib
                                  <br>
                                  (n=248)
                                </th>
                                <th scope="col" colspan="2"
                                  class="text-center table-header bg-dark-gray text-white w-25">
                                  Osimertinib
                                  <br>(n=250)
                                </th>
                              </tr>
                              <tr>
                                <th class="d-none"></th>
                                <th class="text-center table-header">All Grades</th>
                                <th class="text-center table-header">Grade &#8805;3</th>
                                <th class="text-center table-header">All Grades</th>
                                <th class="text-center table-header">Grade &#8805;3</th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td class="border-right-0">EGFR-related</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Paronychia</td>
                                <td class="text-center">182 (73)</td>
                                <td class="text-center">21 (8)</td>
                                <td class="text-center">79 (32)</td>
                                <td class="text-center">2 (1)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Rash</td>
                                <td class="text-center">158 (64)</td>
                                <td class="text-center">41 (17)</td>
                                <td class="text-center">82 (33)</td>
                                <td class="text-center">2 (1)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Diarrhea</td>
                                <td class="text-center">65 (26)</td>
                                <td class="text-center">4 (2)</td>
                                <td class="text-center">105 (42)</td>
                                <td class="text-center">1 (0.4)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Dermatitis acneiform</td>
                                <td class="text-center">73 (29)</td>
                                <td class="text-center">21 (8)</td>
                                <td class="text-center">36 (14)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Stomatitis</td>
                                <td class="text-center">84 (34)</td>
                                <td class="text-center">3 (1)</td>
                                <td class="text-center">79 (32)</td>
                                <td class="text-center">1 (0.4)</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">MET-related</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Hypoalbuminemia</td>
                                <td class="text-center">140 (56)</td>
                                <td class="text-center">17 (7)</td>
                                <td class="text-center">19 (8)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Peripheral edema</td>
                                <td class="text-center">83 (33)</td>
                                <td class="text-center">3 (1)</td>
                                <td class="text-center">10 (4)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">Other</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">IRR</td>
                                <td class="text-center">150 (60)</td>
                                <td class="text-center">7 (3)</td>
                                <td class="text-center">0</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="pl-4">ALT increased </td>
                                <td class="text-center">89 (36)</td>
                                <td class="text-center">10 (4)</td>
                                <td class="text-center">40 (16)</td>
                                <td class="text-center">4 (2)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Constipation</td>
                                <td class="text-center">85 (34)</td>
                                <td class="text-center">0</td>
                                <td class="text-center">34 (14)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="pl-4">AST increased</td>
                                <td class="text-center">77 (31)</td>
                                <td class="text-center">8 (3)</td>
                                <td class="text-center">43 (17)</td>
                                <td class="text-center">3 (1)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">COVID-19</td>
                                <td class="text-center">66 (27)</td>
                                <td class="text-center">4 (2)</td>
                                <td class="text-center">62 (25)</td>
                                <td class="text-center">5 (2)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Decreased appetite</td>
                                <td class="text-center">70 (28)</td>
                                <td class="text-center">4 (2)</td>
                                <td class="text-center">44 (18)</td>
                                <td class="text-center">2 (1)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">VTE<sup>a</sup></td>
                                <td class="text-center">77 (31)</td>
                                <td class="text-center">22 (9)</td>
                                <td class="text-center">14 (6)</td>
                                <td class="text-center">5 (2)</td>
                              </tr>
                            </tbody>
                          </table>
                        </div>
                        <table class="table ref_table">
                          <tbody>
                            <tr>
                              <td>
                                <p class="footnote mt-0">
                                  <sup>a</sup>Grouping includes the following preferred terms: PE, DVT, embolism, venous
                                  thrombosis limb, venous thrombosis, embolism
                                  venous, jugular vein thrombosis, pelvic venous thrombosis, portal vein thrombosis, pulmonary
                                  infarction, pulmonary
                                  thrombosis, superficial vein thrombosis, superior sagittal sinus thrombosis, thrombophlebitis,
                                  and thrombosis.
                                </p>
                              </td>
                            </tr>
                          </tbody>
                        </table>
                      </div>
                      <p class="footnote mt-0">
                        Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate
                        aminotransferase; COVID-19, coronavirus
                        disease 2019; DVT, deep vein thrombosis; EGFR, epidermal growth factor receptor; IRR,
                        infusion-related reaction; MET,
                        mesenchymal-epithelial transition; TEAE, treatment-emergent AE.
                      </p>
                    </div>
                  </div>
                </div>
              </div>
              <!-- Asian Subgroup Safety Popup End -->

              <!-- Exploratory Effects 1 Popup Start -->
              <div class="modal fade" id="exploratory-effects-1-popup" tabindex="-1" role="dialog"
                aria-labelledby="exampleModalLongTitle" aria-hidden="true" data-backdrop="static">
                <div class="modal-dialog modal-dialog-centered" role="document">
                  <div class="modal-content">
                    <div class="modal-header">
                      <h3 class="modal-title table-header font-weight-bold">
                        Patient Characteristics<sup>11</sup>
                      </h3>
                      <button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
                    </div>
                    <div class="modal-body">
                      <div class="content-wrapper-section mt-0">
                        <ul class="cw-list text-left pl-3 mb-4">
                          <li class="pl-0">
                            Patients with (n=188) and without (n=190) dose interruption<sup>a</sup> in the first 4
                            months of RYBREVANT exposure were included in the analysis.
                          </li>
                          <li class="pl-0">
                            Patients who discontinued the study, had disease progression, or died in the first 4 months
                            of RYBREVANT exposure (n=43; 10%) were excluded from the analysis.
                          </li>
                          <li class="pl-0">
                            Median time to first interruption was 43 days (IQR, 16-72).
                          </li>
                          <li class="pl-0">
                            Median duration of interruption in patients who resumed RYBREVANT (94%) was 22 days (IQR,
                            14-41).
                          </li>
                        </ul>

                        <h3 class="modal-title table-header table_header_text  font-weight-bold">
                          Demographics and Baseline Disease Characteristics<sup>11</sup>
                        </h3>
                        <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                        <div class="table_overflow_scroll">
                          <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                            <thead>
                              <tr>
                                <th class="w-25">Characteristic</th>
                                <th class="w-25 text-center">
                                  Dose Interruption
                                  <br>in the First 4 Months
                                  <br>(n=188)
                                </th>
                                <th class="w-25 text-center">
                                  No Dose Interruption
                                  <br>in the First 4 Months
                                  <br>(n=190)
                                </th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td>Median age, years (range)</td>
                                <td class="text-center">63 (35-86)</td>
                                <td class="text-center">62 (24-88)</td>
                              </tr>
                              <tr>
                                <td>Female, n (%)</td>
                                <td class="text-center">120 (64)</td>
                                <td class="text-center">120 (63)</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">Race, n (%)</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Asian</td>
                                <td class="text-center">108 (57)</td>
                                <td class="text-center">114 (60)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Non-Asian</td>
                                <td class="text-center">78 (41)</td>
                                <td class="text-center">76 (40)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Unknown</td>
                                <td class="text-center">2 (1)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td>ECOG PS 1, n (%)</td>
                                <td class="text-center">122 (65)</td>
                                <td class="text-center">127 (67)</td>
                              </tr>
                              <tr>
                                <td>History of smoking, n (%)</td>
                                <td class="text-center">61 (32)</td>
                                <td class="text-center">54 (28)</td>
                              </tr>
                              <tr>
                                <td>History of brain metastases, n (%)</td>
                                <td class="text-center">80 (43)</td>
                                <td class="text-center">71 (37)</td>
                              </tr>
                              <tr>
                                <td class="border-right-0" colspan="2"><i>EGFR</i> mutation, n (%)</td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Exon19del</td>
                                <td class="text-center">101 (54)</td>
                                <td class="text-center">124 (65)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Exon 21 L858R</td>
                                <td class="text-center">87 (46)</td>
                                <td class="text-center">66 (35)</td>
                              </tr>
                            </tbody>
                          </table>
                        </div>
                        <table class="table ref_table">
                          <tbody>
                            <tr>
                              <td>
                                <p class="footnote mt-0">
                                  <sup>a</sup>Dose interruption was defined as missed doses that were not compensated for. This
                                  group of patients also included patients
                                  who had a dose reduction or discontinued treatment.
                                </p>
                              </td>
                            </tr>
                          </tbody>
                        </table>
                      </div>
                      <p class="footnote mt-0">
                        ECOG PS, Eastern Cooperative Oncology Group performance status; <i>EGFR</i>,
                        epidermal growth factor receptor;
                        Exon19del, Exon 19 deletion; IQR, interquartile range.
                      </p>
                    </div>
                  </div>
                </div>
              </div>
              <!-- Exploratory Effects 1 Popup End -->

              <!-- Exploratory Effects 2 Popup Start -->
              <div class="modal fade" id="exploratory-effects-2-popup" tabindex="-1" role="dialog"
                aria-labelledby="exampleModalLongTitle" aria-hidden="true" data-backdrop="static">
                <div class="modal-dialog modal-dialog-centered" role="document">
                  <div class="modal-content">
                    <div class="modal-header">
                      <h3 class="modal-title table-header font-weight-bold">
                        Efficacy in Patients With and Without Dose Interruptions in the First
                        4 Months of RYBREVANT Exposures<sup>11</sup>
                      </h3>
                      <button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
                    </div>
                    <div class="modal-body">
                      <div class="content-wrapper-section mt-0">
                        <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                        <div class="table_overflow_scroll">
                          <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                            <thead>
                              <tr>
                                <th scope="col" class="text-wrap">
                                  Outcome, Median
                                  <br>(95% CI)
                                </th>
                                <th scope="col" class="text-center w-25">
                                  Dose Interruption<br>
                                  (n=206)
                                </th>
                                <th scope="col" class="text-center w-25">
                                  No Dose<br>
                                  Interruption<br>
                                  (n=215)
                                </th>
                                <th scope="col" class="text-center w-25">
                                  All Randomized<br>
                                  Patients<br>
                                  (n=429)
                                </th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td>PFS, months</td>
                                <td class="text-center">23.9 (18.5-NE)</td>
                                <td class="text-center">23.7 (18.4-NE)</td>
                                <td class="text-center">23.7 (19.1-27.7)</td>
                              </tr>
                              <tr>
                                <td>ORR, %</td>
                                <td class="text-center">87 (81-91)</td>
                                <td class="text-center">89 (84-93)</td>
                                <td class="text-center">86 (83-89)</td>
                              </tr>
                              <tr>
                                <td>DOR in confirmed responders, months</td>
                                <td class="text-center">25.8 (16.7-NE)</td>
                                <td class="text-center">26.1 (20.1-NE)</td>
                                <td class="text-center">25.8 (20.1-NE)</td>
                              </tr>
                            </tbody>
                          </table>
                        </div>
                      </div>
                      <p class="footnote mt-0">CI, confidence interval; DOR, duration of response; NE,
                        not estimable; ORR, objective response rate;
                        PFS, progression-free survival.</p>
                    </div>
                  </div>
                </div>
              </div>
              <!-- Exploratory Effects 2 Popup End -->

              <!-- Exploratory Effects 3 Popup Start -->
              <div class="modal fade" id="exploratory-effects-3-popup" tabindex="-1" role="dialog"
                aria-labelledby="exampleModalLongTitle" aria-hidden="true" data-backdrop="static">
                <div class="modal-dialog modal-dialog-centered" role="document">
                  <div class="modal-content">
                    <div class="modal-header">
                      <h3 class="modal-title table-header font-weight-bold">
                        Efficacy in Patients With and Without Dose Interruptions After the First
                        4 Months of RYBREVANT Exposures<sup>11</sup>
                      </h3>
                      <button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
                    </div>
                    <div class="modal-body">
                      <div class="content-wrapper-section mt-0">
                        <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                        <div class="table_overflow_scroll">
                          <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                            <thead>
                              <tr>
                                <th scope="col" class="text-wrap">
                                  Outcome
                                </th>
                                <th scope="col" class="text-center w-25">
                                  Dose<br>
                                  Interruption<br>
                                  (n=188)
                                </th>
                                <th scope="col" class="text-center w-25">
                                  No Dose Interruption<br>
                                  (n=190)
                                </th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td>Median PFS, months (95% CI) </td>
                                <td class="text-center">27.5 (20.3-NE)</td>
                                <td class="text-center">25.7 (22.2-NE)</td>
                              </tr>
                              <tr>
                                <td>Patients who achieved PFS at 24 months, %</td>
                                <td class="text-center">52</td>
                                <td class="text-center">52</td>
                              </tr>
                            </tbody>
                          </table>
                        </div>
                      </div>
                      <p class="footnote mt-0">CI, confidence interval; NE, not estimable; PFS,
                        progression-free survival.</p>
                    </div>
                  </div>
                </div>
              </div>
              <!-- Exploratory Effects 3 Popup End -->

              <!-- Exploratory Comparison 1 Popup Start -->
              <div class="modal fade" id="exploratory-comparison-1-popup" tabindex="-1" role="dialog"
                aria-labelledby="exampleModalLongTitle" aria-hidden="true" data-backdrop="static">
                <div class="modal-dialog modal-dialog-centered" role="document">
                  <div class="modal-content">
                    <div class="modal-header">
                      <h3 class="modal-title table-header font-weight-bold">
                        PFS Across Subgroups
                        <sup>12</sup>
                      </h3>
                      <button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
                    </div>
                    <div class="modal-body">
                      <div class="content-wrapper-section mt-0">
                        <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                        <div class="table_overflow_scroll">
                          <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                            <thead>
                              <tr>
                                <th scope="col" class="w-25 text-wrap">
                                  Prespecified Subgroup
                                </th>
                                <th scope="col" colspan="3" class="text-center w-25">
                                  Lazertinib vs Osimertinib
                                  <br>HR (95% CI)
                                </th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td>Asian race</td>
                                <td colspan="3" class="text-center">1.02 (0.77-1.35)</td>
                              </tr>
                              <tr>
                                <td class="border-right-0"><i>EGFR</i> mutation</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Exon19del</td>
                                <td colspan="3" class="text-center">1.03 (0.78-1.37)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Exon 21 L858R</td>
                                <td colspan="3" class="text-center">0.91 (0.65-1.28)</td>
                              </tr>
                            </tbody>
                            <thead>
                              <tr>
                                <th scope="col" rowspan="2">High-risk Subgroup</th>
                                <th scope="col" class="text-center" colspan="2">Median PFS (95% CI), Months</th>
                                <th scope="col" class="text-center" rowspan="2">
                                  HR (95% CI);
                                  <br><i>P</i>-Value
                                </th>
                              </tr>
                              <tr>
                                <th class="d-none"></th>
                                <th class="w-25 bg-red text-white text-center">
                                  Lazertinib
                                  <br>(n=216)
                                </th>
                                <th class="w-25 bg-dark-gray text-white text-center">
                                  Osimertinib
                                  <br>(n=429)
                                </th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td class="border-right-0" colspan="2">History of brain metastases</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Yes</td>
                                <td class="text-center">
                                  n=86<br>
                                  16.4 (12.9-19.4)
                                </td>
                                <td class="text-center">
                                  n=172<br>
                                  13 (12.2-16.4)
                                </td>
                                <td class="text-center">
                                  0.90 (0.65-1.25);<br>
                                  <i>P</i>=0.54
                                </td>
                              </tr>
                              <tr>
                                <td class="pl-4">No</td>
                                <td class="text-center">
                                  n=130
                                </td>
                                <td class="text-center">
                                  n=257
                                </td>
                                <td class="text-center">
                                  1.01 (0.75-1.35)
                                </td>
                              </tr>
                              <tr>
                                <td class="border-right-0" colspan="2">Detectable ctDNA at baseline</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Present<sup>a</sup></td>
                                <td class="text-center">
                                  n=115<br>
                                  18.4 (14.6-20.2)
                                </td>
                                <td class="text-center">
                                  n=274<br>
                                  14.8 (12.9-16.6)
                                </td>
                                <td class="text-center">
                                  0.88 (0.66-1.17);<br>
                                  <i>P</i>=0.38
                                </td>
                              </tr>
                              <tr>
                                <td class="pl-4">Absent</td>
                                <td class="text-center">
                                  n=31
                                </td>
                                <td class="text-center">
                                  n=42
                                </td>
                                <td class="text-center">
                                  1.32 (0.99-1.75)
                                </td>
                              </tr>
                              <tr>
                                <td class="border-right-0" colspan="2"><i>TP53</i> mutation status at baseline</td>
                                <td class="border-right-0 border-left-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4"><i>TP53</i> co-mutations<sup>a</sup></td>
                                <td class="text-center">
                                  n=62<br>
                                  14.6 (11.0-19.4)
                                </td>
                                <td class="text-center">
                                  n=144<br>
                                  12.9 (11.1-14.7)
                                </td>
                                <td class="text-center">
                                  0.85 (0.58-1.23);<br>
                                  <i>P</i>=0.38
                                </td>
                              </tr>
                              <tr>
                                <td class="pl-4"><i>TP53</i> wild-type
                                </td>
                                <td class="text-center">
                                  n=84
                                </td>
                                <td class="text-center">
                                  n=172
                                </td>
                                <td class="text-center">
                                  0.95 (0.71-1.26)
                                </td>
                              </tr>
                            </tbody>
                          </table>
                        </div>
                        <table class="table ref_table">
                          <tbody>
                            <tr>
                              <td>
                                <p class="footnote mt-0">
                                  <sup>a</sup>Pathogenic alterations were detected with the Guardant Health G360<sup>®</sup>
                                  panel.
                                </p>
                              </td>
                            </tr>
                          </tbody>
                        </table>
                      </div>
                      <p class="footnote mt-0">
                        CI, confidence interval; ctDNA, circulating tumor DNA; <i>EGFR</i>, epidermal
                        growth factor receptor;
                        Exon19del, Exon 19 deletion; HR, hazard ratio; PFS, progression-free survival.
                      </p>
                    </div>
                  </div>
                </div>
              </div>
              <!-- Exploratory Comparison 1 Popup End -->

              <!-- Exploratory Comparison 2 Popup Start -->
              <div class="modal fade" id="exploratory-comparison-2-popup" tabindex="-1" role="dialog"
                aria-labelledby="exampleModalLongTitle" aria-hidden="true" data-backdrop="static">
                <div class="modal-dialog modal-dialog-centered" role="document">
                  <div class="modal-content">
                    <div class="modal-header">
                      <h3 class="modal-title table-header font-weight-bold ">
                        ORR, Best Response, and DOR by BICR<sup>12</sup>
                      </h3>
                      <button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
                    </div>
                    <div class="modal-body">
                      <div class="content-wrapper-section mt-0">
                        <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                        <div class="table_overflow_scroll">
                          <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                            <thead>
                              <tr>
                                <th scope="col" class="d-md-none" style="width: 0%;">
                                  BICR-Assessed<br>Response<sup>a</sup></th>
                                <th scope="col" class="w-25 d-none d-md-table-cell">
                                  BICR-Assessed Response<sup>a</sup></th>
                                <th scope="col" class="text-center table-header bg-red text-white w-25">
                                  Lazertinib <br>(n=216)
                                </th>
                                <th scope="col" class="text-center table-header bg-dark-gray text-white w-25">
                                  Osimertinib <br>(n=429)
                                </th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td class="border-right-0">ORR, % (95% CI)</td>
                                <td class="border-left-0 border-right-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">All responders</td>
                                <td class="text-center">83 (77-88)</td>
                                <td class="text-center">85 (81-88)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Confirmed responders</td>
                                <td class="text-center">75 (68-80)</td>
                                <td class="text-center">76 (71-80)</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">Best response,<sup>b</sup> n (%)</td>
                                <td class="border-left-0 border-right-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">CR</td>
                                <td class="text-center">9 (4)</td>
                                <td class="text-center">15 (4)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">PR</td>
                                <td class="text-center">168 (79)</td>
                                <td class="text-center">335 (81)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">SD</td>
                                <td class="text-center">23 (11)</td>
                                <td class="text-center">42 (10)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">PD</td>
                                <td class="text-center">9 (4)</td>
                                <td class="text-center">11 (3)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">NE</td>
                                <td class="text-center">5 (2)</td>
                                <td class="text-center">11 (3)</td>
                              </tr>
                              <tr>
                                <td>Median DOR,<sup>c</sup> months (95% CI)</td>
                                <td class="text-center">16.6 (14.8-20.2)</td>
                                <td class="text-center">16.8 (14.8-18.5)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Ongoing responses, n/n (%)</td>
                                <td class="text-center">77/160 (48)</td>
                                <td class="text-center">151/314 (48)</td>
                              </tr>
                            </tbody>
                          </table>
                        </div>
                        <table class="table ref_table">
                          <tbody>
                            <tr>
                              <td>
                                <p class="footnote mt-0">
                                  <sup>a</sup>Number of patients with measurable disease at baseline by BICR was 214 for
                                  lazertinib and 414 for osimertinib.<br>
                                  <sup>b</sup>Includes all responders.<br>
                                  <sup>c</sup>Among confirmed responders.
                                </p>
                              </td>
                            </tr>
                          </tbody>
                        </table>
                      </div>
                      <p class="footnote mt-2">BICR, blinded independent central review; CI, confidence
                        interval; CR, complete response; DOR, duration
                        of response; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR,
                        partial response; SD, stable
                        disease.
                      </p>
                    </div>
                  </div>
                </div>
              </div>
              <!-- Exploratory Comparison 2 Popup End -->

              <!-- Exploratory Comparison 3 Popup Start -->
              <div class="modal fade" id="exploratory-comparison-3-popup" tabindex="-1" role="dialog"
                aria-labelledby="exampleModalLongTitle" aria-hidden="true" data-backdrop="static">
                <div class="modal-dialog modal-dialog-centered" role="document">
                  <div class="modal-content">
                    <div class="modal-header">
                      <h3 class="modal-title table-header font-weight-bold">
                        Summary of TEAEs<sup>12</sup>
                      </h3>
                      <button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
                    </div>
                    <div class="modal-body">
                      <div class="content-wrapper-section mt-0">
                        <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                        <div class="table_overflow_scroll">
                          <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                            <thead>
                              <tr>
                                <th scope="col" class="w-25 text-wrap" rowspan="2">
                                  Most Common TEAEs<br>
                                  (≥20%) by Preferred Term,<br>
                                  n (%)
                                </th>
                                <th scope="col" class="text-center table-header bg-red text-white w-25" colspan="2">
                                  Lazertinib <br>(n=213)
                                </th>
                                <th scope="col" class="text-center table-header bg-dark-gray text-white w-25"
                                  colspan="2">
                                  Osimertinib <br>(n=428)
                                </th>
                              </tr>
                              <tr>
                                <th class="d-none"></th>
                                <th class="text-center">Grade 1-2</th>
                                <th class="text-center">Grade ≥3</th>
                                <th class="text-center">Grade 1-2</th>
                                <th class="text-center">Grade ≥3</th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td class="border-right-0" colspan="2">EGFR inhibition-related</td>
                                <td class="border-left-0 border-right-0"></td>
                                <td class="border-left-0 border-right-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">Diarrhea</td>
                                <td class="text-center">64 (30)</td>
                                <td class="text-center">4 (2)</td>
                                <td class="text-center">187 (44)</td>
                                <td class="text-center">3 (1)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Rash</td>
                                <td class="text-center">91 (43)</td>
                                <td class="text-center">4 (2)</td>
                                <td class="text-center">128 (30)</td>
                                <td class="text-center">3 (1)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Paronychia</td>
                                <td class="text-center">59 (28)</td>
                                <td class="text-center">2 (1)</td>
                                <td class="text-center">119 (28)</td>
                                <td class="text-center">2 (0.5)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Stomatitis</td>
                                <td class="text-center">37 (17)</td>
                                <td class="text-center">1 (0.5)</td>
                                <td class="text-center">89 (21)</td>
                                <td class="text-center">1 (0.2)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Dermatitis acneiform</td>
                                <td class="text-center">45 (21)</td>
                                <td class="text-center">0</td>
                                <td class="text-center">55 (13)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">Other</td>
                                <td class="border-left-0 border-right-0"></td>
                                <td class="border-left-0 border-right-0"></td>
                                <td class="border-left-0 border-right-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">COVID-19</td>
                                <td class="text-center">39 (18)</td>
                                <td class="text-center">3 (1)</td>
                                <td class="text-center">94 (22)</td>
                                <td class="text-center">9 (2)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Cough</td>
                                <td class="text-center">36 (17)</td>
                                <td class="text-center">1 (0.5)</td>
                                <td class="text-center">88 (21)</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Anemia</td>
                                <td class="text-center">40 (19)</td>
                                <td class="text-center">3 (1)</td>
                                <td class="text-center">84 (20)</td>
                                <td class="text-center">7 (2)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Thrombocytopenia</td>
                                <td class="text-center">19 (9)</td>
                                <td class="text-center">1 (0.5)</td>
                                <td class="text-center">79 (18)</td>
                                <td class="text-center">5 (1)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">AST increased</td>
                                <td class="text-center">42 (20)</td>
                                <td class="text-center">3 (1)</td>
                                <td class="text-center">53 (12)</td>
                                <td class="text-center">5 (1)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">ALT increased</td>
                                <td class="text-center">44 (21)</td>
                                <td class="text-center">6 (3)</td>
                                <td class="text-center">49 (11)</td>
                                <td class="text-center">8 (2)</td>
                              </tr>
                              <tr>
                                <td class="pl-4">Muscle spasms</td>
                                <td class="text-center">49 (23)</td>
                                <td class="text-center">1 (0.5)</td>
                                <td class="text-center">32 (7)</td>
                                <td class="text-center">0</td>
                              </tr>
                            </tbody>
                          </table>
                        </div>
                      </div>
                      <p class="footnote mt-2">ALT, alanine aminotransferase; AST, aspartate
                        aminotransferase; COVID-19, coronavirus disease 2019;
                        EGFR, epidermal growth factor receptor; TEAE, treatment-emergent AE.</p>
                    </div>
                  </div>
                </div>
              </div>
              <!-- Exploratory Comparison 3 Popup End -->

              <!-- Exploratory Comparison 4 Popup Start -->
              <div class="modal fade" id="exploratory-comparison-4-popup" tabindex="-1" role="dialog"
                aria-labelledby="exampleModalLongTitle" aria-hidden="true" data-backdrop="static">
                <div class="modal-dialog modal-dialog-centered" role="document">
                  <div class="modal-content">
                    <div class="modal-header">
                      <h3 class="modal-title table-header font-weight-bold">
                        Cardiac Safety Profile of Lazertinib vs Osimertinib<sup>12</sup>
                      </h3>
                      <button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
                    </div>
                    <div class="modal-body">
                      <div class="content-wrapper-section mt-0">
                        <img src="assets/images/scroll-band.svg" alt="" class="w-100 mb-3 d-md-none">
                        <div class="table_overflow_scroll">
                          <table class="table table-bordered table-sm overflow-table mb-0 adverse-event-table">
                            <thead>
                              <tr>
                                <th scope="col" class="w-25">Patients, %</th>
                                <th scope="col" class="text-center table-header bg-red text-white w-25">
                                  Lazertinib
                                </th>
                                <th scope="col" class="text-center table-header bg-dark-gray text-white w-25">
                                  Osimertinib
                                </th>
                                <th scope="col" class="text-center table-header w-25"><i>P</i>-value</th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td>LVEF<sup>a</sup></td>
                                <td class="text-center">1</td>
                                <td class="text-center">4</td>
                                <td class="text-center">0.056</td>
                              </tr>
                              <tr>
                                <td class="border-right-0">QT interval prolongation<sup>b</sup></td>
                                <td class="border-left-0 border-right-0"></td>
                                <td class="border-left-0 border-right-0"></td>
                                <td class="border-left-0"></td>
                              </tr>
                              <tr>
                                <td class="pl-4">>450 msec</td>
                                <td class="text-center">9</td>
                                <td class="text-center">17</td>
                                <td class="text-center">0.005</td>
                              </tr>
                              <tr>
                                <td class="pl-4">>500 msec</td>
                                <td class="text-center">0</td>
                                <td class="text-center">0.7</td>
                                <td class="text-center">-</td>
                              </tr>
                            </tbody>
                          </table>
                        </div>
                        <table class="table ref_table">
                          <tbody>
                            <tr>
                              <td>
                                <p class="footnote mt-0">
                                  <sup>a</sup>Patients with LVEF &lt;LLN and >10% absolute decrease from baseline.<br>
                                  <sup>b</sup>Patients with maximum postbaseline values.
                                </p>
                              </td>
                            </tr>
                          </tbody>
                        </table>
                      </div>
                      <p class="footnote mt-2">LLN, lower limit of normal; LVEF, left ventricular
                        ejection fraction.
                      </p>
                    </div>
                  </div>
                </div>
              </div>
              <!-- Exploratory Comparison 4 Popup End -->
            </div>
          </div>
        </div>
      </div>
    </div>

  </div>
  <script src="assets/js/jquery.slim.min.js"></script>
  <script src="assets/js/bootstrap.bundle.min.js"></script>
  <script src="assets/js/main.js"></script>
</body>

</html>